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Summary 
 
Coeliac disease is reported to affect around 1% of the western 
population, with ingestion of gluten typically initiating inflammation of the 
bowel. Current diagnostic assays based on biomarkers of gluten sensitivity 
are only specific for patients with classical gastrointestinal symptoms, such 
as those displayed in coeliac disease. However, studies have shown that 
gluten sensitivity can manifest with symptoms other than those related to 
inflammation of the bowel, notably neurological symptoms including ataxia 
and neuropathy. Identification of gluten sensitive patients, with a 
predisposition to develop neurological deficits, is crucial to prevent 
irreversible damage to neural tissue, as this tissue has a poor intrinsic repair 
capacity. 
A novel transglutaminase, TG6, has been discovered and shown to be 
predominantly expressed by a subset of neurons in the central nervous 
system. Furthermore, anti-TG6 IgG and IgA autoantibodies have been shown 
to be prevalent in gluten ataxia, independent of intestinal involvement. 
Therefore, TG6 antibodies have been identified as possible biomarkers to 
diagnose those patients that may be at risk of developing neurological 
disease in association with gluten sensitivity. 
The aim of this project was to develop a mechanistic understanding of 
autoantibody development and extraintestinal disease-manifestations. 
Specifically, the research aimed to determine whether autoantibody 
development to TG6 occurs in conjunction with that of TG2, i.e. in the gut, or 
if it has its origin in independent events.  
 By immunofluorescent analysis of intestinal biopsies, this research 
was able to detect, for the first time, the presence of TG6-reactive B-cells 
and plasma cells in the intestinal mucosa of patients presenting with gluten-
related disorders. Additionally the research was able to identify macrophages 
as possible sources of TG6 at the intestinal level. 
These findings have led to the proposition that autoantibodies that 
drive the extraintestinal manifestiations of gluten related disorders are 
developed in the gut.  
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Chapter 1 Introduction 
 
1.1 The transglutaminase family 
 
The transglutaminase (TG) family consists of a group of enzymes 
related in function and structure, which mediate post-translation modification 
of proteins. In the human genome, 9 TG genes have been identified, of which 
8 are encoding catalytic active enzymes: TG1, TG2, TG3, TG4, TG5, TG6, 
TG7 and Factor XIIIa (FXIIIa). The remaining gene codes for a catalytically 
inactive protein, erythrocyte membrane protein band 4.2, found as a 
structural protein in erythrocytes (Iismaa et al. 2009).  
TGs evolved from the papain family of proteases and are products of 
different genes arising from duplication and rearrangement of an ancestral 
proto-gene (Grenard et al., 2001; Lorand & Graham, 2003; Thomas et al., 
2013). Therefore, is not surprising that there’s a high degree of structural 
conservation between the TG family members. They share a similar protein 
structure that consists of 4 structurally distinct domains: 1 N-terminal β-
sandwich, 1 catalytic core and 2 C-terminal β-barrel domains ( Yee et al., 
1994; Pinkas et al., 2007). Additionally, TG1 and FXIIIa contain a pro-peptide 
before the N-terminal β-sandwich that is cleaved for enzyme activation 
(Iismaa et al. 2009). Fig. 1.1 demonstrates the relationship between TGs 
gene organization and protein structure.  
Apart from protein band 4.2, all transglutaminases share the same 
amino acid sequence at the active site (the equivalent of Cys277, His335 and 
Asp358 in human TG2) and conserved Trp241 and Trp332 residues that 
stabilize the transition state during catalysis (Liu et al. 2002). 
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Fig. 1.1 Genomic organization of transglutaminases (adapted from Iismaa et al. 2009) 
 
1.2 Enzymatic reactions mediated by transglutaminases  
 
TGs are able to catalyse at least 5 types of post-translational protein 
modifications. These enzymes preferably target the γ-carboxamide group of 
the side chain of glutamine residues, located within unstructured flexible 
regions of protein substrates (Hohenadl et al., 1995). The desired glutamine 
seems to depend more on its accessibility than on the primary sequence 
surrounding it, although there seems to be sequence specificity (Stamnaes et 
al., 2010). Also, TGs do not react with the free amino-acid glutamine (Folk & 
Finlayson, 1977; Mehta & Eckert, 2005). 
Modification of the γ-carboxamide group of the glutamine residue 
depends on the nature of the substrates available and catalyzed reactions 
can be grouped into transamidation, hydrolysis or esterification (Fig. 1.2) 
(Aeschlimann & Thomazy 2000). 
The reaction starts when a glutamine-containing protein or peptide 
(acceptor substrate) reacts with the active site cysteine, transiently acylating 
its thiol group to form a covalently linked γ-glutamyl-thioester (acyl-enzyme 
intermediate). This step is rate-limiting and results in the release of ammonia 
(Lorand & Graham 2003). This initial acylation step can be followed either by 
reaction with water or by binding of a second substrate, such as an amine or 
an alcohol, to cleave the thioester bond (the deacylation step) with 
generation of the hydrolysed, transamidated or esterified product and 
enzyme regeneration (Folk, 1980; Beninati & Piacentini, 2004; Mehta & 
Eckert, 2005; Iismaa et al., 2009). 
Protein(
Genes((
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Transamidation reactions can result in crosslinking of proteins by 
formation of a Nε(γ-glutamyl)lysine isopeptide bond between the glutamine 
residue of one protein and the ε-amino group of a deprotonated lysine 
residue present in another protein. Other transamidation reactions can result 
in the amine or polyamine incorporation into the acceptor glutamine residue 
or acylation of a lysine residue on the donor protein (Lorand & Graham 
2003). Hydrolysis will occur in the absence of a second donor substrate, 
when a water molecule will drive the reaction. This leads to deamidation of 
the glutamine residue on the acceptor substrate. Given the aqueous 
environment, it remains to be structurally explained why reaction with water 
occurs in some instances but not others. Hydrolysis can also occur in the 
presence of an already crosslinked polypeptide, by cleavage of the 
isopeptide bond, demonstrating reversibility of the second step of the 
reaction. 
The reactions of transamidation compete between each other and with 
esterification, and are reversible. However, both reactions leading to 
hydrolysis proceed only in one direction (Lorand & Graham 2003).  
The reactions catalysed by TGs are essential for biological processes 
such as blood coagulation, skin barrier formation, and extracellular matrix 
(ECM) assembly (Iismaa et al. 2009). 
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Fig. 1.2 Post-translational reactions catalysed by transglutaminases. TGs mediate 
Ca2+-dependent acyl-transfer reactions that can be grouped into transamidation (a, b, c), 
esterification (d) or hydrolysis (e, f). Type of reaction is dependent on the second nucleophile 
donor. Gln acceptor residue (blue rectangle); Lys donor residue (purple ellipse); R (side 
chain of primary amine); R’ (Gln containing peptide); R’’ (a ceramide); R’’’ and R’’’’ (the side 
chains in branched isopeptides). Retrieved from Lorand & Graham 2003.  
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1.3 Biological function of transglutaminases 
 
Different members of the TG family have different distribution patterns 
and different biological functions (Table 1.1). For example, the presence of 
TGs is important in the differentiation of keratinocytes, with TG1 and TG5 
being involved in the crosslinking of epidermal proteins and formation of 
cornified envelopes in the epidermal cells (Mehta & Eckert 2005). FXIII takes 
part in the coagulation cascade and catalyzes the formation of γ-glutamyl-ε-
lysine cross-links between fibrin chains, thus stabilizing the fibrin clot during 
blood coagulation (Bagoly et al., 2012). TG2 is ubiquity expressed and is 
involved in the stabilization of the extracellular matrix by selectively 
crosslinking proteins (Aeschlimann & Thomazy, 2000). Also, deamidation of 
peptides by TG2 is critically related to the pathogenesis of coeliac disease 
(Sollid, 2002).   
For the purpose of this project, I will introduce TG members TG2, TG3 
and TG6, as they are closely related (H. Thomas et al., 2013) and implicated 
in gluten-sensitivity disorders, which is the context of this project 
(Hadjivassiliou et al. 2010). 
 
1.4 Transglutaminase 2 
 
1.4.1 Protein expression and function 
 
Transglutaminase 2 (TG2), also known as tissue transglutaminase, 
was first discovered by the Waelsch group in 1957 (Sarkar, Clarke, & 
Waelsch, 1957). It is encoded by TGM2 on human chromosome 20q11-12 
and has a molecular weight of ≈77kDa. TG2 is the only member of the 
transglutaminase family that is ubiquitously expressed at substantial levels 
and hence makes up above 90% of transglutaminase activity in many tissues 
in mammals (Lorand & Graham, 2003). Because of its wide distribution, TG2 
is the most studied enzyme of the TG family and consequently, several of its 
intra and extracellular functions have been delineated. The protein is found in 
epithelium, myeloid cells and many mesenchymal-derived tissues including 
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smooth muscle cells, chondrocytes, osteoblasts and fibroblasts 
(Aeschlimann & Thomazy, 2000). On a cellular level, it is predominantly a 
cytosolic protein (80%), but it can also be found associated with the cell 
membrane (10-15%) and nuclear membrane (Lorand & Graham, 2003). 
 
Table 1.1 The transglutaminase family – expression, function and links with disease 
Protein Synonyms Tissue expression Function Disease 
TG1 
TGk, 
keratinocyte TG 
Keratinocytes, 
Brain 
Cornified-envelope 
formation  
Lamellar 
ichthyosis 
TG2 
tissue TG,  
TGc, Ghα 
Ubiquitous 
Cell adhesion and 
motility, matrix 
assembly, signal 
transduction, cell 
survival, apoptosis, 
cell differentiation 
and many others  
Coeliac disease 
TG3 
TGe,  
epidermal TG 
Epidermis, 
hair follicle, brain 
Cell-envelope 
formation  
Dermatitis 
herpetiformis 
TG4 
TGp,  
prostate TG 
Prostate Semen coagulation  
Unknown 
 
TG5 TGx 
Ubiquitous except 
for CNS and 
lymphatic system 
Cornified cell 
envelope formation  
Peeling skin 
syndrome 
TG6 TGy Testis, lung, CNS Unknown 
Gluten ataxia 
Spinocerebellar 
ataxia 
TG7 TGz Ubiquitous Unknown Unknown 
FXIIIa 
Fibrin-stabilizing 
factor, 
fibrinoligase, 
plasma TG 
Platelets, placenta, 
synovial fluid, 
astrocytes, 
macrophages, 
dendritic cells 
Blood clot 
formation, wound 
healing, embryo 
implantation during 
pregnancy  
Bleeding 
disorders 
Spontaneous 
abortion 
 
Band 
4.2 B4.2 
Erythrocytes, bone 
marrow, spleen 
Scaffolding protein 
in membrane of 
erythrocytes  
Hereditary 
spherocytosis 
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Although investigated extensively, TG2 function in the body is still 
unclear, as many roles have been proposed, some of which are 
contradictory. In part this relates to the complexity added by its many 
proposed activities: transamidase, GTPase, disulphide isomerase, receptor 
ligand or structural protein, and the possible overlap in functions between 
members of the TG family. TG2 has been associated with stabilisation of the 
extracellular matrix and mineralization of skeletal tissues (Aeschlimann et al. 
1995), cell survival (Boehm et al. 2002), neuronal differentiation (Tucholski et 
al. 2001), injury repair and inflammatory responses and programmed cell 
death (Aeschlimann & Thomazy 2000) among many others functions. 
Surprisingly, studies on TG2 knock-out mice revealed no overt 
developmental abnormalities, no obvious defects in organ function and 
normal reproduction (Laurenzi & Melino, 2001). The lack of obvious 
abnormalities in TG2 deficient mice may be explained by the activity of other 
TGs (FXIIIa in particular) that partially compensate for TG2 deficiency (Mehta 
& Eckert 2005). However, deficiencies are clearly evident when these mice 
are analysed in injury or disease models (Aeschlimann & Knauper, 2016), 
supporting a key role for the enzyme in tissue repair processes. 
 
1.4.2 Protein structure and regulation of enzymatic activity  
 
Similar to other members of the TG family, TG2 is composed of four 
domains: 1 N-terminal β-sandwich, 1 catalytic core and 2 C-terminal β-barrel 
domains. The catalytic triad is formed by the residues cysteine (C277), 
histidine (H335) and aspartate (D358). The active site C277 is situated in the 
catalytic core, in a pocket formed by three α-helices and stabilized by two 
tryptophan residues (W241 and W332). The core domain is connected to N-
terminus of β-barrel 1 by a flexible loop (S. Liu et al., 2002; Pinkas et al., 
2007). 
Catalytic activity of TG2 is allosterically regulated by binding of 
calcium ions (Ca2+) or guanine nucleotides (GTP/GDP) (Achyuthan & 
Greenberg, 1987; Begg et al., 2006). Nucleotide binding lowers the affinity 
for Ca2+ and decreases the accessibility of glutaminase donor substrate to 
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the TG2 substrate-binding pocket by inciting TG2 to adopt a “closed” 
conformation (compact form), masking the active site and therefore inhibiting 
its transamidation activity (Fig. 1.3A) (Casadio et al., 1999; S. Liu et al., 
2002; Pinkas et al., 2007). The GTP-bound compact conformation of TG2 
can be changed by calcium concentrations of >0.2mM. Enzyme activation 
requires binding of at least three Ca2+ ions. Activated TG2 adopts an 
expanded ellipsoid structure, whereby the two C-terminal β-barrels rotate 
almost 180 ̊ into the plane of the core/β-sandwich domain of the enzyme, 
revealing its active site and allowing substrate access (Fig. 1.3B) (Pinkas et 
al. 2007). This unusual large conformational change could potentially expose 
self-epitopes normally not present within the tissue and drive immunological 
responses (Pinkas et al., 2007). In fact, the production of autoantibodies 
against TG2 has been detected in the context of coeliac disease (Dieterich et 
al., 1997).  
Binding of nucleotide or Ca2+ is mutually exclusive and hence guided 
by the respective affinity constants and local Ca2+/nucleotide concentrations. 
Since calcium concentration is normally lower inside the cell (<10µM) 
compared to the extracellular environment (1.5-2mM), cytosolic TG2 remains 
in a GTP-bound inactive conformation.  
Once secreted, TG2 binds Ca2+ and assembles immediately in the 
ECM or binds tightly to the cell surface (Lorand & Graham, 2003). However, 
the secretion mechanism of TG2 still needs to be fully elucidated. A recent 
study from our group shows that the externalization process is controlled by 
purinergic signalling, and more specifically P2X7 receptor (Adamczyk et al., 
2015). Some reports suggest that extracellular TG2 activity is short-lived as 
the enzyme undergoes oxidative inactivation (Stamnaes et al. 2010).  
TG2 is the only member of the transglutaminase family for which clear 
evidence exists that it also functions as a signal transducing G protein, i.e. in 
hormone receptor signalling (Lesort et al. 2000). Its GTPase activity is linked 
to regulation of transmembrane signalling through cell surface receptors such 
as α1-adrenergic receptor or oxytocin receptor (Fesus & Piacentini, 2002). 
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Fig. 1.3 Crystal structures of GDP-bound and inhibitor-bound TG2. The N-terminal β-
sandwich is shown in blue (N), the catalytic domain (core) in green, and the C-terminal β-
barrels (β1 and β2) in yellow and red, respectively. (A) GDP-bound TG2. (B) TG2 inhibited 
with the active-site inhibitor Ac-P(DON)LPF-NH2 (adapted from Pinkas et al. 2007). 
 
The transamidating and GTPase activities of this protein are mutually 
exclusive: Ca2+ bound TG2 has no GTPase activity, whereas GTP-bound 
TG2 does not exhibit transamidase activity (Feng et al. 1999). 
As a transamidase, in addition to crosslinking proteins in a Ca2+ 
dependent manner, TG2 can modify proteins by amine incorporation and 
site-specific deamidation. In addition, when externalized from cells, it can 
non-covalently bind to integrins, fibronectin and other proteins of the 
extracellular matrix to modulate cell-matrix interactions (Fesus & Piacentini, 
2002; Stephens et al., 2004). 
A large number of substrates have been identified in intracellular 
compartments, including the cytosol, nucleus and mitochondria, as well as on 
the cell surface and in the extracellular matrix (Csosz et al., 2008). Hence, 
the enzyme can have a variety of functions dependent on the local context. 
 
 
 
GTP 
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1.4.3 TG2 in pathological processes  
 
The importance of studying the pleiotropic functions of 
transglutaminases emerged from the understanding that deficiency or 
aberrant activity of these enzymes has a major contribution to the 
pathophysiology of blood and skin disorders and in various inflammatory, 
autoimmune and degenerative diseases (Iismaa et al., 2009). 
Upregulation or aberrant activity of TG2 has been linked with a 
number of different diseases. The enzyme has been implicated in various 
pathological states including cancer, atherosclerosis, fibrosis, 
neurodegenerative disorders as Alzheimer’s, Parkinson’s and Huntington’s 
disease and various autoimmune conditions including diabetes (Lesort et al., 
2000; Porzio et al., 2007). The common factor being a role of TG2 in the 
altered inflammatory responses associated with these conditions. The most 
convincing evidence has been accumulated to suggest a major role of TG2 in 
coeliac disease (Dieterich et al., 1997). This will be discussed in detail in 
section 1.8.2.  
 
1.5 Transglutaminase 3 
 
Transglutaminase 3 (TG3), also known as epidermal 
transglutaminase, is an enzyme encoded by TGM3 on human chromosome 
20q11-12. TG3 is an unusual member of the TG family in that this protein is 
synthesized as an inactive ≈77kDa zymogen that is proteolytically activated 
by cathepsin-L to become an active 50/27kDa complex (Iismaa et al., 2009). 
The zymogen consists of four folded domains that share a common structure 
with other TGs. Activation of the zymogen requires cleavage at Ser469, 
located in a hinge region that separates the catalytic core and β-barrel 1 
domains. The resulting 50/27kDa fragments remain associated together in 
the active enzyme (Ahvazi et al. 2002). 
The crystal structure of TG3 has been solved in the presence of Ca2+ 
(Ahvazi et al., 2002). The acquired data revealed that the presence of 3 
Ca2+ions is required for enzyme activity (Fig. 1.4). The first Ca2+-binding site 
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seems to be constantly occupied and this Ca2+ ion cannot be removed 
without protein denaturation. Although this binding site is crucial for TG3 
activity it is not sufficient. The remaining two Ca2+-binding sites are unsealed 
by cleavage of the zymogen. Occupation of the second Ca2+ binding site 
prompts a small structural change, however, it is the binding of the third Ca2+ 
ion that mediates the crucial conformational change and full enzyme 
activation. This allows for exposure of residues Trp236 and Trp327, involved 
in stabilization of TGs active site.  
 
 
Fig. 1.4 Structural comparison of TG3 zymogen and active form. The electrostatic 
surface potential maps are shown in the centre. The acidic regions are coloured red and the 
basic regions in blue. Calcium ions are shown as yellow spheres. The arrow indicates a 
channel that opens after binding of a Ca2+ in site 3. On the left and right are secondary 
structure images of the zymogen and activated TG3 in the same orientations (retrieved from 
Ahvazi et al. 2003). 
 
Similarly to TG2, TG3 has been reported to interact with guanine 
nucleotides (Ahvazi et al., 2004). TG3-GTP binding is associated with 
substitution of Ca2+ with Mg2+ at the third calcium-binding site. This binding 
causes a conformation change that culminates in enzyme inactivation 
through closing of the active site channel. Subsequent hydrolysis of the 
bound GTP and nucleotide dissociation results in a reversion of the enzyme 
to the active state. Calcium-activated TG3 is inhibited by GTP at low µM 
concentrations. 
TG3 functions involve the cross-linking of trichohyalin and keratin 
intermediate filaments to harden the inner root sheath, which is critical for 
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hair fibre morphogenesis and the assembly of the cornified envelope of the 
stratum corneum in terminally differentiated keratinocytes (Beninati & 
Piacentini, 2004). It is also known that TG3 knockout mice display no obvious 
defect in skin development, and no evident changes in barrier function or 
ability to heal wounds, as TG3 is compensated-for by other TG family 
members. On the other hand TG3-/- mice present thinner hair with major 
alterations in the cuticle cells and hair protein cross-linking markedly 
decreased, suggesting that without TG3 expression, the hair cuticular cells 
are directly compromised (John et al., 2012). 
TG3 has been implicated in the gluten-sensitivity related disorder 
Dermatitis Herpetiformis (Sárdy et al., 2002; Stamnaes et al., 2010) and this 
will be covered in section 1.8.3. 
 
1.6 Transglutaminase 6 
 
Transglutaminase 6 (TG6) is an enzyme encoded by the TGM6 gene 
on human chromosome 20q11, located in the same gene cluster with TGM3 
and in close proximity to TGM2 (Grenard et al. 2001).  TG6 has a molecular 
mass of ≈79kDa. Not much is yet known about this protein. Its close 
relationship with TG2 led to speculation that they could have comparable 
properties, in terms of activities and regulation by Ca2+ ions and nucleotides 
Fig. 1.5 (H. Thomas et al., 2013). 
TG6 is widely expressed in murine brain tissue such as cerebral 
cortex, olfactory lobe, cerebellum and also the spinal cord (H. Thomas et al., 
2013). The expression pattern during central nervous system (CNS) 
development in the cortical plate suggests its involvement in neuronal 
differentiation (H. Thomas et al., 2013). A comprehensive study of TG6 in the 
central nervous system of adult mice showed robust expression of this 
enzyme in brain regions involved in locomotive control. In the cerebellum, 
neurons expressing TG6 were present in both the cerebellar cortex and 
nuclei. TG6 is also expressed in Purkinje cells, which are the only neurons 
responsible for sending output from the cortex (Liu et al., 2013).  
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The physiological role of TG6 at the molecular level in the CNS 
remains to be elucidated. However, TGM6 has been reported to be the 
causative gene for a form of spinocerebellar ataxia (SCA 35) (Wang et al., 
2010), and TG6 importance has been highlighted by the original identification 
of its involvement in autoimmune ataxia (Hadjivassiliou et al., 2008).  
  
 
Fig. 1.5 Model of the structure of full-length human TG6. The overall structure modelled 
based on the calcium activated TG3 structure. Cylinders and arrows denote α-helical and β-
strand conformations, respectively. The four domains (β sandwich, catalytic core, β-barrel 1, 
β-barrel 2) are depicted in different colours. The position of three bound calcium ions is 
shown by yellow spheres (retrieved from Thomas et al. 2013). 
  
TG6 has specifically been implicated in gluten ataxia pathophysiology 
(Hadjivassiliou et al. 2008). This topic is going to be discussed in detail 
below.  
 
1.7 Gluten 
 
The development of agriculture about 10,000 years ago led to major 
changes in the composition of human diet. One of those changes was the 
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introduction of gluten-containing cereal such as wheat, barley and rye, as a 
major component of daily food intake. These form the basis of a variety of 
flour and other cereal-based food products consumed throughout the world 
(Anna Sapone et al., 2011). The introduction of these cereals in human diet 
created the conditions for the advent of human diseases related to gluten 
exposure.  
Gluten was one of the initial protein fractions described by chemists, 
being described for the first time by Beccari in 1728 (see translation by Bailey 
1941).  
Gluten is the main structural protein complex formed by the prolamins 
gliadin and glutenin and is present in the starchy endosperm cells of wheat 
grain (Shewry et al. 2002). Gliadin is an alcohol-soluble monomeric 
component with a molecular weight between 30 and 60kDa. Glutenin is a 
large alcohol-insoluble complex stabilized by disulphide and noncovalent 
bonds (Rubin et al. 1992). 
These proteins are rich in the amino acids proline (~15%) and 
glutamine (~35%), which give them distinctive features that contribute to their 
immunogenic properties. The high proline content makes gluten resistant to 
proteolytic degradation within the gastrointestinal tract, as the human body 
lacks gastric and pancreatic enzymes with post-proline cleaving activity. The 
high glutamine content makes gluten a good substrate for TG2 (Stepniak & 
Koning, 2006). As a result, immunogenic/immunotoxic peptides accumulate 
and are transported by retrotranscytosis across the intestinal epithelium 
where they initiate a detrimental adaptive and innate immune response in 
genetically susceptible individuals (Iismaa et al., 2009). 
 
1.8 Gluten-related disorders  
 
Gluten-related disorders (GRD), which affect 1-2% of the general 
population, are a group of immune-mediated diseases with diverse 
manifestations, caused by dietary exposure to wheat gluten, or related 
protein from barley and rye. As wheat is an ingredient used in many food 
products, exposure to relatively large amounts of gluten starts very early in 
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life. Gluten is introduced into the diet as early as 6 months of age, with a 
child of 12 months typically eating between 6 and 9 g of gluten daily (Koning 
et al. 2005). 
Symptoms of gluten-related disorders usually disappear with a gluten-
free diet (GFD) and reoccur with gluten ingestion. The best known GRD is 
coeliac disease (CD), however there are others that may not involve 
gastrointestinal manifestations, such as gluten ataxia and dermatitis 
herpetiformis (Iismaa et al., 2009) 
 
1.8.1 Wheat allergy 
 
Wheat allergy (WA) is a type I hypersensitivity immunologic reaction to 
wheat proteins. It occurs in individuals previously sensitized to the allergen 
gluten (A. Sapone et al., 2012). 
IgE antibodies have a strong predisposition to bind to mast cells and 
basophils, which possess high-affinity receptors for the Fc-portion of IgE. 
When a mast cell or a basophile containing cytophilic IgE antibodies is re-
exposed to gluten, a multivalent binding of the antigen to more than one IgE 
molecule causes the cross-linkage of adjacent IgE antibodies. This leads to 
the aggregation of the cytoplasmic portion of the IgE Fc-receptor complexes 
and consequently, activation of signal transduction pathways (Cotran et al. 
1999). This triggers a release of primary and secondary mediators, such as 
histamine or pro-inflammatory cytokines and will lead to the typical symptoms 
of an acute allergic reaction. IgE mediated allergy to wheat may be 
presented with various severity from simple urticaria to anaphylaxis (Lee et 
al., 2013) 
Wheat allergy is common among bakers and is commonly known as 
Baker’s Asthma. It affects 4% to 10% of bakery workers in European 
countries as they are constantly exposed to this allergen, present in wheat, 
rye and soybean flour. Symptoms among this group are usually asthma and 
allergic rhinitis (Sander et al., 2011). 
 
 
 16 
1.8.2 Coeliac disease 
 
Coeliac disease (CD), also known as gluten sensitive enteropathy, is 
one of the most common gluten-related disorders, and affects approximately 
1% of the general population. CD is a type IV hypersensitivity, initiated by the 
ingestion of gluten and related proteins, and is characterized by an increased 
permeability in the small intestine, allowing for enhanced passage of 
antigens and the activation of an innate and adaptive immune responses, in 
susceptible individuals (Koning et al., 2005). Typical symptoms include 
chronic diarrhoea, fatigue and weight loss, associated with a lesion in the 
upper small intestine, characterized by villous atrophy, crypt hyperplasia, 
increased number of intraepithelial lymphocytes and a chronic inflammatory 
response driven by the lamina propria lymphocytes. These symptoms usually 
disappear when the patient starts a gluten-free diet (GFD), as the CD4+ T cell 
response driving the disease process is gluten-dependent. When there is no 
response to a GFD, a condition called refractory coeliac disease (RCD) may 
have been developed (Hadjivassiliou et al., 2010). 
RCD should be considered when all other causes for failure to 
improve on a gluten-free diet have been excluded. It is defined as having the 
classical symptoms and small intestinal inflammation that persist after one 
year on a strict GFD. Histological findings consist of raised intraepithelial 
lymphocytes and crypt hyperplasia, with progression of the inflammation to 
villous atrophy. Symptoms of RCD are similar to the ones observed in CD: 
diarrhoea, malabsorption and weight loss as well as vitamin and mineral 
deficiencies (Ludvigsson et al., 2012). RCD is divided into two types, based 
on special studies of flow cytometric analysis of lymphocytes performed on 
small intestinal biopsies (Semrad, 2008). Type I is characterized by a normal 
T-cell population spread along the intestinal lining, usually with good 
response to treatment with steroids or azathioprine and a good prognosis. 
Type II presents with abnormal T-cell population spread along the intestinal 
lining. It has a poor response to steroid treatment, often requiring intravenous 
nutrition. Individuals with Type II RCD have a high risk of developing T-cell 
lymphoma. 
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1.8.2.1 The genetics of coeliac disease 
 
CD is an autoimmune disease that has genetic, environmental and 
immunological components (Vader et al., 2002). A high prevalence among 
first-degree relatives of CD patients indicates that the susceptibility to 
develop CD is strongly influenced by inherited factors. The genetic influence 
in CD is also supported by a high concordance rate (75%) in monozygotic 
twins (Koning et al., 2005). 
It is known that CD, as well as other GRD, is strongly associated with 
specific human leukocyte antigen (HLA) genes. About 95% of CD patients 
are positive for HLA-DQ2.5 (DQA1*05,DQB1*02) encoded in cis or trans with 
the remaining 5% carrying HLA-DQ8 (DQA1*03,DQB1*0302) (Fig. 1.6) 
(Sapone et al., 2012; Sollid & Jabri, 2011). Individuals that carry these genes 
have a relative risk of disease development increased by 30-fold when 
compared to HLA-association seen in many other auto-immune diseases 
such as type I diabetes or rheumatoid arthritis (Koning et al., 2005). 
 
 
 
Fig. 1.6 HLA gene association in coeliac disease. The majority of CD patients express 
the HLA-DQ2 heterodimer encoded by DQA1*05 and DQB1*02 genes, either in cis (top row) 
or trans (bottom row). The remaining patients that are DQ2-negative express DQ8 encoded 
on the DR4-DQ8 haplotype (retrieved from Qiao et al. 2009). 
 
Alleles 
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In CD, HLA of a specific type is an indispensable, but not sufficient 
factor for disease development, and most individuals who express these 
genes will never develop CD (Sollid & Jabri, 2011). HLA-genes contribute 
about 40% of genetic load but other genes are involved in the pathology of 
the disease. The involvement of non-HLA genes in CD is yet to be 
understood. About 40 other genes have been shown to confer a small 
amount of risk each, but these are not shown among CD patients and 
therefore this does not explain disease heritability (Mistry et al., 2015).  
Although HLA genes are specific for CD, non-HLA genes contribute 
more to the genetic background of CD than HLA genes. Each non-HLA gene 
adds only a modest contribution to disease development (Sollid, 2002). Risk 
variants for CD have been found in the 4q27 region 
harbouring IL2 and IL21 genes (van Heel et al., 2007). IL-2 is a cytokine 
secreted by antigen-stimulated T-cells and is involved in T-cell activation and 
proliferation. IL-21, another T-cell derived cytokine, enhances B-cell, T-cell, 
and natural killer cell proliferation and IFN-γ production. They are both 
implicated in the mechanism of other autoimmune diseases, such as type 1 
diabetes and rheumatoid arthritis, suggesting that this region can represent a 
general autoimmune disease risk locus (Catassi & Fasano, 2008). 
The region that has been linked most consistently to CD is on the long 
arm of chromosome 5 (5q31–33) (Greco et al., 2001). This region is rich in 
possible candidates for susceptibility genes, including the Th2 cytokine 
cluster, which is related to Crohn’s disease, the lipopolysaccharide receptor 
gene CD14; Tmp1, which controls interleukin-12 (IL-12) responsiveness, 
IL12B, which is implicated in type-1 diabetes and Tim, which is implicated in 
asthma (Sollid, 2002). In fact, most of the genes now implicated in CD 
identified by the Genome Wide Association Studies have a role in modulating 
the immune response (Mistry et al., 2015). 
 
1.8.2.2 Pathomechanisms of coeliac disease 
 
For most dietary proteins, it is true that they are broken down into 
small, non-immunogenic fragments by proteases in the intestinal lumen. 
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However, the gluten protein gliadin is highly resistant to luminal and 
brush-border proteolysis, and large fragments remain intact after digestion, 
such as the 33mer peptide derived from α-gliadin that is the major T-cell 
epitope in CD (Stamnaes et al., 2010). This is due to its high content of 
proline residues.  
The physiological role of the HLA-system is to present peptide 
fragments of antigens to T-cells. HLA-DQ2 and HLA-DQ8 molecules could 
confer susceptibility to CD by presenting gluten peptides to specific CD4+ T 
cells in the intestinal mucosa. In fact, Halstensen and colleagues reported 
that in vitro stimulation of small-intestine biopsies with gluten results in the 
activation of CD4+ lamina-propria T cells in biopsies of treated individuals 
who have coeliac disease, but not in controls (Halstensen et al. 1993). 
Both HLA molecules have a preference for peptides with negatively 
charged amino acids at multiple anchor positions. However, the negatively 
charged anchor residues are differentially located along the binding grooves 
of the two MHC molecules (Fig. 1.7). HLA-DQ2.5 favours negatively charged 
residues at positions P4, P6 and P7 (Johansen et al. 1996) whereas DQ8 
prefers negatively charged residues at positions P1 and P9 (Godkin et al., 
1997). Hence, different peptides are immunodominant epitopes in individuals 
carrying the respective HLA’s.  
This binding is highly specific and it is the ability to form stable 
peptide-MHC complexes that appears to be a key factor for the in vivo 
generation of T-cell responses and development of coeliac disease (Sollid & 
Jabri, 2011). 
Interestingly, gluten proteins normally contain few negatively charged 
residues. Reports that coeliac derived T-cells primarily recognize deamidated 
gluten peptides, brought TG2 into the context of the disease (Sjöström et al., 
1998). TG2 is known to catalyse a deamidation reaction in the absence of a 
second donor substrate. It has also been reported that the ratio of 
deamidation to transamidation, in the presence of primary amines, is 
markedly increased at a pH below 7.3 (Fleckenstein et al., 2002). With 
duodenum pH being ≈6 (Fallingborg, 1999) it is possible that deamidation of 
gluten peptides in the gut is mediated by TG2. Furthermore, TG2 expression 
 20 
was also shown to be increased in active coeliac disease, which may lead to 
enhanced deamidation of gluten peptides (Molberg et al., 1998).  
As mentioned, gluten peptides are ingested as part of a normal diet 
and survive small bowel digestion because of their high content of proline 
and glutamine residues. This also makes gluten peptides preferable targets 
for TG2. 
Gluten peptide deamidation by TG2 is highly sequence context 
specific. The glutamine residue (Q) is not a target of the enzyme in the 
sequences QP and QXXP but can be modified in the sequence QXP (Vader 
et al., 2002). Selective modification of glutamine by TG2 can result in the 
generation of a large repertoire of gluten peptides that can bind to HLA-DQ2 
or HLA-DQ8 and stimulate T cells in the intestine of CD patients. In fact, the 
sequence specificity of TG2 is reflected in the bias of T-cell epitopes that 
have been linked to coeliac disease (Stamnaes et al., 2010).   
 
 
Fig. 1.7 Peptide binding signatures of DQ2 and DQ8 molecules. The DQ2 and DQ8 
epitopes recognized by lesion derived T cells of CD patients share the same 9 amino acid 
core sequence. This sequence contains three glutamate residues formed by TG2-mediated 
deamidation in positions P1, P4 and P9. DQ2 prefers negatively charged glutamate residue 
in P4 whereas DQ8 prefers glutamate in P1 and P9 (adapted from Qiao et al. 2009). 
  
 The hallmark of coeliac disease is the presence of antibodies reactive 
to TG2 (autoantigen) in addition to antibodies reactive to gluten (Dieterich et 
al., 1997). Both anti-TG2 and anti-gluten antibodies disappear once coeliac 
patients commence a strict gluten-free diet and reappear upon gluten 
challenge. Hence, production of autoantibodies is gluten driven. 
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Antibodies are produced by plasma cells, which differentiate from B 
cells after recognition of antigen by the B-cell receptor (BCR). On average, 
10% of plasma cells in the coeliac lesion are specific for TG2 (Roberto Di 
Niro et al., 2012). Such a response to a single target is highly unusual. 
However, the mechanism by which production of antibodies against the self-
protein TG2, in response to exposure to a foreign antigen still remains to be 
elucidated. It has been proposed that production of TG2 reactive antibodies 
is related to T-cell help to TG2-specific B cells by gluten-specific T cells (Fig. 
1.8) (Sollid et al. 1997).  
It is possible that TG2 forms stable complexes with gluten peptides, 
either through crosslinking or as a reaction intermediate (Stamnaes et al., 
2010). These complexes could be bound by surface immunoglobulins on 
TG2-specific B cells and subsequently internalized. Deamidated gluten 
peptides could then be presented in the context of HLA-DQ2 or HLA-DQ8 to 
gluten-reactive T-cells. T-cells would then become activated, and TG2-
specific B-cells could receive cognate help from gluten-specific T cells, 
leading to production of anti-TG2 antibodies. The interaction between T cells 
and B cells not only gives rise to antibodies, but also amplifies the anti-gluten 
T-cell response. It has been shown that monoclonal anti-TG2 antibodies 
recognize the N-terminal part of the enzyme. (Stamnaes et al. 2015). As 
lysine residues of TG2 involved in isopeptide bonds are mainly present in the 
C-terminal part of TG2, the N-terminal part of the enzyme is free to bind to 
TG2-reactive antibodies. Furthermore, there is evidence that complexes of 
gluten-TG2 can be bound by TG2-specific BCRs, internalized and 
processed, thereby releasing the covalently linked gluten T- cell epitopes for 
MHC class II presentation to T cells (Roberto Di Niro et al., 2012; Jorunn 
Stamnaes et al., 2015). However, evidence that these events take place in 
vivo is still lacking. 
TG2-gluten peptide complexes may also activate DQ2 or DQ8 
restricted T-helper cells that proliferate and produce mainly Th1-type 
cytokines, such as interferon-gamma (IFN-γ). The secretion of IFN-γ 
activates the release of enzymes that can damage the intestinal mucosa, 
with a loss of villous structure. Th1 cytokines will in turn lead to higher 
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expression of the HLA-DQ molecules and also TG2 and thereby, an increase 
in gluten peptide presentation, creating a chronic feedback loop driving the 
inflammatory process as long as gluten is introduced in the diet (Tjon et al. 
2010).  
When interacting with epithelial cells, macrophages and dendritic cells 
in the lamina propria, toxic gluten peptides provoke an innate immune 
response, up-regulating the expression of different mediators such as 
interleukin 15 (IL-15). This leads to a massive increase of intraepithelial 
lymphocytes and is ultimately responsible for the damage of the mucosal 
matrix (Ferretti et al. 2012; Shewry 2009). This later response is primarily 
responsible for villous destruction and hence generation of the flat mucosa, 
the hallmark of CD. 
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Fig. 1.8 Antibody production in the context of coeliac disease. Gluten-reactive CD4+ T 
cells provide help to both TG2-reactive B-cells and (deamidated) gluten-reactive B-cells. 
TG2 forms stable complexes with gluten peptides. TG2-gluten complexes are internalized by 
TG2-reactive B-cells through BCR-mediated endocytosis. After internalization, (deamidated) 
gluten peptides in addition to TG2 derived peptides can be presented following breakdown of 
the complexes. Deamidated peptides can bind to MHC-II (HLA-DQ2 or HLA-DQ8) and be 
presented to T cells. Thereby, gluten-reactive T-cells provide help to TG2-reactive B-cells for 
subsequent production of antibodies against the self-protein. Interaction of gluten-reactive 
T-cells with gluten-reactive B-cell leads to production of antibodies against (deamidated) 
gluten peptides. (Adapted from Du Pre 2015) 
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1.8.2.3 Diagnosis and treatment 
 
Diagnosis of CD cases by screening of the population is an important 
objective, since early institution of a GFD may prevent long-term sequels, 
such as osteoporosis, CNS disease, secondary autoimmunity, or even 
malignancy. A firm diagnosis of CD can only be established after a 
representative small intestinal biopsy, revealing a flat jejunal mucosa with 
absence of normal intestinal villi (Fig. 1.9). 
 
 
Fig. 1.9 Normal and coeliac-disease small-intestine mucosa. A - Histology of a normal 
small intestine showing villi (V) and crypts (C). B - The coeliac mucosa is characterized by 
villous atrophy, enlarged hyperplastic crypts and increased infiltration of lymphoid cells in the 
lamina propria (LP) and epithelium (adapted from Sollid 2002). 
 
Histological examination further demonstrates a cellular infiltration of 
the lamina propria by plasma cells and lymphocytes. Small intestinal 
changes can vary from a nearly normal mucosa with increased intra-
epithelial lymphocytes to a completely flat mucosa, depending on the stage 
of disease and amount of gluten consumption (Catassi & Fasano, 2008). 
The diagnosis of CD should not depend only on intestinal biopsy, but 
also on the clinical features, genetic profile and serology of the patient. The 
availability of highly accurate serologic tests, developed after identification of 
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TG2 as the autoantigen in CD, greatly facilitates the diagnosis of this 
disease. Most patients were initially tested for conventional IgA and IgG anti-
gliadin (AGA) antibodies and IgA anti-endomysium antibodies (EMA). Anti-
gliadin antibodies are not disease-specific and are frequently found in the 
normal population. With the identification of TG2 as the target CD 
autoantigen recognised by EMA, the development of easy to perform and 
observer-independent ELISA tests has also become possible (Koning et al., 
2005). 
CD-specific antibodies comprise auto-antibodies against TG2, 
including endomysial antibodies (EMA), and antibodies against deamidated 
forms of gliadin peptides (DGP). A test for CD-specific antibodies is the first 
tool that is used to identify individuals for further investigation to diagnose or 
to rule out CD. 
It is now recommended that the initial test be IgA class anti-TG2 from 
a blood sample. If total serum IgA is not known, then this also should be 
measured. In subjects with either primary or secondary humoral IgA 
deficiency, at least 1 additional test measuring IgG class CD-specific 
antibodies should be done (IgG anti-TG2, IgG anti-DGP or IgG EMA, or 
blended kits for both IgA and IgG antibodies) (Husby et al., 2012). 
Tests measuring antibodies against DGP may be used as additional 
tests in patients who are negative for other CD-specific antibodies but in 
whom clinical symptoms raise a strong suspicion of CD. Tests for the 
detection of IgG or IgA antibodies against native gliadin peptides 
(conventional gliadin antibody test) should not be used for CD, as they lack 
specificity (Husby et al., 2012). 
Currently there is no known cure for CD. However, most of the 
patients show substantial improvement when subjected to a GFD, and can 
live a relatively normal, symptom-free life. 
 
1.8.3 Dermatitis herpetiformis  
 
Dermatitis herpetiformis (DH) is an autoimmune disease that was first 
described by Louis Duhring in 1884 (Duhring, 1884). It may be present at any 
 26 
age but generally begins between the ages of 15-40. Its prevalence is 
thought to be about 1/10,000 in the UK (Fry, 1995). 
DH presents with skin pruritic polymorphic lesions mainly distributed in 
typical areas such elbows, forearms, buttocks, knees and scalp (Bolotin & 
Petronic-Rosic, 2011a). Histologically, the disease is characterized by 
subepidermal blistering and accumulation of neutrophils at the dermal 
papillae, while the most common immunological finding consists of granular 
IgA deposits along the basement membrane, mainly localized in the dermal 
papillae (Bolotin & Petronic-Rosic, 2011b).  
Patients with DH produce two IgA antibody populations against TG3. 
The first binds TG3 exclusively, whereas the second cross-reacts between 
TG3 and TG2. However, only TG3 seems to colocalize with skin IgA deposits 
found in DH patients, suggesting that TG3 rather than TG2 is the primary 
autoantigen in this disease (Sárdy et al. 2002). A more recent study, further 
demonstrates that detection of IgA antibodies against TG3 is a highly 
sensitive test for the primary diagnosis of DH (Rose et al., 2009).  
DH is a multifactorial disease and its pathogenesis involves 
environmental, genetic and autoimmune factors. Genetically, patients 
presenting with DH show the same high prevalence of HLA-DQ2 and DQ8 
haplotypes as CD (Spurkland et al., 1997).  
A potential explanation for the pathological mechanism of DH is that in 
susceptible individuals the development of skin lesions is related to an active 
chronic bowel inflammation as a result of persistent gluten consumption 
(Bonciani et al., 2012). This initially leads to a local immune response and 
the production of mucosal IgA in the bowel. Circulating IgA (anti-TG3) binds 
to the skin. The immune response in the small intestine results in increased 
levels of circulating cytokines, which may partially activate neutrophils as well 
as T-cells and endothelial cells. Exposure to UVB light and microtrauma to 
the skin increase local cytokines production, leading to the release of 
neutrophils, deposition of IgA at the dermo-epidermal junction, and thus to 
the development of DH skin lesions (Bonciani et al., 2012). A mouse model 
has indeed shown that circulation derived antibodies can recapitulate the 
blistering condition in transplanted skin (Zone et al., 2011). 
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Similar to CD, DH symptoms usually disappear once the patient starts 
a gluten-free diet.  
 
1.8.4 Gluten Ataxia 
 
Neurological disorders have only recently been recognised as 
potential presenting manifestations of coeliac disease. They have been 
reported to occur with a frequency of up to 10% in coeliac disease patients 
(Lagerqvist et al. 2001). Gluten ataxia (GA) is one of the most common 
neurological manifestations in the context of gluten-sensitivity, with a 
prevalence of about 35% (Hadjivassiliou et al., 1998) 
The presence of an enteropathy in gluten-related neurological 
disorders is not a requirement. In fact, the majority of patients with GA do not 
have overt gastrointestinal symptoms and only a third of patients with GA will 
have evidence of enteropathy on biopsy. (Hadjivassiliou, 2003) 
GA is the most common and potentially treatable type of cerebellar 
ataxia. It usually presents as pure cerebellar ataxia, with gaze-evoked 
nystagmus and other ocular signs of cerebellar dysfunction also commonly 
observed (Hadjivassiliou et al., 2010). The majority of GA patients express 
the HLA-DQ2 or DQ8 genes (Hadjivassiliou, 2003) 
Just like TG2 in a CD intestine and TG3 in a DH skin, TG6 was 
discovered to be the primary autoantigen in the CNS in GA (Hadjivassiliou et 
al., 2008, 2013). TG6 shares genetic, structural and enzymatic properties 
with TG2 and TG3. In fact, it has been shown that TG6 can catalyse the 
reactions that drive T and B cells responses (Stamnaes et al., 2010). 
TG6 is a transglutaminase primarily expressed in neural tissue (H. 
Thomas et al., 2013). Furthermore, extensive deposition of TG6 has been 
found to colocalize with perivascular IgA deposits around brain vessels in 
post-mortem examination of a GA patient, suggesting that deposition of 
characteristic antibody complexes could involve targeting of TG6 
(Hadjivassiliou et al., 2008). It is also known that patients with GA have an 
immunological response (autoantibodies) primarily directed against TG6 
even in the absence of enteropathy (Hadjivassiliou et al., 2008). 
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Furthermore, this disease may also be associated with antibody cross-
reactivity between antigenic epitopes on Purkinje cells and gluten proteins 
(Hadjivassiliou et al., 2010). 
The observed IgA deposits indicate that vasculature-centred 
inflammation may compromise the blood-brain barrier, allowing persistent 
exposure of the CNS to the gluten-related pathogenic antibodies, and 
therefore, may be the trigger of nervous system involvement (Hadjivassiliou 
et al. 2008). Evidence supporting that such antibodies may potentially be 
pathogenic comes from experiments in mice. Boscolo and colleagues 
demonstrated that sera from a patient suffering from a gluten-related 
disorder, contain antibodies capable of causing ataxia when transferred into 
the central nervous system of mice (Boscolo et al., 2007, 2010). As 
recombinant TG-specific scFv ‘antibodies’ that lack the Fc region lead to a 
loss of motor function, this implicated an scFv-antigen interaction rather than 
Fc receptor-triggered immune response in the disease process. The risk of 
developing neuronal damage could also be related, at least in part, to the 
presence of anti-TG2 antibodies in the cerebrospinal fluid. Indeed, in some 
GA patients, intrathecal anti-TG2 antibody production has been detected 
(Boscolo et al., 2007). Even though anti-TG2 antibodies are able to cause 
dramatic effects in mice, they are not sufficient to explain the diverse 
neurological conditions associated with gluten sensitivity, and why only a 
fraction of CD patients are affected. In line with this, results obtained using 
serum from a GA patient suggest the presence of additional anti-neural 
antibodies that may be involved in ataxia, as this patient had no circulating 
anti-TG2 antibodies (Boscolo et al., 2007). This neural reactivity has been 
linked to the presence of antibodies reacting with TG6 (Boscolo et al., 2010).  
One of the critical differences between GA and CD/DH is that, even 
though GA patients also seem to respond to a GFD (Hadjivassiliou et al. 
2003), the brain has a limited potential to regenerate, unlike the skin and the 
gastrointestinal epithelium. Thus, the degree of permanent functional deficit 
will depend on the amount of Purkinje cell loss sustained by the cerebellum 
by the time gluten is eliminated form the diet (Hadjivassiliou et al. 2003). An 
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early identification of these patients is therefore essential, as they will suffer 
from irreversible damage to the neural tissue. 
 
1.9 The aims of the project 
 
The variation in manifestation of gluten-related disorders indicates that 
the immune system reacts to gliadin in different ways. This could be due to 
the genetic background in the individuals affected. Of all the GRD, CD is the 
only one with a clear understanding of the pathological mechanism. 
However, it is also crucial to improve the understanding of the 
pathophysiology of extraintestinal disease including DH and GA in order to 
develop appropriate diagnostic protocols and potential strategies for therapy 
beyond GFD.  
In this project, I aim to develop a mechanistic understanding of 
autoantibody development and extraintestinal disease manifestations.  
Within this context, I intend to answer the following main question: 
Does autoantibody development to TG6 occur in conjunction with that to 
TG2, i.e. in the gut, or does it have its origin in independent events? 
Answering this question would widen our understanding of the 
pathomechanisms involved in gluten ataxia and could later be used in the 
development of novel therapies in the disease context.  
 
Therefore, the following topics formed the basis for the research I 
have undertaken: 
1. Are TG6-specific plasma cells developed at the level of the gut 
in GRD patients? 
2. Investigate whether B-cells specific for TG6 and TG2 are 
present in the gut of all patients with GRD or restricted to 
patients with distinct manifestations, such as GA. 
3. Identify what cells in the gut express TG6, i.e. is a specific 
subset of macrophages the source of TG6. 
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Chapter 2 Materials and Methods  
 
2.1 Protein concentration determination  
 
Protein concentration was derived from the absorbance reading at 
280nm through spectrophotometric analysis (Beckman Coulter, DU 800), 
using the Beer-Lambert Law c=absorbance/(ε·d), where ε is the theoretical 
extinction coefficient of a specific protein (calculated using ProtParam 
software from ExPASy Bioinformatics Resource Portal) (Table 2.1) and 
d=cuvette diameter (d=1cm). 
 
Table 2.1 Theoretical extinction coefficient used for calculation of protein 
concentration. 
Protein Theoretical extinction coefficient (ε) at Abs 0.1% 
rhTG2 1.35cm2/g 
rhTG6 1.45 cm2/g 
Hemocyanin 1.39 cm2/g 
 
 
2.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Denaturing SDS-PAGE was performed using Novex 4-20% Tris-
glycine polyacrylamide gels supplied by Invitrogen. Protein samples were 
mixed with an equal volume of 2x sample loading buffer comprised of 25mM 
Tris/HCl, pH 6.8, 39mM EDTA, 4% (w/v) SDS, 30% (v/v) glycerol, 0.3% (w/v) 
bromophenol blue and 2% (v/v) β-mercaptoethanol. Samples were boiled for 
2min at 98°C and a specific amount of protein was loaded per lane along 
side a molecular weight standard - 30µg of Amersham Low Molecular Weight 
Marker (GE Healthcare). Electrophoresis was performed at a constant 
voltage of 125V/cm2 and ∼35mA for 2h. Running buffer was composed of 
25mM Tris/HCl, pH 8.8, 192mM glycine and 0.1% w/v SDS.  
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2.3 Coomassie blue staining 
 
Coomassie blue staining solution was prepared by adding 3g/L of 
Coomassie blue R-250 powder to a solution containing 10% v/v glacial acetic 
acid, 40% dH2O and 50% (v/v) methanol. When described, SDS and Native 
gels were stained overnight with gentle agitation. Excess staining was 
removed by serial washes with a solution of 25% isopropanol and 10% acetic 
acid in dH2O followed by serial washes with a solution of 10% isopropanol 
and 10% acetic acid in dH2O.  
 
2.4 Real-time fluorescence assay for determining transglutaminase 
isopeptidase activity 
 
Transglutaminase enzymatic activity was determined by a real-time 
fluorescent assay previously developed by our group and described by 
Adamczyk et al., 2013. TG isopeptidase activity was quantified by measuring 
changes in fluorescent levels over time, resulting from the hydrolysis of an 
isopeptide bond of a quenched fluorescent probe, Abz-APE(γ-cad-Dnp)QEA 
λ max=418nm (A102; Zedira, Darmstadt, Germany). Reaction kinetics were 
captured at 37°C in black optical bottom 96-well plates (165305, Nunc) using 
a FLUOstar Optima or OMEGA plate reader (BMG LABTECH). The reaction 
was carried out in 100µl of assay buffer containing 50mM Tris/HCl, pH 7.5, 
10mM glycine methylester, 100mM NaCl, 50µM Abz-APE(γ-cad-Dnp)QEA, 
5mM DTT, and indicated concentration of TG2. For determining TG6 
isopeptidase activity, glycine methylester and NaCl concentrations were 
raised to 50mM and 300mM, respectively. The pH adjustment to 7.5 was 
carried at 37°C.  
Well-specific fluorescence was measured during 400s (10x 40s) and 
cleavage of the quenched substrate was triggered by automated injection of 
Ca2+ (2 or 10mM) at cycle 10. For control samples, 10µl of H2O were injected 
instead of Ca2+. Using a plate-mode protocol, fluorescence was measured 
using the 320ex nm excitation filter and the 440nm emission filter (top optics, 
gain set to 2450). Substrate conversion was measured for a 1h period and 
 32 
fluorescent acquired every 40s (a total of 90 cycles). Well-specific 
fluorescence of the first 8 cycles was averaged and subtracted from the 
curves obtained after Ca2+-injection. Control curves (no Ca2+ injection) were 
subtracted from the data to account for fluorescence bleaching and the final 
data was fitted using linear regression. 
 
2.5 Statistical analysis  
 
Data were analyzed using the GraphPad Prism® software version 
7.0b or the IBM SPSS statistical software. The data presented corresponds 
to the mean ± standard deviation (SD). For contingency tables the χ2 test 
was conducted. A p value of ≤0.05 was considered as significant. 
 
2.6 Expression and purification of rhTG2 
 
Recombinant human TG2 (rhTG2) was successfully expressed and 
purified using a modified protocol based on the methodology described by 
Hadjivassiliou et al, 2008.  Escherichia coli BL21 was transformed with 
constructs containing native TG2 sequence with an added His6-tag to the N-
terminus that were already available within the group. E.coli transformed with 
the expression constructs was streaked onto Luria–Bertani-Agar (LB-Agar) 
plates containing 50µg/ml of ampicillin and grown overnight at 37°C. A single 
colony was selected and grown in baffled Erlenmeyer flasks, with LB broth 
containing 50µg/ml of ampicillin and incubated at 200rpm, 37°C to an optical 
density of 0.6 at 600nm. When the required optical density was reached, 
TG2 expression was induced by adding L-Rhamnose to a final concentration 
of 0.5% w/v. The suspension was incubated for 24h at 150rpm at 20°C. 
Bacteria were collected by centrifugation at 12128x g for 30min, at 4°C in a 
Sorvall centrifuge. Bacterial pellets were used or otherwise frozen at -20°C. 
Bacterial pellet was resuspended in buffer A1 (50mM Na2HPO4, pH 
8.0, 300mM NaCl) and cell lysis performed using three passages through a 
Stansted pressure cell homogenizer (Harlow, Essex, UK) at 1.2bar. The 
bacterial lysate was then diluted with A1 buffer to a final volume of 100ml and 
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cleared from insoluble material by ultracentrifugation at 47808x g for 30min, 
at 4°C using a Sorvall centrifuge. Protein was applied to a 5ml His-Trap HP 
column (GE healthcare) pre-equilibrated in buffer A1 at 4°C using a flow rate 
of 2ml/min. The resin was initially washed with buffer A1 until an A280 
of 0.02, and then with 10% buffer B1 (50mM Na2HPO4, pH 8.0, 300mM NaCl, 
300mM imidazole) before eluting TG2 with 50% buffer B1. Eluted material 
was diluted 3-fold with 20mM Tris/HCl, pH 7.2, 1mM EDTA and further 
purified by ion exchange chromatography using a HR10/10 column packed 
with Resource Q15 resin (GE healthcare) equilibrated in buffer A2 (20mM 
Tris/HCl, pH 7.2, 1mM EDTA, 100mM NaCl). TG2 was eluted as a single 
peak within a 20-column volume gradient of 0 to 60% buffer B2 (20mM 
Tris/HCl, pH 7.2, 1mM EDTA, 1M NaCl). Purified rhTG2 was stored at -20°C.  
RhTG2 purity was analysed by SDS-PAGE followed by staining with 
Coomassie brilliant blue R. 
 
2.7 Expression and purification of rhTG6 
 
RhTG6 was expressed in Spodoptera frugiperda, SF9 insect cell line 
using a baculovirus expression system containing the human TG6 sequence 
with an added His6-tag to the C-terminus.  
Cells were expanded in Erlenmeyer flasks to a desired volume and 
cell density, infected with the virus and cultured for 96h. Cells were harvested 
using centrifugation at 190x g for 15min at 4°C. The supernatant was 
discarded and the cell pellet resuspended with lysis buffer and kept on ice. 
Cell lysis was performed using three passages through a Stansted pressure 
cell homogenizer (Harlow, Essex, UK) at 1bar, followed by ultracentrifugation 
at 47808x g for 30min at 4°C. Protein was incubated with 1ml of Ni2+-
Sepharose 6 Fast Flow resin (GE Healthcare) for 45min at 4°C on an orbital 
shaker. The suspension was centrifuged at 180x g for 7 minutes and 
supernatant removed. The resin was resuspended and washed in a series of 
specific buffers before being eluted in a buffer containing imidazole. Purified 
TG6 was buffer exchanged to 10mM Tris/HCl pH 7.8, 500mM NaCl, 10mg/ml 
sucrose using a pre-equilibrated PD10 desalting column containing 8.3mL of 
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SephadexTM G-25 resin (GE Healthcare). Purified rhTG6 was lyophilized and 
stored at -20°C. Upon use, samples were reconstituted to the same original 
volume.  
 
2.8 Chemical labeling of rhTG2, rhTG6 and hemocyanin (in solution) 
 
TG2 was chemically labeled with commercially available fluorescent 
dye Atto-565 NHS ester or Atto-647N NHS ester (Cat. No: 72464 and 18373, 
Sigma Aldrich). Protein was buffer exchanged to 50mM Borate/NaOH, pH 
8.5, 150mM NaCl or 0.1M Na2HPO4/NAH2PO4, pH 7.6 using a pre-
equilibrated PD10 desalting column containing 8.3mL of SephadexTM G-25 
resin (GE Healthcare). Buffer exchanged TG2 (≈1mg) was added to the 
column and eluted by adding 1.5 column volumes of borate or sodium buffer 
while collecting 0.5ml fractions. Absorbance at 280nm for the different 
fractions was measured through spectrophotometry using a Beckman 
Coulter DU800 spectrophotometer. Fractions containing the highest 
concentration of protein were pooled and used for labeling process. The 
pooled protein working solution was ≈1mg/ml.  Protein was incubated with or 
without 1mM GTP for 1min. Subsequently, a 3-fold or 10-fold molar excess of 
Atto-dye over protein was added and incubated for 2h at room temperature in 
the dark and with gentle agitation. Excess free dye was blocked by 
incubation with 1M ethanolamine for 15min. Labelled protein was separated 
from free label using the same desalting column, re-equilibrated in 10mM 
Tris/HCl, pH 7.4, 150mM NaCl. Labelled TG2 was eluted from the column by 
adding 1.5 column volumes of Tris-buffer while collecting 0.5ml fractions. 
Spectroscopic analysis of collected fractions was performed and fractions 
containing eluted labelled TG2 were pooled. The same labelling process was 
performed at 4°C with an increased incubation time to 4h, and blocking time 
to 1h.  
Labelling of TG6 was initially carried out in solution as per TG2, 
however some adjustments had to be made to buffer conditions to keep TG6 
in solution. Labelling buffer was composed of 0.1M Na2HPO4/NaH2PO, pH 
7.8, 500mM NaCl, and 10mg/ml sucrose. Protein was then buffer exchanged 
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as before to yield a protein solution for labelling of about 1mg/ml. Labelling 
was performed with a 3-fold molar excess of Atto-565 NHS ester over protein 
and in the presence of 5mM GTP. Labelled TG6 was eluted while returned to 
10mM Tris/HCl, pH 7.8, 500mM NaCl and 20% glycerol. 
Hemocyanin from Limulus polyphemus hemolymph was purchased 
from Sigma. Labelling of hemocyanin was performed, as per TG2, using the 
following modifications: hemocyanin (≈1mg) was labelled with Atto-565 NHS 
ester in 0.1M Na2HPO4/NAH2PO4, pH 7.6, in the presence of a 140-fold molar 
excess of dye over protein and no added GTP. The remaining steps of the 
labeling process were kept the same as for TG2. Use of labeled Hemocyanin 
is described in chapter 5. Labelled proteins were stored at -20°C until further 
use. 
 
2.9 Chemical labelling of rhTG6 (in column) 
 
RhTG6 was also labelled during purification. This was performed 
before the elution step of the Ni2+-chelating column. TG6/sepharose slurry 
(≈1ml) was washed twice with a buffer containing 0.1M sodium phosphate, 
pH 7.8 and 300mM NaCl before being collected by centrifugation for 1min at 
180x g. Total amount of TG6 present in the Ni2+-slurry mixture was 
extrapolated from previous purification experiments and determined to be 
≈500µg at ≈6.3µM. A 3 or 10-fold molar excess of Atto-565 dye over protein 
was used for labelling, which was added to the 1 or 2ml volume of slurry, 
respectively.  Labelling was performed for 1h at room temperature, in the 
dark, with constant shaking. Purification of labelled TG6 was performed as 
per non-labelled TG6. Purified labelled TG6 was buffer exchanged to 10mM 
Tris pH 7.8 500mM NaCl, 10mg/ml sucrose using a PD10 column.  
 
2.10 Labeled protein concentration determination  
 
Final concentration of labeled proteins was estimated from standard 
curves generated from serial dilutions of Atto-565 or Atto-647N dyes. Both 
labelled proteins and a series of 2-fold dilutions of the relevant dye (Neat to 
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1:128) were subjected to spectrophotometric analysis. Atto-dye concentration 
in original solution was the same as that used for the correspondent labeling 
process. Absorbance at 280nm and 565nm or 647nm was measured, and 
respective standard curves created. The corrected absorbance value at 
280nm of the labelled protein was estimated by calculating label molar 
concentration in the protein solution and subtracting the correspondent 
280nm absorbance contribution. Final protein concentration was then 
calculated using the Beer-Lambert Law. 
 
2.11 Protein concentration as determined by Bradford assay  
 
Labeled protein concentration was also assessed by Bradford assay. 
Bradford protein assay was performed according to the protocol provided by 
the manufacturer (Bio-Rad, USA). In order to calculate protein 
concentrations, bovine serum albumin (BSA) was used as a standard (20 – 
2000 µg/ml). 10µl of each standard and sample, as well as appropriate 
blanks, were placed into wells of a 96-well plate, to which 200µl of dye 
reagent solution/well was added. Dye reagent was obtained by diluting 1 part 
Dye Reagent Concentrate with 4 parts double distilled H2O water before 
filtering through a Whatman grade 1 filter to remove particulates. The plate 
was sealed and agitated thoroughly for 30s, and incubated for 5min at room 
temperature. Absorbance was read at 590 nm using a plate reader. The 
standard curve for BSA was derived by linear regression and protein 
concentrations calculated from the standard curve.  
 
2.12 Native polyacrylamide gel electrophoresis (Native-PAGE)  
 
A native polyacrylamide gel electrophoreses was performed to 
analyse conformational changes in TG2 upon co-factor binding. Native-
PAGE was undertaken using Novex 10% Tris-Glycine polyacrylamide gels 
supplied by Invitrogen (EC6078BOX). Where indicated, protein samples 
were incubated with 600µm of GTP for 1min prior to electrophoresis. Protein 
samples were mixed with an equal volume of 2x sample loading buffer 
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containing 200mM Tris/HCl pH 6.8, 30% glycerol, 0.2% w/v bromophenol 
blue and 20mM DTT to prevent sample oxidation. The gel running buffer 
comprised of 25mM Tris/HCl pH 7.8 and 192mM glycine. Where indicated, 
an additional 25µM GTP was added to the running buffer. The gel/chamber 
was placed in an ice-water bath and electrophoresis was carried out for 3 h 
at 100V/cm2, 35 mA. The pH adjustment for all solutions was carried out at 
4°C.  
 
2.13 ‘In gel’ incorporation of FITC-cadaverine by TG2 
 
Native gels, pre-loaded with specified TG2 samples, were washed 3x 
5min in TBS (20mM Tris/HCl, pH7.4 150mM NaCl), before overnight 
incubation at 37°C, with a solution containing 50mM MOPS/NaOH, pH6.5, 
10mM CaCl2, 1mM DTT and 100µM FITC-cadaverine (81504, ANASPEC). 
The following day, gels were extensively washed (≈10 changes of buffer) in 
TBS for 24h. FITC-cadaverine incorporation and other described 
fluorophores were visualized by scanning the gels with the Typhoon 9400 
variable mode imager (GE Healthcare) using the following settings: for 
visualization of FITC, the 488nm blue laser line was used for excitation in 
combination with a 520nm band pass filter; for visualization of Atto-565 NHS 
ester the 532nm laser line was used together with a 560nm long pass filter; 
and for visualization of Atto-647N, the 633nm laser line was used together 
with a 670nm band pass filter. Photomultiplier tube voltage was set to obtain 
the best possible image without affecting the legitimacy of the results. 
 
2.14 TG2 inhibition with active site-directed inhibitors 
 
Two different TG2 site-directed irreversible inhibitors were purchased 
from Zedira, Germany: B003 (tert-Butyloxycarbonyl-(6-Diazo-5-
oxonorleucinyl)-LGlutaminyl-L-Isoleucinyl-L-Valinmethylester) and Z006 
(Benzyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-L-Valinyl-L-Prolinyl-L-
Leucinmethylester). 
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TG2 (10µg) was mixed with a core solution containing 5mM MgCl2 
and 5mM Tris/HCl, pH 8.3, +/- 50µg N-Voy (supplied by Expedeon). Protein 
was incubated on ice until needed or incubated at 37°C for 30min. Additional 
TG2 samples were inhibited by incubating the protein at 37°C supplemented 
with 50µM B003 in 2 sequential steps of 30min. In the second step, 10mM 
CaCl2 +/- 1mM putrescine were added. Samples were used as described. In 
a similar experiment, inhibition of TG2 was carried out as described, but this 
time no N-Voy was added and incubation of B003 was carried at 4°C. 
In experiments using Z006, TG2 (10µg) was mixed with the same core 
solution as described above. Inhibition of the enzyme was achieved by 
incubating the protein at 4°C, supplemented with 50µM Z006 in 2 or 7 
sequential steps of 30min. In the second step, 10mM CaCl2 was added. 
 
2.15 In vitro incorporation of FITC-cadaverine by TG2 
 
Different forms of TG2 (B003 inhibited, wt, open, E329) were mixed in 
a solution containing 50mM Tris/HCL pH8.3, 5mM MgCl2, 5mM DTT, 100µM 
FITC-cadaverine and either 1mM EGTA or 10mM CaCl2. Samples were then 
incubated at 37°C for 20min in a warm-bath or on ice as specified. Samples 
were run on a SDS-PAGE, and gels scanned using the Typhoon 9400 
variable mode imager as described in 2.13. 
 
2.16 Inhibition of TG2 with Z006 for protein crystallization 
 
TG2 (8.3x10-8mol) was incubated with a 10-fold molar excess of Z006 
inhibitor. Total volume of the reaction was calculated to keep DMSO 
concentration at 1% (the inhibitor is stored in DMSO). TG2 was initially 
diluted to 1mg/ml with 20mM Tris/HCl pH7.5. The inhibition took place in two 
different steps. Firstly, 40% of the total volume of Z006 was diluted to 1ml 
and added to the protein solution over a 30min period at 4°C, by dripping the 
inhibitor with a syringe while stirring. In the second step, the remaining 60% 
of inhibitor were diluted to 1.5ml and added to the protein simultaneously with 
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1ml of CaCl2 (10mM final concentration) solution over a 60min period at 4°C 
while stirring. The calcium solution will drive the remaining non-inhibited TG2 
to its open conformation, allowing irreversible binding of Z006. Note that, 
before the second step, TG2 was further diluted to reach the total volume of 
reaction, while accounting for added volume of inhibitor and CaCl2. Inhibited 
protein was concentrated using a Centiprep Ultracel YM-10 concentrator 
(Millipore), according to manufacturer specifications, to a volume of ≈2-3ml. 
Inhibited TG2 was buffer exchanged to the more appropriate storage buffer 
of 10mM Tris/HCl pH 7.5, 100mM NaCl, by using a pre-equilibrated PD10 
column. Protein was centrifuged for 10min at 16000x g, at 4°C to remove any 
aggregates and analysed by spectrophotometry. Final protein concentration 
was calculated using Beer-Lambert Law. 
 
2.17 Crystallisation of Z006-inhibited TG2 
 
Crystallisation of inhibited TG2 was attempted using methodology 
based on the previously published crystallization experiments by Pinkas et 
al., 2007. 
Inhibited TG2 (6.8mg/ml; 87,7µM) was plated for crystallisation in the 
presence of either no ligand (Apo) or one of two different amines (ligand A or 
B). Ligands were used at 10-fold molar excess over protein. Three different 
precipitant buffers were used. The base of all buffers was a 100mM HEPES, 
pH7.2, solution, to which ammonium sulphate was added to three different 
concentrations: 1M, 2M and 3M. These buffers were also used +/- 15% 
glycerol, and +/- N-Voy (20-fold molar excess over protein). Different ratios of 
protein-precipitant were seeded: 2:1; 3:2; 1:1 and 1.3:2 to obtain protein 
concentrations of approximately 13.5mg/ml, 10mg/ml, 6.7mg/ml and 
4.4mg/ml respectively.  
Crystallisation was performed using vapour diffusion, sitting drop 
methodology. Protein, ligands and precipitants were loaded into 96-well 
plates using a Phoenix Liquid Handling System robot. Plates were scanned 
at day 0, 1, 5, 7, 15 and after 1 month. 
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In a second crystallisation experiment, inhibited TG2 (6.1mg/ml) and 
ligands were loaded as before, but using different precipitant buffers. The 
precipitant buffer used was 100mM HEPES, 2M ammonium sulphate at pH 
6.8, 7.2, 7.4, 7.5, 7.7 and 8.0. Crystallisation was carried out with and without 
15% glycerol and no N-Voy. Plates were scanned at day 0 and 1, 5, 7, 13 
days and also after 1 month.  
 
2.18 Tissue processing and sectioning of D2 intestinal biopsies 
 
Intestinal biopsies from the second part of the duodenum (D2) were 
obtained from the Gastroenterology Service of the Royal Hallamshire 
Hospital in Sheffield, with the approval of the Yorkshire Research Ethics 
Committee and after consent forms were signed by the patients. Biopsies 
were collected by a specialist gastroenterologist, through endoscopy and 
processed on the site by the author of this study.  
All biopsies were rinsed in sterile PBS (137mM NaCl pH7.3, 0.3mM 
KCl, 0.8mM Na2HPO4, 1.5mM KH2PO4) and immediately processed after 
collection according to 3 different protocols: rapid freezing without fixation, 
cryopreservation after fixation, and paraformaldehyde fixation and paraffin 
embedding.  
For rapid freezing without fixation, biopsies were snap-frozen in liquid 
nitrogen and transferred into a container pre-equilibrated at -80 ̊C.  
For cryopreservation after fixation, samples were first fixed in 0.5% 
paraformaldehyde/PBS for 2h at RT, and then in 4% paraformaldehyde/PBS 
overnight with gentle agitation. The tissue was washed extensively in PBS 
over 12-24h with several changes, transferred into small containers, soaked 
overnight in a 1M sucrose/PBS solution and subsequently in 2.3M 
sucrose/PBS solution for 5-6h or until equilibrated. Samples were then frozen 
on a block of dry ice and afterwards overlaid/embedded in tissue freezing 
medium (OCT) for sectioning. 
Samples processed according to both of these protocols were stored 
at -80°C.  
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For paraffin embedding, D2 biopsies were initially fixed in 4% 
paraformaldehyde/PBS twice for 24h with gentle agitation and washed 
extensively in PBS over 48h with several changes. Tissue processing then 
followed the routine paraffin embedding protocol in the histopathology 
laboratories at the School of Dentistry, Cardiff University. 
 Orientation of biopsies was performed so a transversal section of 
intestinal crypts and villi were observed. D2 biopsies were cut at -27°C in a 
cryostat or at RT on a general microtome. Sections were cut to a thickness of 
3µm and tissue was collected onto gelatin-coated glass slides. Slides were 
stored at -80°C or RT, according to type of tissue processing used. 
 
2.19 Immunofluorescence staining 
 
Cryosections were air-dried overnight prior to immunostaining. 
Paraffin sections were deparaffinised for 10min in xylene before rehydration 
by dipping slides 3-5x in decreasing concentrations of 100%, 90% and 70% 
ethanol and distilled water.  
Sections were washed twice in TBS for 5min. To prevent non-specific 
binding, tissue was blocked in 1% BSA/TBS for 30min at RT. Sections were 
incubated, in the dark, for 10min with labeled TG2 or 1h at RT with labeled 
TG6 or labeling reagents as detailed in Table 2.2. As a control, Hemocyanin 
was incubated at the same concentration and for the same time as 
corresponding labeled TG. Sections were then washed 3 times for 5min in 
TBS. When specified, secondary antibody was incubated for 1h at RT in the 
dark. All labeling reagents were diluted in 1%BSA/TBS, as specified, before 
centrifugation for 5min at 10000x g. Sections were finally washed 3 times for 
5min in TBS and mounted in Vectashield® mounting medium containing 
DAPI supplied by Vector labs.  
 
2.20 Cell counting 
 
Adherent cells were detached from the growing surface with 1ml 
trypsin/EDTA solution (0.05%) (Invitrogen) and left for 2-5 min at 37°C. 
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Trypsin was ‘inactivated’ by addition of 5ml of medium containing 10% fetal 
bovine serum (FBS) and cells were collected by centrifugation for 5 min at 
400x g. The non-adherent cells were collected by centrifugation at 400x g for 
5 min.  
Cells were suspended in appropriate medium. Desired volume of cell 
suspension was mixed with Trypan Blue solution (0.4%) (Sigma) in 1:1 ratio. 
A total of 10µl of cell suspension was loaded into a Neubauer counting 
chamber and unstained cells counted according to the manufacturer’s 
protocol. 
 
Table 2.2 List of labelling reagents used in immunofluorescent staining of D2 
intestinal biopsies 
Name Species 
Final 
concentration 
Catalog number and 
manufacturer  
Atto-565 TG2 Human 10µg/ml in house labeling 
Atto-565 TG6 Human 20µg/ml in house labeling 
Atto-565 hemocyanin 
Limulus 
polyphemus  
10µg/ml or 20µg/ml in house labeling 
FITC-conjugated anti-
human IgA α-chain 
Goat  1.5µg/ml (1:1000) 
109-095-011,  
Jackson Immuno 
Research 
Anti-human CD138 Mouse  4µg/ml (1:25) 
MCA2459GA, 
AbDSerotec 
Anti-human CD20cy Mouse  1:100 M0755, Dako 
Anti-mouse IgG (H+L) 
secondary antibody 
Alexa Fluor 488  
Donkey  4µg/ml (1:500) A21202, Invitrogen 
VECTASHIELD® 
Mounting Medium with 
DAPI  
NA 1.5µg/ml H-1200, Vector Labs 
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2.21 THP-1 cell culture. differentiation and activation 
 
Human monocytic leukemia cells (THP-1) were kindly gifted by Dr. 
Xiaoqing Wei. THP-1 cells were grown in RPMI 1640 medium (Sigma) 
supplemented with 10% FBS (Gibco), 2mM L-glutamine (Gibco) and 
antibiotics (100 µg/ml streptomycin, 100 U/ml penicillin) (Gibco). Cells were 
maintained at 37 °C in a humidified incubator with 5% CO2.  
Cells were seeded in complete RPMI medium at 0.5x105 cells/cm2. 
Differentiation into a resting macrophage stage was achieved by 
supplementing the medium with 12-O-Tetradecanoyl-phorbol-13-acetate 
(TPA) (50ng/ml in dimethyl sulfoxide (DMSO)) (Merck Millipore, 524400) for 
48h. When specified, cells were further polarized into pro-inflammatory M1 or 
anti-inflammatory M2-type macrophages by adding to the medium 
granulocyte-macrophage colony-stimulating factor (rhGM-CSF) (20ng/ml in 
dH20) (ImmunoTools, 11343113) or macrophage colony stimulating factor 
(rhM-CSF) (20ng/ml in dH2O) (ImmunoTools, 11343123) for 3 days. After 3 
days, activation of macrophages was promoted by stimulation for 4h or 24h 
with 100ng/ml bacterial lipopolysaccharide (LPS) from Salmonella sp. or 
1x105 heat killed candida (HKC) (both kindly donated by Dr Xiaoqing Wei). 
Total RNA was extracted from the cells at the described time points 
according to methodology described in section 2.24. 
 
2.22 Mouse bone marrow derived macrophages: isolation, culture and 
differentiation 
 
Culture and differentiation of mouse bone marrow-derived 
macrophages was performed based on methodology used within our 
department and provided by Dr. Xiaoqing Wei and Dr. Niels Hans. 
An appropriate number of adult mice were sacrificed by CO2 exposure 
or cervical dislocation. The femurs were removed aseptically, with care to 
retain the intact bone, and not to expose the bone marrow. Muscle tissue 
was removed from the bone and femurs were stored on ice, in 1640 RPMI 
medium supplemented with L-glutamine, 10% FBS, 100u/ml penicillin and 
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100µg/ml streptomycin. Bone marrow was harvested from femurs by 
 flushing with complete RPMI medium. The hip and knee joints were 
removed using a scalpel and 0.5-1 ml of RPMI was flushed through the 
femur, via a cut in one end, using a syringe and needle. The recovered cells 
were pooled in a centrifuge tube and spun at 400x g for 5min. The cell pellet 
was resuspended in 1ml of red blood cell lysis buffer, containing ammonium 
chloride, and incubated for 90s. A large excess of fresh RMPI was added 
and centrifuged at 400x g for 5min. The pellet was resuspended in 
appropriate volume of RPMI and cells were counted. Cells were seeded at a 
density of 0.6x105cells/cm2 and cultures for 7 days in complete RPMI 
medium supplemented with 20ng/ml mGM-CSF or 20ng/ml of both mM-CSF 
and mIL-4 (cytokines were kindly donated by Dr Xiaoqing Wei). Medium was 
changed every 3 days. After day 7 cells were trypsinised as describe in 
section 2.20 and re-seeded on a 24-well plate at a density of 
1.25x105cells/cm2. Cells were allowed to adhere overnight. On the following 
day, macrophage activation was promoted by stimulation with 100ng/LPS for 
2, 6 or 24h. Total RNA was extracted at these time points and processed as 
described in section 2.24. 
 
2.23 Human PBMC derived macrophages: isolation, culture and 
differentiation 
 
Peripheral blood samples were obtained from Cardiff University, 
School of Dentistry, with the approval of the Research Ethics 
Committee:  REC10/MRE09/28 and after consent forms were signed by the 
volunteers. Peripheral blood monocyte cells (PBMC) were purified from total 
blood solution as described below. 
Approximately 15ml of peripheral blood was collected into a syringe 
containing 10U/ml of heparin and diluted 1:1 with cold RPMI1640 serum free 
medium. The diluted blood was divided into 8 ml fractions and carefully laid 
over 5ml of Ficoll-Paque Premium (GE, 17-5442-02), in Falcon tubes. Tubes 
were centrifuged at 510x g for 25 min at 4°C, with lowest settings for brake 
and acceleration. After centrifugation, the upper layer was aspirated with a 
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Pasteur pipette to within 0.5cm of the opaque interface containing 
mononuclear cells. The opaque interface was carefully transferred into a 
clean Falcon tube and washed by adding 10ml of serum-free medium 
followed by centrifugation at 400x g for 10min, 4°C (brake 0, acceleration 0). 
Cells were resuspended in 5 ml of serum-free medium and a second wash 
was performed in the same way. The pellets from all tubes (from the same 
patient) were combined and resuspended in 1-2ml of serum-free medium, 
depending on size of the pellet. Cells were counted with a haemocytometer 
after lysis of remaining erythrocytes through addition of 2% acetic acid. They 
were then seeded at a density of 1x106cells/ml and cultured for 7 days, at 5% 
CO2 and 37°C with 1640 RPMI medium supplemented with 10% FBS, L-
glutamine, 100u/ml penicillin and 100µg/ml streptomycin and either 20ng/ml 
rhGM-CSF or 20ng/ml rhM-CSF (ImmunoTools) for M1 and M2 
differentiation, respectively. Medium was exchange every 3 days. On day 7, 
cells were washed, trypsinised and counted as described in section 2.20. 
Cells were re-seeded at a density of 0.5x105cells/cm2 and allowed to 
adhere overnight. The following day, cells were stimulated with either 
complete medium only, 100ng/ml LPS or 1x105cells HKC for 4h. Cells were 
prepared and total RNA extracted as described in section 2.24. 
 
2.24 Isolation of total RNA and reverse transcription 
 
Cells were washed 3 times with pre-warmed (37°C) PBS. Isolation of 
purified total RNA was achieved by using RNeasy mini kit (Qiagen), 
according to manufacturer specifications.  The concentration of total RNA 
was estimated from the OD260/280 ratio, determined using a Nanovue (GE 
Healthcare). Total RNA was stored at -80°C as an ethanol precipitate: 1µl of 
glycogen (5mg/ml), 1/10 of the total volume of 3M sodium acetate, pH5.2, 
and 2.5x volume of 100% ethanol. For recovery, the precipitated RNA was 
collected by centrifugation at 12,000 x g for 20min at 4°C. The pellet was 
washed with 80% ethanol and collected again by centrifugation in the same 
conditions for 10min. Pellet was briefly air-dried and reconstituted in 
nuclease free H2O.  
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Reverse transcription was carried using SuperScriptTMII Reverse 
Transcriptase enzyme (Invitrogen). For a 20µl reaction volume, 500ng of total 
RNA were used. The following components were added into a nuclease-free 
microcentrifuge tube: 1µl of 0.5µg/µl Oligo(dT)15 (Promega), 1µl dNTP Mix 
(10mM each), specified RNA and nuclease free H2O to bring the volume up 
to 13µl. Mixture was heated to 65°C for 5min and quick chilled in ice The 
following reagents were then added: 4µl of 5x First-Strand Buffer and 2µl of 
0,1M DTT (Invitrogen). Samples were incubated for 2min at 42°C and 0.5µl 
of enzyme was added. Samples were incubated at 42°C for 52min and then 
at 95°C for 2min, followed by quick chill on ice and a further addition of 0.5µl 
of enzyme. The incubation at 42°C was repeated. The reaction was finally 
stopped by incubation at 70°C for 15min. Samples were stored at -20°C until 
further use.  
 
2.25 Analysis of M1 and M2 cell markers by qPCR 
 
Samples were tested for gene expression of different M1 and M2 
markers, as specified, by real-time quantitative polymerase chain reaction 
(qPCR) using the forward (f) and reverse (rev) primers described in Table 
2.3. Where described, hGAPDH or mβ-Actin were used as internal control 
genes. 
The different fragments were amplified using 40 cycles in a total 
reaction volume of 20µl. The amplification of 5µl cDNA (1µl diluted 5-fold) 
was performed using 10µl of Mesa Green 2x PCR master mix (Eurogentec), 
0.2µl of SYBR green reference dye (Sigma, R4526) and 0.5µM of each 
primer. Data was acquired using the QuantStudio™ 6 Flex Real-Time PCR 
System and the parameters described in Table 2.4.  
All samples were run in triplicate. The relative expression of each 
sample was acquired using the 2-∆∆Ct method, after normalizing for internal 
control gene. Results are shown in comparison to a control sample.  
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Table 2.3 Primers used for analysis of M1 and M2 markers by qPCR. 
Name Sequence 
miNOS f P1 5’ - TGGCTCGCTTTGCCACGGACGAGACGGA - 3’ 
miNOS rev P2 5’ – GGAGCTGCGACAGCAGGAAGGCAGCGGG - 3’ 
mArg1 f P1 5’ - AGCTGGCTGGTGTGGTGGCAGAGGTCCA - 3’ 
mArg1 rev P2 5’ - GGGTGGACCCTGGCGTGGCCAGAGATGCT - 3’ 
mβ-Actin f P3 5’ - TCTTTGCAGCTCCTTCGTTGCCGGTCC - 3’ 
mβ-Actin rev P4 5’ - GTCCTTCTGACCCATTCCCACCATCACAC - 3’ 
hIL-12p40 f 5’ - CCCTGGTTTTTCTGGCATCTCCCCTCGT - 3’ 
hIL-12p40 rev 5’ - GAGGACCACCATTTCTCCAGGGGCATCC - 3’ 
hEBI3 f P1 5’ - AAACTCCACCAGCCCCGTGTCCTTCATT - 3’ 
hEBI3 rev P2 5’ - CGGTGACATTGAGCACGTAGGGAGCCAT - 3’ 
hGAPDH f 5’ - TCCTCCTGTTCGACAGTCAGCCGCATC - 3’ 
hGAPDH rev 5’ - GGTGACCAGGCGCCCAATACGACCAAAT - 3’ 
 
 
Table 2.4 Parameters used for amplification by real-time quantitative PCR 
Stage Temperature Duration N. of cycles 
Activation of polymerase 95°C 2min 1 
Denaturation 95°C 15s 
40 Annealing 60°C 30s 
Elongation 72°C 30s 
Melt Curve 
95°C 15s 1 
60°C 1min 1 
95°C 15s 1 
Completion 4°C ∞ 1 
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2.26 Screening of transglutaminase expression by PCR 
 
cDNA was amplified using polymerase chain reaction (PCR) and the 
forward (f) and reverse (rev) primers as described in Table 2.5. 
 
Table 2.5 Primers used for transglutaminase amplification in THP-1 samples. 
Name Sequence 
hTG1 f 5’ - ACCCTGTGACCATGCCAGTG - 3’ 
hTG1 rev 5’ - GCTGCTCCCAGTAACGTGAGG - 3’ 
hTG2 f 5’ - ATGAGAAATACCGTGACTGCCTTAC - 3’ 
hTG2 rev 5’ - CAGCTTGCGTTTCTGCTTGG - 3’ 
hTG3 f 5’ - GCTGTTGGGTAACCTGAAGATCG - 3’ 
hTG3 rev 5’ - GCTACGTCGATGGACAACATGG - 3’ 
hTG4 f 5’ - TCACGTCTTTCCAGTACCCTGAGT - 3’ 
hTG4 rev 5’ - CAGGCTTTCCAAAGAGAACTTGAC - 3’ 
hTG5 f 5’ - CAAAGAGCATCCAGAGTGACGAGCGGG - 3’ 
hTG5 rev 5’ - GGGCTGTCCTGGCTCAGTGATGTGGGC - 3’ 
hTG6 f 5’ - GTGAAGGACTGTGCGCTGATG - 3’ 
hTG6 rev 5’ - CGGGAAGTGAGGGCTTACAAG - 3’ 
hTG7 f 5’ - CCTCATCAATGGGCAGATAGC - 3’ 
hTG7 rev 5’ - CTTGACCTCGTTGCTGCTGA - 3’ 
hFXIII f 5’ - GACCAATGAAGAAGATGTTCCGT - 3’ 
hFXIII rev 5’ - GAAGGTCGTCTTTGAATCTGCAC - 3’ 
h36B4 f 5’ - AGATGCAGCAGATCCGCAT - 3’ 
h36B4 rev 5’ - ATATGAGGCAGCAGTTTCTCCAG - 3’ 
 
The different TG fragments were amplified using 40 cycles in a total 
reaction volume of 25µl. The amplification of 1µl cDNA was performed using 
1.25U of GoTaq G2 hot start DNA Polimerase (Promega, 5U/µl) and 0.25µM 
of each primer in the presence of 5µl Flexi buffer (Promega), 2mM MgCl2 
(Promega) and 10mM dNTPs (New England Labs) and parameters as 
specified in Table 2.6.  
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Table 2.6 Parameters used for transglutaminase amplification by PCR 
Stage Temperature Time N. of cycles 
Activation of polymerase 94°C 2min 1 
Denaturation 94°C 30s 
40 Annealing 60°C 45s 
Elongation 72°C 45s 
Completion 72°C 7min 1 
 4°C ∞ 1 
 
For analysis, the amplified PCR products were separated on a 1% 
agarose gel containing 1.25mM ethidium bromide in TAE running buffer 
(40mM Tris/acetate, pH 8.5, 2mM Na2EDTA). Electrophoresis was performed 
under constant voltage (100V/cm2) and bands were visualized by UV 
exposure using a gel-doc system (BioRad). Bands were quantified based on 
subjective observation of two independent subjects.  
 
2.27 Analysis of TG2 and TG6 expression by qPCR 
 
Analysis of TG2 and TG6 expression was performed by qPCR, using 
the forward (f) and reverse (rev) primers and probes described in Table 2.7. 
h36B4 was used as the internal control gene. Human primer and probe 
sequences were able to amplify mouse cDNA due to the high degree of 
homology between sequences in the two species.  
The different TG fragments were amplified using 50 cycles in a total 
reaction volume of 25µl. The amplification of 1µl cDNA was performed using 
12.5µl of 2x TaqMan Fast Advanced Master mix (Applied Biosystems) and 
primers at the described concentration (Table 2.7). Data was acquired using 
the QuantStudio™ 6 Flex Real-Time PCR System and the parameters 
described in Table 2.8.  
All samples were run in triplicate. The relative expression of each 
sample was acquired using the 2-∆∆Ct method, after normalizing for internal 
control gene, h36B4. Results are shown in comparison to a control sample.  
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Table 2.7 Primers and probes used for qPCR analysis of TG2 and TG6 expression and 
respective final concentrations used 
Name Sequence Final 
Concentration 
mTG2 f 5’ - CGAATCCTCTACGAGAAGTACAGC - 3’ 150nM 
mTG2 rev 5’ - GTCAAACGCCAAAACGAACC - 3’ 150nM 
hTG2 probe 5’ - AGCTACCTGCTGGCTGAGAGAGATCTC - 3’ 175nM 
mTG6 f3 5’ - CAGCAGTGGTAGGAGTGACAG - 3’ 300nM 
mTG6 rev 7 5’ - CTCTTGGAAGGGGTTATGTTG - 3’ 600nM 
mTGy probe 5’ - CAAGGACAGCTAAGTATTGAGGTGCCCAG - 3’ 200nM 
h36B4 f 5’ - AGATGCAGCAGATCCGCAT - 3’ 300nM 
h36B4 rev 5’ - ATATGAGGCAGCAGTTTCTCCAG - 3’ 300nM 
h36B4 probe 5’ - AGGCTGTGGTGCTGATGGGCAAGAAC - 3’ 100nM 
hTG3 f 5’ - GCTGTTGGGTAACCTGAAGATCG - 3’ 300nM 
hTG3 rev 5’ - GCTACGTCGATGGACAACATGG - 3’ 300nM 
hTG3 probe 5’ - CGGAGTGGCACCAAGCAACTGCTCGC - 3’ 100nM 
hTG6 f 5’ - GTAAAGGACTGTGTGCTGATG - 3’ 300nM 
hTG6 rev 5’ - TGGGAACTGTGAGCTGACAAG - 3’ 300nM 
hTG6 probe 5’ - CTTCTCCAAGGACAGCTAAGTATTGAG - 3’ 100nM 
 
 
Table 2.8 Parameters used for amplification of TGs in mouse macrophages by qPCR 
Stage Temperature Duration N. of cycles 
Activation of polymerase 95°C 20s 1 
Denaturation 95°C 15s 
50 
Annealing/Elongation 60°C 30s 
Completion 4°C ∞ 1 
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Chapter 3 Protein purification and chemical labelling 
 
3.1 Introduction 
 
Gluten containing diets have been a part of the Western world lifestyle 
for centuries or even millennia. On average, the consumption of gluten is 
approximately 10g to 20g per day in most European countries, and it is also 
rapidly increasing in Eastern countries. With gluten disorders affecting most 
of the Western world, and coeliac disease being estimated to affect 1% of the 
population in these countries, it is natural that gluten related disorders are a 
research focus of the scientific community. Importantly, TG2 has been 
recognised as the predominant auto-antigen in coeliac disease for almost 20 
years (Dieterich et al. 1997). More recently, a novel transglutaminase, TG6, 
has been identified and linked to the autoantibody response specifically in 
the gluten associated neurological manifestations of the autoimmune 
disease, and gluten ataxia in particular (Hadjivassiliou et al. 2008). Even 
though both gluten ataxia and more often coeliac disease have been studied 
across the world by many groups, the mechanism for the development of 
these antibodies against transglutaminase enzymes is still not fully 
understood. It is known that TG2 catalyses highly specific deamidation of 
gluten peptides and most gluten peptides identified as TG2 substrates also 
serve as T-cell epitopes (Arentz-Hansen et al. 2000), and hence drive the 
immune response.  
 It has been suggested that production of antibodies against TG2 is a 
T-cell driven event and relates to the uptake of TG2-gluten peptide 
complexes by pre-existent TG2-specific B cells (Sollid et al. 1997). In fact, it 
has recently been shown that B-cells expressing TG2-specific B-cell 
receptors (BCRs) are able to take up and present TG2-gliadin complexes in 
an antigen presenting cell manner leading to the activation of gluten-specific 
T-cells (Du Pre & Sollid 2015; Di Niro et al. 2012).  
The understanding of the mechanistic role of TG6 in gluten ataxia is 
still quite limited. Stamnaes et al (2010) have shown that, in a similar way to 
TG2, TG6 is able to deamidate gluten peptides containing the most common 
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CD gluten T-cell epitopes. The enzyme has also been shown to form TG6-
gluten peptide complexes that could act in a hapten-carrier fashion and lead 
to presentation of gluten by auto-reactive B-cells to elicit T cell help. Although 
it has been suggested that TG6 antibody populations could originate from 
epitope spreading as a consequence of considerable homology between 
human transglutaminases (Grenard et al 2001; Stamnaes et al 2010), recent 
data by Hadjivassiliou suggests the independent involvement of TG6 in the 
pathogenesis of gluten ataxia, as antibodies in most patients do not cross-
react between different transglutaminase isoforms (Hadjivassiliou et al. 
2008). However, as TG6 is primarily expressed in the central nervous 
system, it is unclear whether these immune events occur at the level of the 
gut or the brain. 
Demonstration of TG6-specific B-cells or TG6 expression in the 
human small intestine would substantiate that production of autoantibodies in 
GA could originate in the small intestine even though the symptoms and 
predominant disease manifestation are extraintestinal.  
 To address this, human TG2 and TG6 were expressed, purified and 
fluorescently labelled for use in immunohistochemical assays. Labelled 
protein will allow us to assess the presence of TG2 and TG6-specific B cells 
in small intestine biopsies of patient with gluten-related conditions. In this 
project, TG2 is being used as a proof of principle/reference point as it has 
been more extensively studied in the gluten disorders context and relevant 
TG2-specific B-cells are evidently present in the small intestine (Di Niro et al. 
2012). It is also a protein that is comparatively easier to work with than TG6, 
which is difficult to produce recombinantly in active form. Furthermore, 
enzymatic activity of labelled proteins will be assessed, to ensure that 
enzymatically functional TG2 and TG6 are obtained, as autoantibodies 
against TG2 have been shown to be conformation dependent (Seissler et al. 
2001; Iversen et al. 2013). 
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The aims of the chapter: 
 
1. To express and purify TG2 and TG6 enzymes. 
2. To establishment a protocol for chemical labelling of TG2 and TG6 
with a fluorescent dye. 
3. To assess labelled enzymes enzymatic activity using a fluorogenic 
activity assay.  
 
  
 54 
3.2 Results 
 
3.2.1 Expression and purification of coeliac disease autoantigen TG2  
 
Detailed methodology can be found in section 2.6 of chapter 2. Briefly, 
RhTG2 was successfully expressed and purified using a modified protocol 
based on the methodology described by Hadjivassiliou et al, 2008.  
Escherichia coli BL21 transformed with constructs containing native TG2 
sequence with an added His6-tag to the N-terminus were already available 
within the group. E. coli was grown in LB medium and expression of TG2 
was induced by addition of rhamnose. Bacteria were collected by 
centrifugation and resuspended in purification buffer. Harvesting of 
expressed protein was achieved by lysis of bacterial cells using a Stansted 
pressure cell homogenizer. RhTG2 was purified from the lysate using Ni2+-
chelating affinity chromatography followed by further purification through 
anion exchange chromatography (Fig. 3.1A). RhTG2 purity was analysed by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing conditions, followed by staining with Coomassie brilliant blue 
R (Fig. 3.1B). 
SDS electrophoresis showed the successful purification rhTG2 from 
the starting material (S). A lot of the proteins in the lysate mixture did not bind 
to the nickel affinity column (F) and from the proteins that bound 
unspecifically or weakly, the majority could be flushed out with 30mM 
imidazole. RhTG2 was eluted effectively from the column with 150mM 
imidazole.  
During anion exchange chromatography, rhTG2 eluted as a second 
peak (P2) with 210-280mM NaCl. Two other peaks were observed: peak 1 
(P1) was detected using 150mM NaCl and corresponds to non-specifically 
bound protein. P3 (P3), detected at 1M NaCl, could possibly correspond to 
DNA. 
Although rhTG2 was successfully purified to a high degree, it was still 
possible to observe some additional bands at ≈45kDa, 30kDa and 25kDa in 
the denaturing electrophoresis. Previous studies within the group using mass 
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A B 
spectrometry, have shown that the bands were TG2 degradation products 
(personal communication, Prof D. Aeschlimann).  
 
  
  
Fig. 3.1 Purification of rhTG2 A: Absorbance spectrum of anion exchange chromatography 
on Source Q15 column. P1 corresponds to unspecific bound protein, P2 corresponds to TG2 
and P3 possibly corresponds to DNA. B: SDS-PAGE (4-20% PA gel, reducing conditions) 
analysis of different fractions of TG2 purification. S corresponds to starting material; F 
corresponds to Ni2+-chelating affinity chromatography flow through; I30 and I150 correspond 
to proteins eluted with 30mM and 150mM imidazole. P1, P2 and P3 correspond to fractions 
of the peaks observed during anion exchange chromatography with P2 corresponding to 
eluted TG2. 
 
Fractions (Fig. 3.2A) containing purified TG2 were pooled and 
spectroscopic analysis for absorbance was performed (Fig. 3.2B). Final 
concentration of the protein was calculated using the Beer-Lambert Law 
c=absorbance/(ε·d), where ε is the theoretical extinction coefficient of the 
protein (ε(TG2)=1.35cm2/g – calculated using ProtParam software from 
ExPASy Bioinformatics Resource Portal) and d=cuvette diameter (d=1cm). 
Concentration of TG2 was calculated to be approximately 2.30mg/ml for the 
preparation shown in Fig. 3.2 and total yield of protein was ≈15mg. 
To assure protein enzymatic activity, a real-time fluorescent assay 
was carried out. This assay monitors transglutaminase activity by 
determining its isopeptidase activity. It was previously developed by 
researchers within our group and is based on the hydrolysis of an isopeptide 
bond of a quenched fluorescent probe, Abz-APE(γ-cad-Dnp)QEA (Abz=2-
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aminobenzoyl; cad-Dnp=2,4-dinitrophenyl-cadaverine). The probe is derived 
from the substrate sequence APQQEAL in osteonectin, and mimics a cross-
linked TG reaction product. Hydrolysis of the isopeptide bond by TG2 
releases the quencher (Dnp) and therefore generates an increase in light 
emission from the fluorophore (Abz) at λ max=418nm (Adamczyk, Heil, & 
Aeschlimann, 2013a). For the reaction to occur, TG2 needs to be activated 
by adding calcium.  
Protein was prepared according to the protocol described by 
Adamczyk et al. 2013, and analysis was carried out using the FLUOstar 
OMEGA multidetection microplate reader. Substrate conversion was 
measured for 90 cycles. Calcium was injected in cycle 10 (400s), to activate 
the enzyme (Fig. 3.2C). Fluorescence was acquired every 40s and average 
fluorescence from the first 8 cycles was subtracted to normalize for well-
specific fluorescence (Fig. 3.2D). The control (without enzyme activation) 
was subtracted from the data to account for fluorescence bleaching and the 
final data fitted using linear regression (Fig. 3.2E) 
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Fig. 3.2 Characterisation of purified rhTG2. A: SDS-PAGE (4-20% PA gel, reducing 
conditions) analysis of purified rhTG2 (pooled fractions). A band observed around the 80kDa 
mark was consistent with TG2 molecular weight of 77325g/mol. B: Absorbance spectrum for 
purified rhTG2. rhTG2 was diluted 1/4 to allow spectroscopic analysis and normalized for 
buffer. C: Raw data for TG2 isopeptidase real-time fluorescent assay. Reaction mixture 
containing ≈20µg/ml TG2 was injected at cycle 10 (400s) with either water (control) or 2mM 
CaCl2. D: Data from TG2 isopeptidase assay after normalization for well-specific 
fluorescence (subtraction of the average of first 320s). E: Data from TG2 isopeptidase assay 
after subtraction of baseline fluorescence to account for fluorescence bleaching. As 
expected, rhTG2 is highly active after calcium injection and reaction rates can be determined 
from linear regression of data. 
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Absorbance spectrum and isopeptidase assay of purified rhTG2 showed the 
successful purification of an active form of the enzyme, which could 
subsequently be used for labelling. 
 
3.2.2 Labelling of TG2 with NHS ester dye results in an enzymatically 
inactive enzyme.  
 
Commercially available Atto-NHS ester dyes were purchased as the 
fluorescent labels of choice. In these well-established dyes, the activated N-
hydroxysuccinimide (NHS) ester group readily reacts with primary amines, 
forming a chemically stable amide bond between the dye and the protein. 
Primary amines exist at the N-terminus of each polypeptide chain and in the 
side-chain of lysine (Lys, K) amino acid residues. The optimum pH range for 
NHS-ester coupling is physiologic to slightly alkaline conditions (pH 7.2 to 
9.0) and hence ideal for protein labelling. At this pH, amino groups of 
proteins are unprotonated to a high degree and highly reactive towards the 
dye-NHS-ester. The reaction releases NHS (Fig. 3.3). 
 
 
 
Fig. 3.3 NHS ester reaction with primary amine. R represents a labelling reagent; P 
represents a protein. NHS ester-activated labelling compound reacts with a primary amine 
optimally in pH 7 to 9, generating a stable amide bond. The reaction releases NHS (retrieved 
from ThermoFisher). 
 
Atto-565 NHS ester was purchased and this dye is a red fluorophore 
belonging to the class of rhodamine dyes. It has a maximum excitation of 
563nm and a maximum emission of 592nm, which will allows its use in 
double immunohistochemistry along side additional green labels already in 
stock in the laboratory. 
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Purified rhTG2 was fluorescently labelled by reaction with Atto-565 
NHS ester dye, with the final aim to use the labelled enzyme in 
immunofluorescence assays on patient’s gut biopsies. Since TG2 was stored 
in Tris-buffer, which contains amino groups and is therefore incompatible 
with the labelling reaction, a buffer exchange was performed. A borate buffer 
was chosen and pH was set to 8.5. This pH would lead to deprotonation of 
protein amino-groups (lysine residues) and allow for efficient reaction of the 
NHS dye with the protein. This pH will also be high enough to prevent rapid 
dye hydrolysis, this way making the labelling reaction highly efficient.  
A PD10 desalting column was used for the buffer exchange process. 
This type of gel filtration chromatography (SephadexTM G-25) allows rapid 
separation of high molecular weight substances from low molecular weight 
substances. Molecules larger than the matrix pores would be excluded from 
the system and elute first, in the void volume of the column. Molecules 
smaller than the pores infiltrate them and, therefore, would elute later. It was 
therefore anticipated to observe an initial peak in the void volume 
corresponding to the protein and a second peak corresponding to the buffer 
salts. 
The desalting column was equilibrated with borate buffer and TG2 
was applied to the system. Fractions corresponding to 0.5ml were collected 
while adding additional buffer to the column. Fractions were then analysed 
using a UV/VIS spectrophotometer, measuring absorbance at 280nm. 
The absorbance analysis showed that the protein eluted first, between 
fractions 7 and 9 with highest absorbance at fraction 8 (V0≈4ml; 
OD280=0.27). As expected a salt peak (VT≈12ml) was observed at fraction 
24 (Fig. 3.4A).  
Fraction 8 (Fig. 3.4B) was calculated to have a protein concentration 
of ≈0.8mg/ml. This fraction was used for the labelling reaction.  
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Fig. 3.4 Absorbance spectrum for buffer exchanged rhTG2. TG2 (0.5ml, 2mg/ml) was 
applied to PD10 column for buffer exchange. Fractions (0.5ml) were collected and diluted 
1:4 for spectroscopic analysis. Data shown was corrected for buffer absorbance. A: 
Absorbance measured at 280nm for each fraction collected. Protein eluted between fractions 
7 and 9 (V0= void volume; VT=total volume). B: Absorbance spectrum giving typical 
spectrum for protein with maximum absorbance near 280nm and no evidence of 
aggregation. 
 
Fluorescent labelling of TG2 was performed in solution, initially using 
a 10-fold molar excess of Atto-565 NHS ester over protein. Labelled protein 
was separated from free label using the PD10 desalting column, while 
returning the protein to its initial, more adequate Tris-buffer. Fractions 
containing eluted labelled TG2 were pooled. Spectroscopic analysis 
confirmed the success of the labelling process, as a 280nm protein peak was 
observed along side the expected 565nm absorbance peak for the 
fluorophore (Fig. 3.5). 
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Fig. 3.5 Absorbance spectrum for Atto-565 labelled rhTG2. Data corrected for buffer 
absorbance. Sample was diluted 1:4 to allow spectroscopic analysis. Labelled protein was 
purified using a PD10 column. It was evident that labelling was successful based on the 
peak observed at 565nm corresponding to Atto-565 dye attached to rhTG2.  
 
Final protein concentration and label density were estimated from a 
standard curve generated from serial dilutions of Atto-565 dye (Fig. 3.6). 
Since the fluorescent label contributes in part to the value obtained for 
OD280 of the sample (Fig. 3.6A), this had to be subtracted to obtain the real 
concentration of TG2. Labelled TG2 was calculated at a final concentration of 
≈318µg/ml and a label density of approximately 2,7 label/TG2. 
Protein concentration was also assessed independently by protein 
assay. Typical BCA assay could not be used as BCA-copper complex has a 
strong absorbance (562nm) that overlaps with the NHS-ester dye 
absorbance peak (565nm). Although a Bradford assay was performed, 
results obtained seemed to be unreasonable. As absorbance for this assay is 
measured at 595nm (Bradford, 1976), there could still be a juxtaposition of 
wavelengths between the assay substrate and the NHS dye that interfere 
with an accurate measurement.  
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Fig. 3.6 Absorbance spectrum of fluorescent dye Atto-565 dilution series and standard 
curves. A: Serial dilution of Atto-565 NHS ester. Molar concentration varies from 0 to 12µM 
as indicated. Active ester component of dye was blocked by reaction with excess of 
ethanolamine prior to analysis. B: Linear regression analysis obtained from absorbance 
values at OD280 for different dye concentrations. C: Linear regression analysis obtained 
from absorbance values at OD565 for different dye concentrations. Standard curves were 
used to estimate the contribution to sample absorbance at 280nm and therefore to derive the 
protein-related absorbance at 280nm. 
 
As labelled TG2 was going to be used to detect B-cell associated IgA 
in immunofluorescence on patient biopsies staining, functionality is likely to 
be of critical importance to the final results. Patient antibodies have been 
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shown to be conformation-dependent and folding of the enzyme may be 
critical for antibody recognition (Iversen et al., 2013; Seissler et al., 2001). To 
assure that the enzyme could adopt conformations associated with catalysis 
following labelling, isopeptidase activity was measured as before. 
Surprisingly, the transglutaminase activity assay showed that labelled TG2 
retained little or no enzymatic activity when compared to the unlabelled 
control (Fig. 3.7). This suggested that modification with Atto-label was 
somehow interfering with the catalytic site or a conformational transition of 
the enzyme, leading to TG2 being inactive.  
 
 
     
 
Fig. 3.7 Atto-565 labelled TG2 isopeptidase activity. A: Enzyme isopeptidase activity for 
20µg/ml TG2 following injection of 2mM Ca2+. Data was normalized for well!specific 
fluorescence and control curve (no Ca2+) subtracted to account for fluorescence bleaching. 
Compared to unlabelled TG2 (blue), Atto-565 labelled TG2 (green) retained little or no 
enzymatic activity. B: Analysis of difference in change in fluorescence over time calculated 
from linear regression (±SD) analysis of the data for the period between 1500s and 2500s of 
a single experiment.  
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3.2.3 Fluorescent labelling of rhTG2 with NHS ester dye: influence of 
conformation 
 
To overcome the fact that the labelling protocol yielded an inactive 
enzyme, a second labelling experiment was performed using a different 
approach. As mentioned in section 1.4.2, TG2 enzymatic activity is 
allosterically regulated by Ca2+ ions and the nucleotides GTP/GDP 
(Achyuthan & Greenberg, 1987; Begg et al., 2006). As a strong allosteric 
inhibitor, GTP supresses Ca2+ activated crosslinking activity. Also, GTP-
binding leads to a structural change in TG2, which acquires a more compact 
“closed” conformation, decreasing the accessibility of the TG2 substrate 
binding-pocket and burying the enzyme active site within the protein (Venere 
et al., 2000). By adding GTP to the labelling reaction, it is expected that the 
consequential conformational change of TG2 to a closed form would prevent 
access of Atto-565 to primary amines located near to the catalytic site or 
substrate-binding pocket of the enzyme, and thereby prevent enzyme 
inactivation. Also, to reduce the extent of labelling in the reaction, the 
previously used borate buffer was changed to a sodium phosphate buffer 
with a lower pH of 7.6. Since the amount of label added to the reaction could 
have a negative impact on the enzyme activity, this was decreased to a 3-
fold molar excess over protein.  
The labelling process was performed as before with the exception of 
addition of 1mM of GTP to the labelling reaction (Fig. 3.8). Spectroscopic 
results obtained using the new methodology were similar to those previously 
obtained, with protein not showing signs of aggregation or precipitation. Final 
concentration of the eluted labelled protein was calculated as being 
≈310µg/ml with a label density of 2,7 label/TG2.  
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Fig. 3.8 Absorbance spectrum for Atto-565 labelled rhTG2. A: TG2 Labelling was 
performed in the presence of 1mM GTP. Labelled protein was purified using a PD10 column. 
Data was normalized for buffer. Sample was diluted 1:4 for spectroscopic analysis. The peak 
observed at 565nm corresponds to Atto-565 dye attached to the protein. B: Absorbance 
spectrum for GTP. Hence, absorbance at 280nm of GTP-bound TG2 is partially due to GTP, 
which has its maximum absorbance at 260nm. 
 
Enzyme activity assay was repeated for the TG2 labelled in the 
presence of GTP, to find out if with the new labelling method could generate 
an active labelled enzyme. For this experiment, the concentration of calcium 
injected was increased to 10mM, to overcome the inhibitory effects of GTP 
and push the equilibrium for binding of allosteric co-factors towards GDP 
release and Ca2+ binding (Fig. 3.9). The isopeptidase assay showed that 
when labelling TG2 in the presence of GTP, the enzyme retained about 50-
56% of its activity when compared to unlabelled control, even though the 
label density was comparable to that observed for the protein labelled in the 
absence of GTP (≈2.7 label/TG2 molecule).  
A further experiment was conducted on a larger scale and similar 
results were observed (Fig. 3.9B). An enzymatically active labelled TG2 
(≈1.22mg/ml) was obtained, which retained about 80% of its activity when 
compared to the wild type control. This percentage was higher than the one 
obtained in the previous experiment and might be related to the lower ratio of 
label to TG2 (0.78 label/protein).  
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Fig. 3.9 Isopeptidase activity of TG2 labelled with Atto-565 in the presence of 1mM 
GTP. A: Enzyme isopeptidase activity of 20µg/ml TG2 following injection of 10mM Ca2+. 
Data was normalized for well!specific fluorescence and control curve (no Ca2+) subtracted to 
account for fluorescence bleaching: FLUOstar OPTIMA (gain 3000). Concentration of 
calcium injected was increased from 2mM to 10mM to compete for the inhibitory effect of 
GTP. Compared to unlabelled TG2 (blue), Atto-565 labelled TG2 (green) retained 
approximately 50% of its enzymatic activity. B: Comparison of fluorescence change for non-
labelled and labelled TG2 calculated from linear regression (±SD) analysis of the data for the 
period between 1500s and 2500s in 2 independent experiments.  
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3.2.4 TG2 labelling: is influence of conformation label specific?  
 
Being aware that label itself could also play a part in TG2 final 
conformation and enzyme activity I decided to repeat the labelling 
experiment using a chemically different Atto-NHS ester dye. Atto-647N also 
emits light in the red spectral region and has a maximum excitation of 644nm 
and a maximum emission of 669nm.  
Even though Atto-565 and Atto-647N NHS-ester compounds react 
with proteins in the same way, they are chemically different (Fig. 3.10). 
Therefore, even though likely attached at the same or overlapping side chain 
permutations, the adjacent protein interactions may be very different, and 
hence, effect on overall protein structure be very different. Different 
structures could have an impact on enzyme activity. This experiment enabled 
the determination as to whether the lack of enzyme activity after labelling 
without GTP was label-dependent or not.  
 
 
          Atto-565 NHS ester                         Atto-647N fluorophore 
 
Fig. 3.10 Chemical structures of Atto-565 and Atto-647N dyes. Note details on Atto 647N 
NHS-ester compound were not publically available and therefore the unmodified dye is 
shown. 
 
The labelling process was repeated in the same way as with Atto-565 
NHS-ester dye, using 0.1M sodium phosphate as labelling buffer. 
Experiments were again performed in the absence/ presence of 1mM GTP.  
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Results obtained when labelling TG2 with Atto-647N were overall 
similar to the ones observed for the Atto-565 dye (Fig. 3.11). TG2 labelled in 
the absence of GTP was calculated to have a final concentration of 
≈217µg/ml with a label density of 2.6 label/TG2. TG2 labelled in the presence 
of GTP was calculated to have a final concentration of ≈96µg/ml with a label 
density of 6.5 label/TG2 (higher than the one obtained in the previous 
experiment). As observed before, when labelling was performed in the 
absence of GTP, labelled protein seemed to lose its catalysis capacity, which 
was maintained if the nucleotide was present during labelling. When 
comparing the isopeptidase activity of the two Atto-647N-labelled proteins 
with its correspondent unlabelled control it was evident that labelled 
TG2+GTP had a relative activity 5x higher than its -GTP pair, despite its 
apparent higher label density (Fig. 3.11E).  
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Fig. 3.11 TG2 labelling with Atto-647 N NHS ester. A: Absorbance spectrum for Atto-647 
labelled rhTG2, labelled in the presence or absence f 1mM GTP. Data is normalized for 
buffer. Sample was diluted 1:4 for spectroscopic analysis. Labelled protein was purified 
using a PD10 Column. Successful labelling is indicated by the presence of a peak at 647nm 
corresponding to Atto-647 dye attached to the protein. B: Serial dilution of Atto-647N NHS 
ester. Molar concentration varies from 0 to 18.66µM. Dye was blocked by reaction with 
ethanolamine prior to analysis. C: Linear regression analysis of absorbance at 280nm for 
different dye concentrations. D: Linear regression analysis of absorbance at 647nm for 
different dye concentrations. Standard curves were used to calculate the label contribution to 
the protein absorbance at 280nm of a protein sample. E: Isopeptidase activity assay was 
carried out as in Fig. 3.9A. Comparison of relative fluorescence change for unlabelled TG2/ 
labelled TG2 calculated by linear regression (±SD) for the period between 1500s and 2500s. 
Atto-647 labelled TG2 retained little enzymatic activity (≈8%) when labelled in the absence of 
GTP.  
 
3.2.5 Influence of temperature on conformation–specific labelling 
 
Unfortunately, upon labelling it was evident that TG2 was aggregating 
at a higher rate than unlabelled protein with prolonged storage without 
freezing. TG2 aggregates were clearly observed as a pink deposit after 
centrifugation of labelled protein. As protein aggregation may be a significant 
factor contributing to loss of activity, it was decided to repeat the labelling 
process with Atto-565 dye but this time at a temperature of 4°C to prevent 
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protein aggregation. It is known that TG2 interaction with substrate at RT but 
not at 4°C render the protein prone to aggregation (presumably due to TG2 
adopting the “open” conformation) (personal conversation with Professor 
Daniel Aeschlimann). 
Buffer exchange of TG2 was performed using a PD10 column and 
0.1M sodium phosphate buffer with pH adjusted to 7.6 at 4°C. The expected 
spectrum with maximum absorbance at 280nm was obtained (Fig. 3.12A). 
Since lowering the temperature was most likely going to slow the labelling 
reaction, the reaction time with NHS-ester was increased to 4h. Also, 
blocking time with 1M ethanolamine was increased to 1h. From the 
spectrophotometry wavelength scan (Fig. 3.12B) it was evident that both 
TG2 labelled in the presence and absence of GTP incorporated the Atto-565 
label. Labelled TG2 -GTP was estimated to have a concentration of 
≈780µg/ml and a label density of ≈4.4 label/protein. Labelled TG2 +GTP had 
a final estimated concentration of 930µg/ml and a label density of ≈6.4 
label/protein, the highest label density obtained so far.  
 However, when performing the isopeptidase assay to assess protein 
enzymatic activity the results were not what was anticipated. Contrary to 
what was observed previously, TG2 labelled in the absence of GTP had 
some enzymatic activity (Fig. 3.12C). Although labelled TG2 -GTP was 
comparatively less active than labelled TG2 +GTP, the former retained ≈11% 
of its activity when compared to the unlabelled control. With labelling at RT, 
this value was close to 0. This suggests that the protein can be effectively 
labelled at 4°C while at the same time protecting protein functionality at least 
partially. 
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Fig. 3.12 Absorbance spectrum of TG2 labelled with Atto-565 at 4°C. A: ≈1mg of TG2 
was applied to two PD10 columns each to enable protein buffer exchange. Fractions 
containing TG2 were pooled and samples were diluted 1:4 for spectroscopic analysis. B: 
Spectroscopic analysis of TG2 labelled +/- GTP at 4°C (data was normalized for buffer in 
graphs A and B). C: Isopeptidase assay was performed with generated labelled TG2 protein 
preparation as in Fig. 3.9A. Relative fluorescence change for unlabelled TG2 and TG2 
labelled in the absence/presence of GTP was calculated by linear regression (±SD) for the 
period between 1500s and 2500s. 
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3.2.6 rhTG6 – protein purification  
 
RhTG6 was expressed in Spodoptera frugiperda, SF9 insect cell line 
using a baculovirus expression system containing the human TG6 sequence 
with an added His6-tag to the C-terminus. Insect cells were collected by 
centrifugation and resuspended in purification buffer. Expressed protein was 
harvested by lysis of insect cells using the Stansted pressure cell 
homogenizer. RhTG6 was purified from the lysate using Ni2+-chelating affinity 
chromatography. Purified protein was analysed by SDS-PAGE under 
reducing conditions, followed by staining with Coomassie brilliant blue R (Fig. 
3.13A). SDS-PAGE shows that the approach was successful in obtaining a 
single protein from the starting material with a molecular weight of ≈80kDa. 
Since it is known that TG6 has a calculated molecular weight of 
approximately 79kDa based on its sequence, this likely affirms that the band 
of purified protein corresponds to the protein of interest. The result is further 
confirmed by co-migration of this band in the gel with a TG6 standard. 
Purified TG6 was subjected to spectroscopic analysis, which showed a single 
peak with a maximum absorbance of around 270nm (Fig. 3.13B). The reason 
for the shift to lower wavelength of the absorbance maximum is unclear, but 
could be related to a nucleotide contamination, either specifically associated 
with the protein or in the form of DNA. Protein concentration was calculated 
to be 405µg/ml using absorbance at 280nm and Beer-Lambert law. 
To ascertain that rhTG6 was enzymatically active, an isopeptidase 
activity assay was performed in a similar way as previously described with 
TG2. It has previously been shown that the quenched substrate is 
recognized by TG6 (Thomas et al. 2013). The assay showed a large 
increase in fluorescence over time after 2mM CaCl2 injection, demonstrating 
enzyme activity (Fig. 3.13C). Water injection, as a negative control, showed 
the Ca2+-dependence of the reaction and thereby the assay specificity.  
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Fig. 3.13 Purification of rhTG6. A: SDS-PAGE (4-20% polyacrylamide gel) under reducing 
conditions showing starting material and final purified rhTG6 after staining with Coomassie 
blue R. When compared to the known TG6 standard it was evident that a purified band 
presented at the same molecular weight. Note. Samples were run on the same gel and 
cropping of the picture has not altered relative positions of bands. B: Absorbance spectrum 
of rhTG6 pool of purified protein corrected for associated buffer absorbance. Spectroscopic 
analysis of purified protein shows a single peak with maximum absorbance at ≈270nm.  C: 
Enzyme isopeptidase activity of 20µg/ml TG6 following injection of 2mM Ca2+. Data was 
normalized for well!specific fluorescence FLUOstar OPTIMA (gain 3000).  
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3.2.7 TG6 labelling with Atto-565 NHS ester (in solution) 
 
Since the focus of the project was the role of TG6 in gluten related 
disorders, purified rhTG6 was labelled using the same principle as the 
approach described for rhTG2. As with labelled TG2, TG6 was labelled for 
future use in immunofluorescence assays.  
The same 0.1M sodium phosphate buffer was used for the labelling 
process, but with the addition of 500mM NaCl, 10mg/ml sucrose and with the 
pH increased to 7.8. These conditions were previously found to preserve 
TG6 activity by researchers in our group. TG6 was buffer exchanged into 
sodium phosphate buffer using a PD10 column. Protein solution was cleared 
from any aggregates by centrifugation and spectroscopic analysis showed a 
non-aggregated protein, with maximum absorbance around 275-280nm, 
which was expected for highly pure protein (Fig. 3.14A). Labelling of TG6 
was performed in solution with a 3-fold molar excess of Atto-565 NHS ester 
over protein and in the presence of 5mM GTP. A higher GTP concentration 
was employed due to the lower affinity of TG6 for GTP compared to TG2 
(Thomas et al. 2013). Spectroscopic analysis of labelled TG6 showed that 
labelling of the protein was successful, as indicated by the presence of an 
absorbance peak at 565nm corresponding to the Atto dye (Fig. 3.14B). 
However, even though in principle successful labelling TG6 occurred, the 
modified protein appeared to aggregate at a high rate, showing a high 
degree of aggregation in the spectroscopic analysis immediately after 
completion of labelling reaction. Nevertheless, an isopeptidase assay was 
performed to assess labelled TG6 enzymatic activity. For this assay, the 
NaCl concentration of the reaction mixture was raised from to 125mM to 
375mM, as a higher salt concentration is required for stability of TG6 
(personal communication, Professor Aeschlimann). The activity assay 
showed a loss of activity of labelled TG6 when compared to its unlabelled 
control after 10mM CaCl2 injection, with labelled TG6 retaining only ≈6% of 
its activity (Fig. 3.14C). There was also a loss of activity after buffer 
exchange of TG6, which highlights the sensitivity of TG6 to different chemical 
environments.  
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Labelled protein continued to rapidly aggregate over time and freezing 
of the samples lead to protein precipitation, making it impossible to use this 
material in our immunofluorescence assay.  
 
3.2.8 TG6 labelling with Atto-565 NHS ester (on column) 
 
To prevent loss of protein during buffer exchange step, it was decided 
to label TG6 while purifying it. It could be that, while attached to the nickel 
column TG6 has less flexibility to undergo conformational changes and 
therefore is less likely to aggregate. 
RhTG6 was purified as described before, but this time, labelling of the 
protein was performed before the elution step from the Ni2+-chelating column. 
TG6/sepharose slurry was washed twice with a buffer composed of 0.1M 
sodium phosphate, pH7.8 and 300mM NaCl to allow for labelling with 
Atto-565 dye. Total amount of TG6 present was extrapolated from previous 
purification experiments to be ≈500µg at ≈6.3µM. Based on this, a 3-fold 
molar excess of labelling reagent over protein was used, which was added to 
the 1ml volume of slurry.  Labelling was performed for 1h at room 
temperature and protein purification continued as normal. Purified labelled 
TG6 was buffer exchanged to 10mM Tris pH 7.8 500mM NaCl, 10mg/ml 
sucrose using a PD10 column, for further analysis and storage. 
Spectroscopic analysis revealed a better quality protein (no aggregation) but 
also that labelling was not as efficient as expected (0.6 label/TG6).  
Therefore, it was decided to increase the amount of label added from 
3- to 10-fold molar excess, and to double the volume of the reaction mixture 
to achieve better mixing of the solid phase during the reaction. This change 
seemed to improve the labelling process. The results of three independent 
preparations of TG6 labelling are shown in Fig. 3.15A. Preparation I was 
calculated to have a final concentration of ≈160µg/ml and a ratio of ≈1.5 
label/TG6. Preparation II was ≈290µg/ml and ≈1.2 label/TG6 and preparation 
III was ≈340µg/ml and ≈1 label/TG6. Overall the labelling of TG6 appeared to 
be quite reproducible. Although some aggregation was still evident from the 
spectra, this appeared to be minimal. 
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Fig. 3.14 Labelling of TG6 with Atto-565 NHS ester dye in solution. A: Absorbance 
spectrum of buffer exchanged TG6. Data normalized for buffer. B: Absorbance spectrum of 
Atto-565 labelled TG6. TG6 was labelled in the presence of 5mM GTP. Data normalized for 
buffer. Absorbance between 320nm and 450nm is indicative of protein aggregation (light 
scattering). C: Isopeptidase activity of unlabelled and Atto-565 labelled TG6. Data was 
obtained with ≈20µg/ml TG6, normalized for well-specific fluorescence and control curve 
without Ca2+-activation was subtracted to account for fluorescence bleaching: FLUOstar 
OPTIMA (gain 3000). Unlabelled buffer exchanged TG6 displays enzymatic activity but most 
of it is subsequently lost during labelling. Labelled TG6 retained only 6% of its activity when 
compared to the starting material control. D: Comparison of relative rate of fluorescence 
change for TG6, buffer exchanged TG6 and Atto-565 TG6 after 10mM CaCl2 injection, 
obtained from linear regression (±SD) of the data for the period between 1250s and 2250s.  
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A B 
The labelled TG6 was subjected to the isopeptidase assay to evaluate 
enzyme activity. The three independent preparations of labelled TG6 
displayed enzymatic activity, with relative activity varying from 16% to 43%, 
depending on preparation, when compared to its unlabelled control. 
Unlabelled TG6 was derived from the same TG6 preparation purified in 
parallel but omitting the labelling step. 
 
 
    
Fig. 3.15 On column Atto-565 labelling of TG6. A: Absorbance spectrum of Atto-565 labelled 
TG6 for 3 different preparations. Data normalized for buffer. The peak observed at 565nm corresponds 
to Atto-565 dye attached to the protein. B: Isopeptidase activity of ≈20µg/ml enzyme. Specific activity 
was derived as in Fig. 3.14 and is expressed as relative activity compared to matched unlabelled 
protein. 
 
Taken together, these data show that TG6 had been successfully 
labelled and purified for use in downstream assays.  
 
3.2.9 TG6 labelling with Atto-565 – effects of labelling process on the 
protein 
 
Although expression, purification and labelling of TG6 were quite 
successful, a rapid increase in aggregation over time was evident if the 
protein was stored at 4°C. Therefore, a batch of TG6 was monitored after 
labelling and purification process over a 3-day period (Fig. 3.16A). The initial 
250 300 350 400 450 500 550 600
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Wavelengh (nm)
A
bs
or
ba
nc
e OD280
OD565
0.2868 0.2694
Prep I
Prep II
Prep III
0.4996
0.1495
0.3684
0.0951
Prep I Prep II Prep III
0.0
0.1
0.2
0.3
0.4
0.5
R
el
at
iv
e 
A
ct
iv
ity
 (A
tto
-5
65
 T
G
6/
w
t T
G
6)
 79 
material was calculated to have a concentration of ≈94µg/ml. After 24h at 
4°C an aliquot was taken and centrifuged for 10min at 16000x g to remove 
any aggregates. A pink pellet was detected in the tube after centrifugation. 
Spectroscopic analysis of the labelled TG6 showed a decrease in 
concentration of ≈18%. After 72h at 4°C, another aliquot was treated and 
analysed as before. At this time, although a pellet was not visible, the 
absorbance spectrum indicated high levels of aggregation of the protein, to 
an extent where further analysis was of no purpose and the experiment was 
therefore terminated. This showed that the labelled TG6 could not be stored 
at 4°C before use in downstream experiments.  
In order to prevent loss of protein over time, another approach was 
attempted, and this involved TG6 lyophilisation. Unfortunately, loss of protein 
was still observed when reconstituting the protein into the original volume 
from the lyophilised form (Fig. 3.16B). As no suitable conditions for storage 
could be identified, the protein had to be prepared fresh for the planned 
immunofluorescence experiments. 
 
 
    
Fig. 3.16 Absorbance spectrum of Atto-565 labelled TG6. Data normalized for buffer. A: 
Spectroscopic analysis of labelled TG6 stored at 4°C over a 3-day period. A decrease in concentration 
was observed after 24h and high levels of protein aggregation were visible after 72h. B: Spectroscopic 
analysis of labelled TG6 before and after lyophilisation. Aggregation/loss of protein is visible after 
lyophilizing process.  
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3.3 Discussion  
 
In this chapter, it was shown that successful labelling of the proteins 
involved in the autoimmune response in coeliac disease and gluten ataxia, 
i.e. TG2 and TG6 respectively, was achieved. The effects of fluorescent 
amine-labelling on TG2 functionality was analysed, with one of the most 
important findings being the positive effect that addition of the nucleotide 
GTP had on generating a labelled enzyme that was functional. This was 
important as autoantibodies have been shown to recognise antigen in a 
conformation-sensitive manner (Iversen et al. 2013; Seissler et al. 2001).  
GTP is known to be an allosteric regulator of TG2, with the nucleotide 
having a negative regulatory effect that can be overcome by high 
concentrations of calcium (Venere et al., 2000). The TG2-GTP binding site 
has been shown to be located in a pocket between the first β-barrel and the 
catalytic core (Jang et al. 2014). The majority of the residues involved in 
GTP-binding come from the end of the first β-strand of the first β-barrel 
domain and the loop that connects it to the next β-strand (Arg476, Arg478, 
Val479, Ser482, Met483, Arg580, and Tyr583). Also, two residues from the 
catalytic core, Lys173 and Phe174, have been shown to contribute to the 
GTP interaction (Begg et al., 2006; Jang et al., 2014; S. Liu et al., 2002).  In 
these experiments it was observed that reaction of TG2 with Atto-565 NHS 
ester led to absence of isopeptidase activity while the presence of GTP 
during labeling generated an enzymatically active protein.  
More generally, NHS ester acts by reacting with primary amines, at 
the N-terminus or side chains of proteins. With 13 lysine residues present 
within the TG2 catalytic core alone it was possible that attachment of 
fluorescent label would result in structural changes that interfere with enzyme 
activation or catalysis. It could also mean that label-attachment blocks 
substrate access to the TG2 active site. That a more “open” conformation 
was linked to enzyme inactivation was supported by the fact that some 
isopeptidase activity was retained when labelling was performed at 4°C even 
in the absence of GTP. Lower temperatures reduce conformational 
transitions and hence reactions with residues available in the extended 
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conformation were substantially less likely. This interpretation is also 
consistent with the observation that the label density per protein molecule 
was not reduced under these labelling conditions. Hence, the availability of 
structurally/functionally critical residues must be the distinguishing factor. 
GTP binding has been reported to cause a conformational change to 
TG2, shifting the protein to a closed conformation and burying the active site 
(Pinkas et al. 2007). With TG2 in a closed conformation and no access to the 
active site, labelling can only occur by reaction with lysines available on the 
surface of the protein. Such surface modification is apparently tolerated and 
an increase in substrate cleavage and release of quenched fluorophore is 
observed upon the conformational change induced by high concentrations of 
calcium. Jeon et al. have suggested that conformational changes caused by 
GTP binding may help maintaining enzyme stability physiologically, to display 
transamidation activity at high calcium concentration(Jeon et al. 2002). 
Similar results were obtained when labeling TG2 using the same 
protocol but a chemically different fluorophore, Atto-647N NHS ester. As 
expected, when labeling was performed without incubation of the protein with 
GTP an enzymatically inactive TG2 was obtained, while pre-incubation of the 
protein with GTP led to an enzyme with isopeptidase activity. This result led 
to the conclusion that the lack of isopeptidase activity after labeling in the 
absence of GTP was not dependent on the nature of the fluorophore per se 
but the site at which the modification occurred, although both fluorophores 
used had relatively hydrophobic structures. 
The same labeling principle was subsequently applied to the 
recognized gluten ataxia antigen, TG6.  Initially, the same procedural 
approach was used as for TG2, i.e. attempted labelling of TG6 in solution. 
Even though buffer modifications were put in place and sucrose was added 
to stabilize TG6, this approach proved unsuccessful. Spectroscopic analysis 
of labelled TG6 showed high absorbance levels between 320nm and 450nm 
indicating substantial protein aggregation.  
As the major problem appeared to be related with stability of TG6 in 
buffer conditions suitable for labelling, it was decided to label TG6 during its 
purification, when bound to a solid support. This approach prevents protein 
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aggregation during labelling and enables re-equilibration (refolding) of protein 
in appropriate buffer solution prior to elution from solid support. By this 
approach and a 10-fold molar excess of label over protein, a sufficiently high 
label density on TG6 (1-2 fluorophores per protein molecule) was obtained. 
Labelled TG6 showed isopeptidase activity using the in-house activity assay. 
Even though active, the specific activity of different preparation varied 
substantially, likely due to the propensity of the labelled protein to aggregate. 
It is unlikely that this result was related to excessive modification of protein 
with label as different preparations that had similar label/TG ratios had quite 
different enzymatic activity levels, and estimated label density was typically 
low (≈1-2 fluorophores per protein molecule). Instead, lower levels of activity 
were likely linked to protein aggregation.  
TG6 seemed to be less stable after labelling with Atto dye as evident 
from the relatively rapid decrease in concentration of soluble protein and 
increase of aggregation over time. As no GTP was used during the solid-
phase labelling process of TG6, Atto-565 could have modified the protein in 
critical positions that lead to protein insolubility. As these experiments were 
costly and of large experimental effort, no further optimization was 
undertaken, but a workable compromise adopted. Labelled TG6 was kept in 
the fridge and used for immunohistochemistry as soon as possible (within 
24h) or frozen at -20°C. Although the freezing process led to loss of protein, 
such aggregates could be removed by centrifugation prior to the experiment 
and the concentration of the remaining soluble protein estimated from 
absorbance measurements. This proved to be a successful strategy, with 
results from downstream experiments being presented in chapter 5. 
In conclusion a successful expression and purification of TG2 and 
TG6 was achieved. Furthermore, Atto-565 labelled TG2 and TG6 were 
produced, and they were shown to be enzymatically active.  
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Chapter 4 Transglutaminase: amine donor substrate binding and 
implications for deamidation reaction 
 
4.1 Introduction 
 
TG2 is the most widely expressed enzyme from the transglutaminase 
family in mammalian tissues. TG2’s expression has been demonstrated at 
both intra and extracellular levels, with endothelial cells, smooth muscle cells 
and fibroblasts showing constitutive expression. In the context of 
autoimmune diseases TG2 has been recognized as the autoantigen in 
coeliac disease (Dieterich et al. 1997) as well as suspected to be involved in 
the pathogenesis of Alzheimer’s,  Parkinson’s,  Huntington’s, osteoarthritis 
and breast and ovarian cancer (Iismaa et al., 2009). 
Although there are numerous non-catalytic actions driven by TG2, the 
ability to introduce novel post-translational protein modifications in a calcium 
dependent way is what seems to relate this enzyme to so many autoimmune 
responses. In fact, the involvement of TG2 in the pathological process of 
coeliac disease is related to deamidation of gluten peptides (Arentz-Hansen 
et al. 2000) and formation of TG2-gluten complexes that culminates in the 
activation of gluten-specific T cells. These can then provide help to TG2-
specific B cells and lead to production of antibodies against the self protein 
(Sollid 1997). 
Amongst the types of post-translational protein modifications, TG2 is 
able to catalyse transamidation and hydrolysis of proteins and peptides. The 
enzyme active site, Cys277, initially targets a glutamine-containing protein or 
peptide resulting in a thiol-ester bound acyl-enzyme intermediate and release 
of ammonia (Folk, 1983).  In a second step the intermediate complex can be 
attacked by an amine donor substrate (primary amines) resulting in a 
transamidated product. In some instances, water can replace the amine 
donor substrates driving the reaction towards hydrolysis. This leads to 
deamidation of the uncharged substrate glutamine and its conversion into the 
charged residue glutamate. Deamidation can also be a by-product of 
isopeptidase of an already cross-linked polypeptide.  
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Although it is known that deamidation of proteins by TG2 occurs, it still 
remains to be clarified why the protein has preference for this reaction, as the 
rich presence of primary amines would favour transamidation.  
Boros et al. reported the TG2 selective deamidation of a glutamine 
residue in the small heat shock protein 20 (Hsp20) under conditions where 
other glutamine residues were transamidated (Boros et al. 2006). These 
results suggest that transamidation and also deamidation could be influenced 
by both substrate and reaction conditions. Stamnaes et al. also 
demonstrated that direct deamidation reactions in the presence of an acyl-
acceptor were conditioned by peptide sequences as well as enzyme 
concentration. Good TG2 substrates were more prone to transamidation, and 
poorer substrates had a higher ratio of deamidation to transamidation 
(Stamnaes et al. 2008). Furthermore, these researchers also reported that 
TG2 could hydrolyse isopeptide bonds where both the acyl-donor and acyl-
acceptor were peptides.  
Previous work performed within our group (by Adamczyk) showed that 
a large difference in the concentration of two different amines (glycine 
methylester and Nα-acetyllysine methylester) was necessary to produce a 
transamidated product in TG2-mediated conversion of an already cross-
linked substrate (Adamczyk, 2013). This suggests that the nature of the 
amine has an impact in the preference for transamidation or deamidation 
reactions by TG2.  
Although a structure of TG2 in complex with an inhibitor that mimics a 
gluten-peptide has been solved (Pinkas et al. 2007), information on how 
amine-donor substrates interact with the enzyme is still lacking. 
In this chapter, a series of experiments was undertaken leading to the 
suggestion that inhibited TG2 specifically interacts with an amine donor 
substrate. This culminated in an attempt to crystalize the enzyme complex. 
By solving this crystal structure, elucidation of how the nature of an amine 
donor substrate could lead to a transamidation or deamidation reaction could 
be forthcoming. Therefore, a report on TG2 interaction with different amine 
donor substrates could be beneficial for novel therapeutic targets in the 
context of gluten-related disorders.  
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The aims of the chapter: 
 
1. To characterize inhibited rhTG2 by assessing its catalytic activity 
using a fluorogenic activity assay and an in gel enzyme assay and to 
compare it against wild-type and mutant forms. 
2. To report on TG2 interaction with different amine donor substrates by 
crystallizing inhibited TG2 in the presence of two different amines.  
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4.2 Results 
 
As shown in the previous chapter, TG2, when labelled in the absence 
of GTP, had no enzymatic activity in an isopeptidase assay. In contrast, TG2 
labelled in the presence of GTP was enzymatically active. The fact that these 
results were observed for chemically different Atto-565 and Atto-647N labels 
(Fig. 4.1) suggests that this was not due to the presence of a particular 
fluorophore and that labelling was not a random event.  
 
Fig. 4.1 Isopeptidase activity for TG2 labelled in the presence/absence of GTP. Each 
column represents relative fluorescence between labelled TG2 and wt TG2 after 2mM 
calcium injection. Linear regression slopes were used for calculations. Relative fluorescence 
demonstrates higher levels of enzymatic activity for the protein labelled in the presence of 
GTP when comparing to the one labelled in the absence of the nucleotide.  
 
The above finding raised the question as to why GTP-bound TG2 was 
resistant to inactivation during protein labelling and as an extension to this, 
could there be a conformational difference between the active and inactive 
labelled TG2. 
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4.2.1 Structural differences of labelled TG2  
 
It was suspected that the absence of GTP led to labelling at specific 
sites that could influence the conformation of the enzyme and hence prevent 
the catalytic cycle. It was therefore decided to run TG2 preparations, labelled 
in the presence and absence of GTP, on a native polyacrylamide gel 
electrophoresis (PAGE). A native PAGE is a non-denaturing type of 
electrophoresis. Here, molecules are separated based on both their charge-
to-mass ratio and also their overall structure. This allows the analysis of 
proteins in their native conformation, as both the conformation and biological 
activity of proteins remain intact. One disadvantage of this method is that 
proteins may not separate in a predictable way, perhaps even remain as 
protein complexes (they cannot move through the polyacrylamide gel as 
quickly as SDS-bound, denatured proteins). Furthermore, it is important to 
keep the equipment cool to minimize the effects of heat denaturation and 
proteolysis in order to maintain the integrity of proteins during 
electrophoresis. The main advantage of this technique is that, because 
proteins remain in the native state, they may be visualised not only by 
general protein staining reagents but also by specific enzyme-linked staining. 
To confirm that adding GTP prior to labelling had an effect on the 
overall structure of the protein and therefore its enzymatic activity, 
preparations of TG2 labelled in the presence or absence of GTP were run 
along side unmodified wild type control TG2 and a commercially purchased 
TG2 (T051 Zedira, Germany), conjugated with an inhibitor at the active site 
Cys residue in order to stabilize the open conformation. To determine 
whether the enzyme bound GTP and subsequently adopted the closed 
conformation, labelled TG2 preparations were incubated with an additional 
600µM of GTP for 1min and, where indicated, 25µM of GTP was added to 
the running buffer to maintain GTP saturation during electrophoresis. The gel 
was analysed using the appropriate filters for the fluorophores using a 
phosphorimager to visualise labelled TG2. Gels were subsequently stained 
for total protein with Coomassie Blue R. 
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When comparing wt TG2 to open TG2 it was observed that they ran in similar 
positions in the absence of GTP (Fig.4.2).  However, when GTP was added, 
a shift in the position of wt TG2 was observed, which was not true for the 
other form of the enzyme, as being covalently bound to the inhibitor, it cannot 
bind GTP.  
Analysis of labelled TG2 showed a shift in the protein position when 
samples were pre-incubated with GTP. Additionally, there seemed to be a 
difference in the proportion of the protein able to bind GTP when comparing 
TG2 labelled in the presence as opposed to the absence of the nucleotide 
(Fig 4.2). The fraction of labelled TG2 capable of binding GTP was identified 
by the condition-dependent switch in migrating position, i.e. it ran at the same 
level as the wt control. Such results led us to the view that it is the enzyme 
able to bind GTP that constitutes the active fraction in the preparation.  
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Fig. 4.2 Native PAGE for different variants of TG2. Atto-565 and Atto-647N labelled TG2 
were run alongside wt and open TG2. The top panel correspond to the samples where no 
GTP was added prior to or during electrophoresis. The bottom panel corresponds to 
samples where 600µM GTP was added prior to electrophoresis. To maintain GTP saturation, 
25µM GTP (final concentration) was added to the running buffer on the bottom panel. 
Coomassie blue R staining is shown as a blue colour. Fluorescence (grey colour) of Atto-565 
labelled TG2 was visualized using a combination between the 532nm laser line excitation 
and a 560nm long pass filter for emission (PMT=470V). For Atto-647N labelled TG2 a 
633nm laser line excitation and the 670BP30 filter for emission (PMT=430V) were used. The 
native electrophoresis showed that labelling in the absence of GTP resulted in enhanced 
loss of GTP-binding capacity. BP= band pass; PMT = photomultiplier tubes 
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4.2.2 Analysis of FITC-cadaverine incorporation of TG2  
 
It was suspected that the band observed at a lower position in the gel 
when adding GTP was the active fraction of the labelled TG2. To understand 
if this hypothesis was correct, an ‘in gel’ enzyme activity assay was 
performed using the FITC-conjugated substrate, cadaverine. Cadaverine is a 
diamine compound that will act as an amine donor substrate for TG2 by 
mimicking a lysine side chain. Incubation of the gel with FITC-cadaverine, 
under appropriate conditions, enables the analysis of activity of different 
fractions of the enzyme within the gel. This is possible because TG2 has the 
ability to cross-link with the substrate and itself. That way, enzymatically 
active TG2, will be covalently modified with the fluorescent substrate. 
The different variants of TG2 were run on a native PAGE in the 
presence of GTP, as previously shown. The gel was then incubated with a 
buffer solution containing calcium to activate the enzyme and allow substrate 
binding. After extensive washing over a 24h period, the gel was analysed for 
FITC fluorescence using a variable mode imager. 
As previously observed, there appeared to be a shift in the migration 
position of the protein when labelling was performed in presence of GTP that 
does not appear in TG2 labelled in absence of the nucleotide. This was true 
for both Atto-565 and Atto-647N fluorophores (Fig. 4.3A), whereby the faster 
migrating bands correspond to the GTP-bound form of TG2. The retarded 
bands (higher position in the gel relative to TG2) correspond to TG2 
complexes. When comparing Atto-565 or Atto-647N with the correspondent 
FITC-cadaverine labelling, it was evident that the faster migrating bands 
mentioned (TG2•GTP) actually corresponded to the active TG2, as they were 
the only bands where the enzyme interacted with the FITC-conjugated amine 
donor substrate.  
FITC-cadaverine is expected to be covalently cross-linked to TG2 
through the autocatalytic action of the enzyme. This result is confirmed by 
wild type TG2, which shows a strong band in the same position for FITC 
labelling (Fig. 4.3A). To further confirm this result, a second experiment was 
performed with an independently labelled batch of enzyme. This time, two 
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separate native PAGE gels were run, with and without the presence of 25µM 
in the running buffer (Fig. 4.3B). Results showed that a shift of the protein 
was only visible when the saturation of GTP in the gel was maintained (Fig. 
4.3B right panel). This was true for wt TG2 and all variants of labelled TG2, 
even when pre-incubated with GTP. However, enzyme activity was 
demonstrated for the proteins labelled in the presence of GTP independent 
of whether GTP was present during electrophoresis. The difference in band 
intensity appears to be due to the ‘sharpness’ of the bands (compared to 
Coomassie blue) consistent with GTP promoting adoption of a defined, 
compact conformation. An interesting result was that a band shift was still 
observed for Atto-565 TG2 even though the protein was not previously 
incubated with GTP. Also, for Atto-565 labelled TG2 in the absence of GTP, 
a proportion remained GTP-sensitive (Fig. 4.3B right panel). This was an 
unexpected result, as the protein should not have the capacity to bind GTP. 
This might be related to residual non-labelled TG2 that was not affected by 
the labelling process and therefore subsequently behaved as wt TG2.  
Another surprising result was that the irreversibly inhibited open TG2 
also ‘reacted’ with the amine substrate (Fig. 4.3A right panel). It was 
speculated that either inhibitor conjugation was incomplete or the enzyme 
conformation represented by this “open form” had a high-affinity binding site 
for the amine donor substrate and therefore bound FITC-cadaverine non-
covalently. To test if the FITC-cadaverine was non-covalently bound to the 
open TG2, different variants of TG2 were incubated in vitro with FITC-
cadaverine in the presence of Ca2+. The samples were analysed by SDS-
PAGE (Fig. 4.3C). As this is a type of denaturing electrophoresis, if the 
cadaverine was not covalently bound to TG2, it should run in the gel front 
due to its low molecular mass. Along with open TG2 and wt TG2, two TG2 
mutants were analysed. The TG2 C277S has a modified active site and 
therefore is enzymatically inactive. However, it should be able to bind 
glutamine donor substrate. The TG2 E329G is a Ca2+-binding site mutation. 
Since calcium is required to bring about a conformation that harbours 
enzymatic activity, this variant was not expected to bind either the glutamine 
donor or the amine-donor substrate. The SDS gel showed that only the open 
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and wt TG2 were able to bind the substrate, presumably in a covalent way, 
as the FITC label was only detected in bands corresponding to these variants 
(Fig. 4.3C). Furthermore, the assay was specific, as Ca2+-binding and active 
site mutant TG2 displayed no cadaverine incorporation. These results 
suggested that open TG2 had considerable residual activity, and that this 
contributed to the unexpected labelling in the ‘in gel’ assay (Fig. 4.3A). 
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Fig. 4.3 ‘In gel’ TG2 enzymatic activity as determined with FITC-cadaverine. A: 2µg of 
labelled TG2 were separated on a native PAGE, wt and open TG2 were used as controls. 
Samples were pre-incubated with 600µM GTP and electrophoresis was carried out in the 
presence of 25µM GTP. Gel was incubated with FITC-cadaverine solution in the presence of 
10mM Ca2+. The first panel corresponds to Atto-647N labelled TG2 visualized using a 
633nm laser line for excitation together with a 670nm band pass filter for emission 
(PMT=450V). The second panel corresponds to Atto-565 labelled TG2 visualized using a 
532nm laser line for excitation and a 560nm long pass filter for emission (PMT=500V). 
These images were captures prior to labelling with FITC-cadaverine.  For visualization of 
FITC (third panel) a 488nm laser line was used for excitation and a 520nm band pass filter 
for emission (PMT=500V) Results show that the shifted band observed for both Atto-647N 
and Atto-565 labelled TG2 +GTP is the active fraction of the protein, as it incorporated the 
FITC-cadaverine. B: To prove that results were not influenced by addition of GTP, a second 
experiment was conducted where samples were pre-incubated +/-600µM GTP and 
electrophoresis was performed +/- 25µM GTP. A shift of the band was only observed in 
samples were GTP saturation was maintained during electrophoresis (right panel). These 
bands were also the ones able to react with the fluorescent amine substrate. C: SDS-PAGE 
of TG2 variants incubated in vitro with FITC-cadaverine substrate in the presence of 10mM 
Ca2+at 37°C for 30min. Coomassie blue R staining is shown on the left, FITC-fluorescence 
on the right (for details see A). Enzymatically inactive TG2 mutants were not able to bind 
FITC-cadaverine covalently. Reaction of the fluorophore with open TG2 suggests this protein 
to have a considerable amount of residual activity.   
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4.2.3 Inhibition of TG2 with B003 
 
To overcome the problem of residual activity of commercially 
purchased inhibited-TG2 and thereby verify whether interaction of FITC-
cadaverine with the open TG2 relates to this residual activity or non-covalent 
binding, it was decided to generate our own rhTG2 in the open conformation. 
The compound tert-Butyloxycarbonyl-(6-Diazo-5- oxonorleucinyl)-
LGlutaminyl-L-Isoleucinyl-L-Valinmethylester, a site specific irreversible 
inhibitor of TG2 known as B003 (Zedira, Germany) was purchased.  
The TG2 protein was inhibited in two steps with a buffer containing 
50µM B003, a 10-fold molar excess over protein. A solution containing 10mM 
CaCl2 +/- 1mM putrescine was added in the second step. Ca2+ activation was 
employed to allow substrate access to the active site. Putrescine, like 
cadaverine, is a high affinity TG2 amide donor substrate (Folk & Finlayson, 
1977). It was added to the reaction as a substrate ‘competitor’, to investigate 
if after adding this amide donor substrate the inhibited protein was still able to 
bind FITC-cadaverine. If the inhibited transamidation intermediate of the 
enzyme bound amide donor substrate strongly and the off-rate was very slow 
as suspected from previous experiments, then competition should be highly 
effective. Thereafter, inhibited TG2 as well as wt TG2, as a control, was 
rebuffered to remove free inhibitor and kept on ice until needed. An 
isopeptidase assay was performed to compare levels of enzymatic activity 
between wtTG2 and inhibited variants. Inhibited TG2, +/- putrescine, both 
showed little or no activity when compared to the wt control (Fig. 4.4A), 
leading to the belief that inhibition was successful. The inhibited proteins 
were also subjected to native PAGE analysis along side wt TG2 as a control. 
After electrophoresis, the gel was incubated with FITC-cadaverine as before 
(Fig. 4.4B) to assess transamidation activity/amine donor substrate 
interaction. As expected our control wt TG2 was able to bind and crosslink to 
the cadaverine. Although both variants of inhibited TG2 were shown to be 
inactive in the isopeptidase assay, some level of fluorescence in the ‘in gel’ 
assay was still detectable. Coomassie blue staining revealed that the 
inhibited TG2 preparations contained significant levels of protein complexes.  
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Given that the reaction was carried out at room temperature it was likely that 
autocatalytic crosslinking readily occurring in the presence of high Ca2+ 
concentrations was responsible for TG2 complex formation. However, it was 
also possible that the transamidation intermediate, open conformation TG2, 
was less stable and therefore formed non-covalent aggregates. These 
results were found to be inconclusive, as both the low levels of fluorescence 
in the gel assay and low enzymatic activity in the isopeptidase assay for 
inhibited protein could be related to TG2 complex formation and not the 
inability of the monomeric protein to bind or react with cadaverine.  
A second experiment was carried out, this time with the addition of N- 
Voy to prevent protein aggregation. N-Voy are commercially available linear, 
uncharged, carbohydrate polymers with highly amphipathic properties. They 
are around 5kDa and designed to increase protein solubility whilst preventing 
aggregation. Their working mechanism is by association at multiple points 
with surface exposed hydrophobic patches of proteins to form multipoint 
reversible complexes (Expedeon, n.d.).  
To assess the ability of N-Voy to prevent protein aggregation, 10µg of 
wtTG2 were incubated in the presence and absence of 50µg of N-Voy. As 
temperature is a critical factor in protein aggregation, incubation was carried 
out at either 4°C or 37°C. B003-inhibited protein was also incubated with N- 
Voy to test whether these carbohydrate molecules could prevent protein 
aggregation. The samples were analysed through native PAGE followed by 
incubation with FITC-cadaverine in the presence of Ca2+ (Fig. 4.4C). 
When analysing wtTG2 incubated without N-Voy it was evident that 
temperature had a dramatic effect on protein aggregation. At 37°C, there was 
a high degree of protein aggregation, and this was not observed if the 
experiment is carried out at 4°C. Unfortunately, protein incubated in the 
presence of N-Voy showed up as a smear in the native gel, which indicated 
that, although the polymer bound to TG2 and stabilised it, it interfered with 
the electrophoretic separation of the protein into a distinct species and 
therefore was not suitable for our assay.  
Since high temperatures seemed to have a negative effect on TG2 
integrity, it was decided to perform the inhibition process at 4°C. TG2 (5µM in 
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25µl reaction volume) was inhibited by 50µM B003 at 4°C, followed by further 
inhibition in the presence of calcium in a second step. The inhibited protein 
was subsequently subjected to the isopeptidase assay as before (Fig. 4.4D). 
Results showed that inhibition of TG2 was successful, as inhibited protein 
showed no measurable activity.  
To further confirm successful inhibition of TG2, inhibited TG2 
(incubated at 4°C), wtTG2, open TG2 (commercial) and mutant E329G were 
incubated, in vitro, with FITC-cadaverine in the presence of 10mM CaCl2 or 
1mM EGTA and then separated on a SDS-PAGE to assess if FITC- 
cadaverine was covalently bound (Fig. 4.4E). TG2 E329 has a mutation in a 
glutamic acid residue that is essential for calcium binding to convert the 
enzyme into its active form. As expected, FITC-cadaverine binding was 
observed for wt TG2 incubated in the presence of calcium at both 
temperatures. Evidently reaction rates differed at these two temperatures, 
which can be clearly appreciated by the size and level of complex formation 
as well as loss of TG2 monomers. As expected, E239G mutant didn’t show 
any incorporation of the substrate. Both commercially available and in house 
generated ‘open’ TG2 appeared to readily react with FITC-cadaverine but 
only when incubated in the presence of calcium at 37°C and this coincided 
with formation of covalently cross-linked complexes. Since inhibited TG2 
incubated at 4°C did not show any measurable enzymatic activity, it was 
thought that the apparent association with cadaverine at 37°C might be 
related to residual activity. Although effective, conversion of TG2 into the 
inhibited ‘open’ conformation was clearly incomplete. 
 
 
 
 
 
 
 
 
 
 98 
B 
C D 
A 
   
 
   
 
 
 
   
 
0 1000 2000 3000 4000
-2500
2500
7500
12500
17500
22500
27500
0
Time (s)
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
wt TG2
wt TG2 + B003
wt TG2 + B003 + Putrescine
Inhibition at 37°C
Ca2+ Injection
wt TG2 
+ B003 
wt TG2 
+ B003 
+ Putrescine 
wt TG2 wt TG2 wtTG2  + B003 
wt TG2 
+ B003 
+ Putrescine 
Coomassie Blue FITC excitation 
 TG2 
complexes 
TG2 
wt TG2 
+B003 
37°C 
N-Voy !!!!!!!!!!!!"!!!!!!!!!!!+!!!!!!!!!!!!!!!!!!!!!!"!!!!!!!!!+!!!!!!!!!!!!!!!!!!!!+!!
wt TG2 
37°C 
wt TG2 
4°C 
0 1000 2000 3000 4000
-2500
2500
7500
12500
17500
22500
27500
0
Time (s)
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
wt TG2
wt TG2 + B003
Inhibition at 4°C
Ca2+ Injection
 99 
E 
  
Fig. 4.4 Inhibition of TG2 with B003 compound. A: Isopeptidase activity of wtTG2 
compared to B003 inhibited TG2 preparations +/- putrescine. Data for enzyme activity of 
20µg/ml TG2, normalized for well!specific fluorescence and following subtraction of control 
curve to account for fluorescence bleaching: FLUOstar OPTIMA (gain 3000). Increasing of 
fluorescence over time following Ca2+ activation indicates that only wtTG2 is enzymatically 
active. B: Native PAGE of wt and B003 inhibited TG2 followed by ‘in gel’ activity assay with 
FITC-cadaverine. In both B and E, FITC-staining was visualized using a combination of the 
488nm laser line for excitation and a 520nm filter for emission (PMT=500V). After visualising 
fluorescence, gel was stained with Coomassie Brilliant Blue R to visualise proteins C: Native 
PAGE of wt and B003 inhibited TG2 in the presence/absence of polymer N-Voy at 4°C and 
37°C. N-voy seems to vastly alter electrophoretic mobility of TG2. D: Isopeptidase activity of 
wtTG2 against 4°C B003 inhibited TG2. Data for enzyme activity of 20µg/ml TG2, 
normalized for well!specific fluorescence and following subtraction of control curve to 
account for fluorescence bleaching: FLUOstar OPTIMA (gain 3000). Inhibition of TG2 was 
successful as there is no apparent activity. E: Different TG2 preparations were incubated 
with FITC-cadaverine in the presence of 10mM CaCl2 or 1mM EGTA at either 4°C or 37°C 
for 20min. Thereafter proteins were separated on a 4-20% SDS-PAGE gel under reducing 
conditions and detected by visualising FITC-fluorescence followed by Coomassie blue R 
staining. Lanes in bold show FITC-bound protein. 
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4.2.4 Multiple step inhibition of TG2 with B003 
 
To tackle the fact that binding of FITC-cadaverine by ‘open’ TG2 could 
be due to residual activity it was decided to drive inhibition of TG2 with B003 
to completion using a multiple step approach. Ten different steps of inhibitor 
treatment were undertaken (Table 4.1) and remaining activity was assessed 
by in vitro incubation with FITC-cadaverine in the presence of calcium. 
Protein was incubated for 15min periods with B003 and temperature was 
increased according to the steps detailed in Table 4.1. A separate inhibition 
of TG2 with 250µM B003 was also performed in two steps. Firstly TG2 was 
incubated with 250µM B003 for 30min at 4°C and then incubated with 
another 250µM B003 in the presence of 10mM CaCl2 for 30min at 37°C. All 
inhibited samples and control wt TG2 were incubated with FITC-cadaverine 
in vitro, and then separated on a SDS-PAGE.  
 
Table 4.1 Steps employed for successive inhibition of TG2. 
Step Temperature Reagents added 
1 4°C + 50µM B003 
2 4°C + 50µM B003 + 10mM CaCl2 
3 4°C +50µM B003 
4 10°C +50µM B003 
5 10°C +50µM B003 
6 20°C +50µM B003 
7 20°C +50µM B003 
8 37°C +50µM B003 
9 37°C +50µM B003 
10 37°C +50µM B003 
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Results showed a decrease in residual activity with increasing B003 
inhibitor over the first 7 steps of inhibition (Fig. 4.5). However, a single 
inhibition with 250µM of B003 seems to be as effective as 7 consecutive 
steps of inhibition with 50µM B003.  
 
 
 
Fig. 4.5 Stepwise inhibition of TG2 with B003. Following inhibitor treatment, samples were 
pre-incubated in vitro with FITC-cadaverine and Ca2+. Samples were separated on a 4-20% 
SDS-PAGE gel under reducing conditions. FITC incorporation into TG2 (top row) was 
visualized using a combination of the 488nm laser line excitation and a 520nm filter 
(PMT=500V). Gel was subsequently stained with Coomassie Brilliant Blue to reveal proteins.  
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4.2.5 Inhibition of TG2 with different active site-directed inhibitor 
 
It was decided to inhibit rhTG2 using a different active site-directed 
inhibitor. Benzyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-L-Valinyl-L-Prolinyl-
L-Leucinmethylester, also known as Z006, was purchased from Zedira. This 
inhibitor was selected as it is the same one used by the company to generate 
the previously used commercial ‘open’ TG2 and because a crystal structure 
for this variant was available. Although it is likely that B003 modified TG2 is 
in the ‘open’ conformation, for Z006 there was direct evidence to substantiate 
this (Pinkas et al., 2007). Using this inhibitor would allow study to assess if 
the abundant binding of FITC-cadaverine previously observed for purchased 
‘open’ TG2 was due to residual transamidation activity or a high affinity 
interaction.  
As before, TG2 was inhibited in 2 steps or 7 steps at 4°C with B003 or 
in 2 steps with Z006. Z006 was employed at the same concentration as 
B003. Half of the volume of the samples was separated by native gel 
electrophoresis. The gel was then incubated overnight with FITC-cadaverine 
in the presence of calcium at 37°C. The second half of the volume of the 
samples was incubated, in vitro, with FITC-cadaverine, and calcium at 37°C 
for 20 minutes and then subjected to SDS-PAGE. Running the two different 
types of electrophoresis for the same samples would allow the elucidation of 
whether interaction of TG2 with the fluorescent substrate was due to 
transamidation or binding, and if it was indeed covalently bound. If a covalent 
bond was not present it would not be possible to observe any fluorescence 
after denaturing electrophoresis.  
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Fig. 4.6 Inhibition of TG2 with B003 or Z006 at 4°C. A: Native PAGE analysis for wt TG2 
and inhibited TG2. Top row shows incorporation of FITC-cadaverine by the different variants 
of TG2 in the ‘in gel’ assay. Bottom row shows subsequent coomassie blue staining to 
visualise protein levels. B: Samples from A were also run on a SDS-PAGE to assess 
covalent incorporation of FITC-cadaverine into TG2 following in vitro reaction, i.e. to directly 
assess residual enzyme activity. FITC-excitation is shown on the top row while Coomassie 
blue staining is shown on the bottom row. FITC-cadaverine binding was visualized using a 
combination of the 488nm laser line for excitation and a 520nm filter for emission 
(PMT=500V for A and 400V for B).  
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Results showed that all variants of the protein demonstrated binding of 
FITC-cadaverine when in their native conformation (Fig. 4.6A). In fact, 5µg of 
7-step B003 inhibited TG2 seemed to bind as much substrate as 5µg of 
wtTG2. Also, no noticeable changes were observed for 2x and 7x-inhibited 
protein. However, a clear difference was seen between 2.5µg and 5µg of 
wtTG2. Therefore, the signal observed appeared to correlate primarily with 
the amount of protein present rather than the enzymatic activity. When 
looking at the denaturing electrophoresis, it was evident that the inhibition of 
wt TG2 with B003 was clearly successful as exemplified by the reduction in 
formation of high molecular weight complexes and reduction in label 
incorporation, with 7x inhibitor treatment being more effective than 2x 
inhibitor treated. In fact, 7x inhibitor treated TG2 displayed very little residual 
activity (Fig. 4.6B), yet showed similar levels of association with FITC-
cadaverine (Fig. 4.6A) suggesting that a high-affinity non-covalent interaction 
may be involved.  
 
4.2.6 Inhibition of TG2 with Z006 for protein crystallization 
 
The results showing that TG2, extensively treated with active site 
directed inhibitors, was still able to efficiently bind cadaverine were quite 
surprising. The fact that the protein-substrate complex did not appear to be 
related to enzymatic activity and that the binding seemed to be non-covalent, 
led us to believe that inhibited TG2 may potentially harbour a structural 
pocket with high affinity for the amine substrate required for the second step 
during catalysis.  
To provide insight on how the amine interacts with the protein at this 
second pocket, it was decided to crystallize TG2 following modification of the 
active site cysteine residue with Z006. From previous work in our laboratory, 
evidence indicated that different amine substrates favour transamidation or 
deamidation as the outcome of the reaction. Therefore, crystallisation of TG2 
with different amine substrates could identify structural determinants 
important for the deamidation reaction. This in turn would provide insight as 
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to why deamidation occurs preferentially in the context of the gut in coeliac 
disease.  
The methodology used in the inhibition process of TG2 for use in 
crystallization experiments can be found in section 2.16 of chapter 2.  
Analysis of inhibited TG2 through spectrophotometry showed the 
classical protein absorbance spectrum, with peak of maximum absorbance at 
approximately 280nm (Fig. 4.7A). No signs of aggregated protein were 
observed. Protein was also subjected to an isopeptidase activity assay to 
assess if inhibition of TG2 was successful. When comparing the wild type 
control to the Z006 inhibited TG2 (Fig. 4.7B) it was evident that inhibition was 
overall successful even though Z006 inhibited TG2 still showed some 
residual enzymatic activity. 
Inhibited TG2 was produced at a high enough concentration to allow 
for protein crystallization.  
 
       
Fig. 4.7 Inhibition of TG2 with Z006. A: Absorbance spectrum of Z006 inhibited TG2. Data 
was normalized for buffer. Protein was diluted 1:10 to perform the analysis. Concentration of 
inhibited TG2 was calculated to be 6.8mg/ml. B: Enzyme isopeptidase activity for 20µg/ml 
TG2, normalized for well!specific fluorescence and following subtraction of control curve (no 
Ca2+) to account for fluorescence bleaching: FLUOstar OPTIMA (gain 1900). Compared to 
wtTG2 (blue), Z006 inhibited TG2 (green) retained about 12% of its enzymatic activity. 
Inhibition was overall successful. 
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4.2.7 Crystallisation of inhibited TG2 
 
TG2 has previously been crystallised in ‘open’ conformation following 
modification of the active site with the peptide inhibitor Ac-P(DON)LPF-NH2 
(Pinkas et al., 2007). Hence, the approach used these published conditions 
as a starting point for attempting crystallisation.  
Inhibited TG2 was plated for crystallisation in the presence of either no 
ligand (Apo) or one of two different amines (ligand A or B). These were 
selected based on previous work within the group demonstrating that they 
exclusively promoted deamidation or transamidation, respectively, despite 
their highly similar structure. Ligands were used at 10-fold molar excess over 
protein. Crystallisation was performed using vapour diffusion, sitting drop 
methodology. In this approach, a droplet containing purified protein, buffers 
and precipitant is in a tightly closed environment with a reservoir containing 
higher concentrations of similar buffers and precipitants (Fig. 4.8). Initially, 
the protein and precipitant in the droplet are in an undersaturated state. Due 
to concentration gradient, water vaporises from the protein droplet and 
collects in the reservoir thereby increasing concentration of protein to a state 
of supersaturation. If all parameters including temperature, pH, type of buffer 
etc. are ideal, protein crystallisation will occur in the drop. The main 
advantage of this method is that it allows for gradual changes in 
concentration of protein, which help in the development of larger and well- 
organized crystals.  
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Fig. 4.8 Vapour diffusion, hanging drop method. A protein solution droplet (left) is in a 
tightly enclosed environment with a reservoir filled with a high concentration precipitant 
solution (right). Concentration gradient leads water to vaporise from the droplet to the 
reservoir, gradually increasing protein concentration and ultimately leading to crystallization 
under ideal conditions.   
 
Detailed methodology of crystallization experiments can be found in 
section 2.17 of chapter 2.  
In order to maximize the chances of obtaining crystals, three different 
precipitant buffers were used based on the previously published 
crystallization experiments (Pinkas et al., 2007). The base of all buffers was 
a 100mM HEPES, pH7.2, solution, to which ammonium sulphate was added 
to three different concentrations: 1M, 2M and 3M. These buffers were also 
used in the presence or absence of 15% glycerol, and with or without N-Voy. 
N-Voy, which has been previously shown to facilitate crystallisation of 
proteins (Singh et al., 2013), was used at 20-fold molar excess over protein. 
Even though purified protein was at a concentration of 6.8mg/ml it was 
possible to seed the protein to ultimately yield different concentrations by 
changing the protein-precipitant ratio (Table 4.2).  
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Table 4.2 TG2 crystallization seeding concentrations. 
Protein  Precipitant  Final concentration 
0.4µl + 0.2µl ⇔ 13.56mg/ml 
0.3µl + 0.2µl ⇔ 10.17mg/ml 
0.2µl + 0.2µl ⇔ 6.78mg/ml 
0.13µl + 0.2µl ⇔ 4.407mg/ml 
Ratio between protein and precipitant was changed to yield different final concentrations of 
TG2 following establishment of the equilibrium in the crystallisation chambers. 
 
Protein was seeded and plates were scanned at day 0, 1, 5, 7, 15 and 
after 1 month. No TG2 crystals developed during this period.  
 
An attempt the to produce protein crystals under modified conditions 
was undertaken. The same batch of inhibited TG2 was used. For the new 
experiment the precipitant buffer used was 100mM HEPES, 2M ammonium 
sulphate. Since pH does have an effect on the crystallisation process a range 
of different pHs were set from 6.8 to 7.6. The experiment was carried out with 
and without 15% glycerol. Final protein concentration in the crystallisation 
chambers was set to 9mg/ml or 12mg/ml.  
The pH of the precipitant was checked when added to the protein 
solution to make sure that there was no alteration of the pH after the two 
volumes were mixed (Table 4.3). The highest volume of protein added to the 
precipitant during crystallisation plating was 0.2µl. After this experiment we 
decided to use the range of precipitants with initial pH 6.8; 7.2; 7.4; 7.5; 7.7 
and 8.0. 
Protein solution was centrifuged before use to remove any potential 
precipitates/aggregates and analysed through spectrophotometry. The final 
concentration of protein was determined as being 6.1mg/ml and seeding 
concentrations were set to 9mg/ml and 12mg/ml. Ligands and amount used 
were kept at the same ratio (10x fold molar excess over protein). 
Plates were scanned at day 0 and 1, 5, 7, 13 days and also after 1 
month. After this period TG2 crystals were not evident. 
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Unfortunately, a lot of protein precipitation was seen in the 
crystallisation droplets, presumably due to protein aggregation. Despite 
attempting a range of conditions around the parameters successfully used for 
TG2 crystallisation by others, it was not possible to overcome this problem.  
A new batch of inhibited TG2 was produced to allow more 
crystallisation experiments. Although experiments were successful at 
obtaining inhibited TG2, the amount of protein that precipitated during the 
process was such that the final concentration of TG2 was not high enough to 
use in crystallisation assays. 
 
Table 4.3 pH ranges used in crystallisation study of TG2 
Ratio 0.2µ l protein + 0.2µ l precipitant at RT (≈25°C) 
Initial pH Final pH 
6.8 6.68 
7.0 6.86 
7.2 6.87 
7.4 7.12 
7.5 7.25 
7.6 7.35 
7.7 7.42 
7.8 7.52 
8.0 7.69 
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4.3 Discussion 
 
In the previous chapter, experiments revealed that addition of GTP to 
TG2 prior to the labelling process had a positive effect on the retention of 
functionality of the protein. Furthermore, the absence of the nucleotide during 
the labelling process led to an enzymatically inactive protein. This was true 
when labelling TG2 with two different labels, Atto-565 and Atto-647N. This 
suggested that absence of GTP lead to labelling at specific sites of TG2 that 
ultimately influenced the conformation of the enzyme and therefore its 
inability to adopt a structural state required for catalysis.  
Using native PAGE, it was shown here that, when GTP saturation was 
maintained during electrophoresis, there was a shift in mobility of bands of 
TG2 labelled in the presence of GTP that was not observed when labelling 
was performed in the absence of GTP. When GTP saturation was not 
maintained, labelled TG2 ran at the same level as controls, wt TG2 and open 
TG2. It is known that when GTP is present, the wild type enzyme will bind to 
it, and will acquire a closed conformation with a higher apparent negative 
charge. This will have an effect on how the protein runs in the gel: a more 
compact and negative protein will have a higher electrophoretic mobility 
(Pinkas et al., 2007). In contrast, the open conformation TG2 was inhibited 
by covalent binding of an inhibitor to the catalytic cysteine, making the 
subsequent conformational changes of the catalytic cycle impossible, 
including binding of GTP, and consequently it had a lower electrophoretic 
mobility. This suggested that the ability of TG2 to bind nucleotides was lost in 
the process of labeling, unless GTP was present at saturating 
concentrations. Since the band shift was only observed for the preparations 
of the enzyme that showed isopeptidase activity, it suggested that GTP-
binding capacity of TG2 was required for catalytic activity or at least, a 
conformational transition linked to catalysis.  
To further investigate enzyme activity in relation to the shift in bands 
observed in the native gel electrophoresis, an ‘in-gel’ activity assay was 
performed. Knowing that cadaverine is an amine donor substrate for TG2 
and that TG2 is able to crosslink with the substrate and itself, the use of 
 111 
cadaverine would be a good method to detect the active fraction of the 
different TG2 preparations. If TG2 was enzymatically active, it would 
incorporate FITC-cadaverine auto-catalytically. As previously mentioned, it 
was suspected that the lower positioned band observed in the gel, i.e. 
enzyme capable of binding GTP, was the active fraction of the labelled TG2 
preparations. This hypothesis was confirmed as FITC-cadaverine was only 
detectable in the faster migrating bands of both Atto-565 and Atto-647N 
labelled TG2. There was a clear correlation between the relative abundance 
of the faster migrating species and the enzymatic activity of the protein 
preparation, whereby complete transition was seen with the unlabelled 
wtTG2. This confirmed that the capacity for GTP binding correlated with the 
enzymatic activity.  
The most surprising result obtained during our native PAGE 
experiments, was the fact that the irreversibly inhibited open TG2 also 
retained the substrate. This led to the consideration that the inhibited 
enzyme, trapped in the open conformation, and reflecting the intermediate 
state during catalysis, had a high-affinity binding site for the amine donor 
substrate. This binding site could enable tight binding of FITC-cadaverine in 
a non-covalent way. This serendipitous observation was clearly significant 
and hence further investigated. If the fluorescent amine donor substrate was 
not covalently bound to the inhibited enzyme, it should separate from the 
protein during denaturing gel electrophoresis. However, SDS-PAGE analysis 
revealed, unexpectedly, that the substrate was at least in part covalently 
bound to open TG2. This meant that open TG2 retained residual enzymatic 
activity and hence made the results uncertain. Moreover, the fact that there 
was not any cadaverine incorporation in the enzymatically inactive forms 
TG2 E329G and TG2 C277S, confirmed specificity of the results. Even 
though this suggested that binding of cadaverine to open TG2 may be 
related to enzyme residual activity it did not exclude the possibility of 
additional non-covalent substrate binding.  
It was decided therefore to tackle the residual activity problem by 
inhibiting enzyme with the commercially available peptidic inhibitor, B003, 
with the aim of driving inhibition to completion. Initially, high levels of  
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protein aggregation were observed and optimization of the inhibition process 
was required. Addition of N-Voy, an amphiphilic polymer, although effective 
in preventing protein aggregation, interfered with the assays and was 
considered not suitable for the experiments being conducted. Decreasing the 
temperature during TG2 inhibition, from 37°C to 4°C, seemed to be the most 
effective way of reducing levels of protein aggregation, as shown in 
subsequent native gel electrophoresis. The isopeptidase assay revealed in 
house inhibition of TG2 to be successful, as protein showed little or no signs 
of activity. As transamidation activity assays are more sensitive than the 
isopeptidase assay, the new inhibited TG2 was pre-incubated with FITC- 
cadaverine and analysed on a denaturing gel to assess for substrate 
incorporation. wt TG2 readily incorporated FITC-cadaverine but only when 
incubated in the presence of calcium. This was expected, as calcium is 
necessary for enzyme activity. Also, there was a substantial decrease in 
amide incorporation at 4°C when compared to 37°C, which was also 
expected as lower temperatures slow down reaction rates. Unexpectedly, 
both commercially bought and ‘in-house’ generated ‘open’ TG2 showed 
some levels of cadaverine incorporation in the presence of calcium at 37°C.  
Despite different approaches to targeting the active site of TG2 it was 
not possible to completely eliminate catalytic activity. Nevertheless, inhibition 
over seven consecutive steps proved highly efficient, resulting in only 
negligible activity in even the most sensitive assays. Surprisingly, when 
analysing such a preparation side-by-side with wt TG2 in the ‘in gel‘ assay 
there was no difference in amounts of amine substrate associated with the 
TG2 band, suggesting that catalytic activity could not explain this result. 
Furthermore, TG2 E329G, which does undergo the calcium-induced 
conformational switch, showed no association with the amine substrate in the 
‘in-gel‘ assay. These results, along side the absence of enzymatic activity in 
the isopeptidase assays suggested that the interaction of FITC-cadaverine 
with the ‘open’ TG2 is specific, but not due to catalytic activity. This led to the 
view that there might be a structural pocket with high affinity for an amine 
substrate that becomes available upon reaction of the enzyme with the first 
substrate, an event mimicked by reaction with the inhibitor in these 
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experiments. This is an exciting observation as it opens the door for 
structural studies investigating the determinants guiding the reactions leading 
to transamidation and deamidation, respectively.  
 In conclusion the experiments in this chapter abled the 
characterization of Inhibited TG2 and have shown for the first time the 
possibility for the existence of a second structural pocket in the TG2-
substrate intermediate structure, with high affinity for an amine substrate.    
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Chapter 5 Identification of anti-TG2 and anti-TG6 antibody-producing 
cells in biopsies 
 
5.1 Introduction 
 
Gluten sensitivity classically presents with inflammation of the bowel, 
triggered by eating gluten, a protein found in wheat and other cereals (Sollid 
2002). Gluten loads are particularly high in the upper small intestine, 
explaining why this is the primary site of GRD manifestation. Current 
diagnostic assays of this disease are specific for patients with classical 
gastrointestinal symptoms, as these were developed for coeliac patients, but 
studies have shown that gluten sensitivity can manifest with symptoms other 
than those related to inflammation of the bowel, such as neurological 
symptoms including ataxia and neuropathy (Hadjivassiliou et al. 2003, 2006).  
It is crucial to identify these patients, which often do not have overt 
gastrointestinal symptoms, as they will suffer from irreversible damage to the 
neural tissue because of the inability of this tissue to regenerate. 
TG6 as been shown to be predominantly expressed by a subset of 
neurons in the central nervous system, including Purkinje cells (D. 
Aeschlimann & Hadjivassiliou, 2008). Studies have shown that an antibody 
response, anti-TG6 IgG and IgA, was prevalent in gluten ataxia, independent 
of intestinal involvement. Furthermore, it was shown that the production of 
these antibodies in patients is gluten dependent (Hadjivassiliou et al., 2013). 
Therefore, TG6 has been identified as a possible biomarker to diagnose 
those patients that may be at risk of developing neurological disease in 
association with gluten sensitivity (Hadjivassiliou et al. 2008). However, it 
was unclear whether this immune response developed at the level of the gut 
or in the CNS. The fact that IgA class antibodies are present suggests that 
the gut may be involved. 
It has been proposed that the production of anti-TG2 IgA in coeliac 
disease is associated with deamidation of gluten peptides by TG2, i.e. 
formation of thiolester complexes, and is likely dependent on T-cell help, 
provided by gluten-specific T-cells to activate TG2-specific autoreactive B-
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cells (Sollid et al. 1997). Furthermore, anti-TG2 IgA deposits have been 
demonstrated in the small intestine of patients with gluten ataxia but not in 
control patients with other forms of ataxia, suggesting that sub-clinical 
inflammatory responses at the gut level are a feature in these patients 
(Hadjivassiliou et al. 2006). However, evidence for a T-cell response in 
gluten ataxia patients has been found in post mortem studies, where 
perivascular lymphocytic infiltration of cerebellar tissue by both CD4+ and 
CD8+ T-cells was observed (Hadjivassiliou et al. 1998). This suggests that 
inflammation at the blood-brain barrier could also be involved in the 
expansion of the immune response to additional targets, including TG6.  
Since TG6 has been shown to deamidate gluten peptides and 
generate T-cell epitopes (Stamnaes et al. 2010), it is possible that the 
immune response in gluten ataxia initiates in the gut, where gluten loads are 
high. 
 In this chapter the aim was to shed some light on the mechanistic 
aspects of autoantibody development in patients with extraintestinal gluten-
related disease manifestations. For this purpose, a series of experiments 
were performed using gut biopsies from GRD and non-GRD patients to 
investigate the presence of TG2 and TG6-specific B-cells. Detection of such 
cells in situ could help confirm that autoantibody development to TG6 occurs 
in conjunction with that to TG2, at the level of the gut or, alternatively, has its 
origin in independent events. 
 
The aims of the chapter: 
 
1. Optimization of an immunofluorescence staining protocol for 
identification of TG2 and TG6-reactive cells in sections from gut 
biopsies of a cohort of gluten-related disorders patients and controls.  
2. Identify TG6-specific B cells in the human gut and whether these are 
common among patients with gluten-related disorders or specific to 
patients with distinct manifestations, e.g., neurology.!
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5.2 Results 
 
5.2.1 Generation of an Atto-565-labelled control protein conjugate 
 
As described in Chapter 3, experiments successfully led to chemically 
labelling of TG2 and TG6 for detection of TG2/TG6 specific B cells through 
immunofluorescent assays. In order to confirm specificity of 
immunofluorescence, it was necessary to generate an Atto-565-labelled 
protein conjugate that could be used as a control in cell labelling of tissue 
sections.  
 For this purpose labelling of hemocyanin was undertaken. This protein 
is commonly found in molluscs and no homologues exist in mammalian cells. 
For this reason, hemocyanin is frequently used as a control, as it is not 
expected to interact with anything in mammalian tissue, including the human 
small intestine. Also, its high molecular weight, solubility and abundance of 
lysine residues make the protein ideal for labelling and to assure staining 
specificity.  
 The labelling process was performed as described for TG2 in chapter 
3. Briefly, hemocyanin was buffer exchanged into sodium phosphate buffer 
using gel filtration chromatography. Collected fractions were analysed by 
spectrophotometry and the fractions with highest absorbance at 280nm were 
used for labelling reaction (Fig 5.1A). Fluorescent labelling was performed in 
solution, using 140-fold molar excess of dye over protein to assure protein 
saturation with label. Gel filtration was again used to separate free label from 
labelled hemocyanin and fractions containing eluted labeled protein were 
pooled. Spectroscopic analysis confirmed the success of the labeling 
process, as a 280nm protein peak was observed along side the expected 
565nm absorbance peak for the fluorophore (Fig 5.1B). Final protein 
concentration and label density were estimated from a standard curve 
generated from serial dilutions of Atto-565 dye. Labelled hemocyanin was 
calculated to have a final concentration of ≈458µg/ml and a label density of 
approximately 100 fluorophores per hemocyanin molecule. 
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Fig. 5.1 Chemical labelling of hemocyanin with Atto-565 NHS ester dye. A: Hemocyanin 
(500µg) was applied to PD10 column for buffer exchange. Spectroscopic analysis shows the 
typical spectrum for protein with maximum absorbance near 280nm. B: Absorbance 
spectrum for Atto-565 NHS ester labelled hemocyanin. Labelled protein was purified using a 
PD10 column. Graph shows pooled protein. Data shown was corrected for buffer 
absorbance.  
 
5.2.2 Detection of TG2-specific antibodies with Atto-labelled TG2 
 
As mentioned in chapter 3, coeliac disease and gluten ataxia related 
autoantigens, TG2 and TG6, were labeled for use in immunofluorescent 
detection of TG-specific B cells. Although the aim of this research was to 
ultimately understand the mechanism behind the production of 
autoantibodies to TG6 in gluten ataxia, labeled TG2 was used as a ‘proof of 
principle’/reference point. Firstly, it is known that TG2-specific plasma cells 
are present in the intestine in CD patients (Di Niro et al., 2012). Secondly, 
anti-TG2 IgA deposits have been detected in the small intestine of patients 
with gluten ataxia, suggesting that anti-TG2 plasma cells may be present 
also in these patients even if they are serologically negative for anti-TG2 IgA 
(Hadjivassiliou et al. 2006). 
Optimization of labelled TG2 (lTG2) use in tissue labelling studies was 
required. Frozen sections of a duodenal biopsy of a coeliac disease patient 
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were available within the group and optimization of lTG2 incubation time was 
initially performed with these sections.  
Unfixed frozen sections were dried overnight and washed with Tris-
buffered saline before blocking with 1%BSA/TBS for 30min. Sections were 
then incubated with 10µg/ml of lTG2 for 2min, 10min or 1h. A 10µg/ml 
labelled hemocyanin solution was used along side lTG2, as negative control 
to assess labelling specificity. Detailed methodology can be found in section 
2.19 of chapter 2.  
Staining for TG2 was detected in the extracellular matrix including 
basement membrane of the small intestine, especially along the intestinal 
crypts and also around mucosal vessels (Fig 5.2). This pattern of staining 
was expected, as TG2 is known to strongly bind to specific ECM components 
(Aeschliman & Paulsson, 1991; Boscolo et al., 2010; Iversen et al., 2013). 
This may reflect a combination of binding directly to TG2 in the ECM as well 
as to autoantibody deposits in the tissue (Korponay-Szabó et al., 2004). 
From the incubation times used, 2 min gave a comparatively weak signal, 
while 1h, generated staining with excessive background fluorescence. 
Overall, the 10min incubation time produced the most appropriate staining, 
strong enough to be detected without high background fluorescence.  Signal 
specificity can be determined by absence of staining when labelled 
hemocyanin control was used.  
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Fig. 5.2 Optimization of labelled-TG2 incubation times with tissue sections. Unfixed 
frozen sections from a coeliac patient were incubated with Atto-565 labelled TG2 (lTG2) for a 
period of 2min, 10min or 1h. Atto-565 labelled hemocyanin was used as a negative control to 
assess staining specificity. Size bar = 50µm 
 
 
5.2.3 Tissue interaction with labelled TG2 is not mediated via catalytic 
activity  
 
In chapter 3 it was found that the choice of methodology used for 
labelling TG2 could affect the enzyme catalytic activity. Since it was possible 
to produce labelled TG2 in its inactive and active state it was decided to 
assess binding of the two forms of the enzyme in a coeliac patient gut 
biopsy. The importance of this experiment comes from the fact that 
autoantibodies against TG2 have previously been shown to be conformation 
dependent (Iversen et al. 2013; Seissler et al. 2001). Unfixed frozen sections 
were prepared as previously described and incubated with 10µg/ml of either 
lTG2 2min lTG2 10min 
lTG2 1h Hemocyanin 1h 
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the enzymatically active (labeled in the presence of GTP) or inactive (labeled 
in the absence of GTP) form of labeled TG2. Sections stained with inactive 
labeled TG2 (Fig 5.3A top panel) appeared to show a lower level of 
fluorescent signal when compared to sections incubated with active labeled 
TG2 (Fig 5.3A bottom panel). This could be related to catalytic activity of 
labeled TG2, i.e. autocatalytic action of the enzyme could contribute to tissue 
immobilization. It could also be that inactive labeled TG2 may not be able to 
interact with the extracellular matrix and may not be recognized by antibodies 
at the surface of cells, due to its inability to adopt a relevant conformation. As 
the observed staining is present mainly in the extracellular matrix it was 
important to rule out that this staining was not a result of labeled TG2 
crosslinking to the ECM.  
Unfixed frozen sections from the same coeliac disease patient used in 
the previous experiments were incubated with 10µg/ml labelled catalytically 
active TG2 for 10min, in the absence or presence of 1mM EDTA. Since 
calcium is an allosteric regulator of TG2, involved in TG activation, EDTA 
was used as a chelating agent to prevent TG2 catalytic activity by binding the 
calcium ion necessary for the reaction. 
Results showed no significant difference in the staining pattern 
obtained for staining in the presence or absence of EDTA (Fig 5.3B). Positive 
staining was observed in the extracellular matrix. Specificity of labelling was 
again demonstrated by using an unrelated protein (hemocyanin) carrying the 
same label. The results allow us to conclude that the TG2 binding to the 
tissue is specific and not mediated by its catalytic activity. 
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Fig. 5.3 Enzyme conformation state but not transamidation activity impact on labelled 
TG2 binding to small intestine sections of a coeliac disease patient. A: Comparison of 
inactive labelled TG2 with active labelled TG2 (10µg/ml) binding to small intestinal tissue 
after 1h incubation. Size bar 50µm. Pictures on the right are amplification of the selected 
area (white square) Size bar 25µm. B: Comparison of tissue labelling with active lTG2 
(10µg/ml) in the presence/absence of 1mM EDTA after 10min incubation. Labelled 
hemocyanin (10µg/ml) was used as a control. Positive staining is visible in the extracellular 
matrix (arrows). Size bar = 50µm 
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5.2.4 Tissue processing and detection of anti-TG IgA deposits in the gut 
 
It is known that fixation and processing methods can substantially 
influence protein localization studies on tissue sections. The majority of 
routine diagnosis is based on analysis of formaldehyde fixed and paraffin 
embedded (FFPE) tissue sections.  In the literature however, unfixed frozen 
tissue sections are the preferred processing method in 
immunohistochemistry, due to the preservation of antigen structure (Di Niro 
et al. 2012; Hadjivassiliou et al. 2006). However, this comes at the cost of 
losing soluble protein and lack of preservation of cellular architecture. It was 
therefore important to determine which processing method was the most 
appropriate in detecting TG-specific B cells in human gut sections. This was 
of clear relevance to subsequent use in diagnostic testing.  
 In the present study a comparison of 3 different processing methods 
was undertaken. In the first one, samples were snap frozen in liquid nitrogen 
immediately after collection. In the second approach, tissue was fixed in 
paraformaldehyde and then processed using a routine approach. The 
method was one employed by a certified pathology laboratory, and involved 
dehydration and paraffin embedding. A third approach was introduced, where 
gut biopsies were fixed in paraformaldehyde and then gradually soaked in 
high concentrations of sucrose to prevent ice crystal formation during 
freezing, before being frozen in liquid nitrogen. Biopsies from each patient 
were in parallel processed using these 3 approaches.  
Snap frozen sections gave us poor cell structure and tissue 
morphology. The routine formaldehyde-fixed and paraffin embedded (FFPE) 
sections showed good cell structure but gave high background staining in 
labelling experiments and lead to poor antigenicity, probably due to 
modification of surface proteins that made detection impossible or unreliable. 
The third processing protocol, where samples were sucrose treated and then 
frozen was the one that yielded the best cell structure without compromising 
the immunofluorescent assay results. Based on the initial results the FFPE 
protocol was not employed further in this study, as labelling with either 
antibodies or labelled enzyme proved unsuccessful. The interest here is in 
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the features relevant to GRD diagnosis, including detection of TG-specific 
plasma cells, autoantibodies deposits and the relevant TGs.  
In the following sections, I will give one example of the findings 
regarding tissue processing for illustration purposes. During experimentation 
with different processing protocols an interesting result was encountered 
regarding the pattern of IgA distribution between sections processed by snap 
freezing without fixation and sections snap frozen after fixation. When 
comparing the human-IgA detection with antibodies, between the two 
processing protocols, the pattern observed was significantly different (Fig 
5.4). On the snap frozen biopsy sections, the IgA deposits, which have been 
reported to be a specific early feature of CD (Hadjivassiliou et al., 2013), 
seemed to be associated with specific structures of the extracellular matrix. 
However, on the fixed frozen section, the IgA presented as a more localized 
signal, associated with individual cells surrounding the intestinal crypts. It is 
possible that either TG2 or IgA directed to TG2 in non-fixed biopsies may 
diffuse from inside the cells to the extracellular matrix during sectioning of the 
tissue, causing the change in pattern observed in all patients analysed.  
 Referring back to the literature, colocalization of IgA and TG2 in a 
characteristic pattern in snap frozen sections of coeliac patients has been 
reported as evidence for in situ formation of IgA deposits in the gut 
(Korponay-Szabó et al., 2004). Since the pattern observed for IgA deposits in 
non-fixed frozen sections in the literature (Fig 5.4 left panel) was similar to 
the one observed in this study, the effect is likely to be an artefact due to the 
methodology employed. Tissue processing/sectioning seems to critically 
impact on protein distribution and the colocalization observed in conventional 
frozen sections may not be representative of protein localization in the gut in 
vivo. The fact that the ‘deposits’ were apparently disease-specific can be 
explained by the fact that 1: TG2-specific autoantibodies are only present in 
patients and 2: TG2 is highly upregulated in disease due to the inflammation. 
Hence, although these ‘deposits’ are most likely an artefact, this artefact is in 
fact, disease-specific.  
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Fig. 5.4 Comparison of TG2-specific IgA deposits between frozen sections processed 
with and without fixation. The left panel provided example of a negative (normal column) 
and positive (developing CD column) staining for IgA deposits against TG2 on snap frozen 
D2 biopsies from 2 patients. The presence of such deposits is a reliable marker of gluten-
related disorders (image retrieved from Hadjivassiliou et al. 2013). The right panel shows 
this study comparison of IgA labelling between snap frozen and fixed frozen D2 biopsy serial 
sections of one single patient. The pattern observed is significantly different.  
 
 
5.2.5 Optimization of antibodies for detection of B-cells and plasma-
cells 
 
While performing immunofluorecent staining in D2 biopsies a large 
number of IgA+ cells were observed in the lamina propria of all patients 
analysed. This is expected, as the human intestine is the primary place for 
production of IgA. However, when trying to detect B cells or plasma cells 
using antibodies against CD20 or CD138 respectively, in the same biopsies, 
only very few or in some cases no cells were found. This was an unexpected 
observation as plasma cells are producers of IgA.  
Normal Developing CD 
IgA IgA 
IgA/DAPI IgA/DAPI 
IgA/DIC IgA/DIC 
Fixed&and&Frozen&Snap&Frozen&
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To make sure that the results obtained were not related to issues with 
the antibodies used - some antibodies can be incompatible with some tissue 
processing methods – and to exclude that this was the reason why an 
unusual low number of B cells/plasma cells were being detected, it was 
decided to test these antibodies in a positive control tissue. A human palatine 
tonsil was obtained through the University Hospital of Wales. The tissue was 
processed in the same way as our D2 biopsies. Tonsils are intramucosal 
collections of lymphocytes or aggregated lymphoid tissue closely associated 
with the overlying epithelium (Stedman’s Medical DIctionary entry on Tonsil). 
The palatine tonsils are located at the back of the throat and constitute part 
of the mucosa-associated lymphoid tissue (MALT), where B cell maturation 
takes place.   
Tonsil tissue sections were used as positive controls to confirm that 
the anti-B cells/plasma cells antibodies were compatible with the fixed-frozen 
processing method used in the immunofluorescent experiments. Antibodies 
against B-cell marker CD20 and plasma cell marker CD138 were tested (Fig 
5.5).  
The fluorescent signal for B-cell marker CD20 was clear and was 
present on the membrane of individual cells, which were highly abundant 
throughout the germinal centres. Fewer cells labelled positive for the plasma 
cell marker CD138 and although labelling was present, it was not as 
extensive as for CD20. Individual CD138+ cells were observed in the 
periphery of the germinal centres.  
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Fig. 5.5 Optimization of antibodies against B-cell and plasma cell markers in tonsil 
tissue. Tonsil H&E staining (retrieved from Stevens & Lowe, 2004) (A). The tonsillar crypts 
increase the contact surface between the lymphoid tissue and the environment, while B-cell 
differentiation occurs in the germinal centres. Tonsillar tissue was positive for B-cell marker 
CD20 (panel C and higher magnification on D) and plasma cell marker CD138 (panel E and 
higher magnification F). Specificity of staining is demonstrated by negative control (B). Size 
bars = 50µm in B, C and E. Size bars = 15µm bars in D and F. 
 
5.2.6 Patient selection and biopsy collection for pilot clinical study 
 
 Patients were recruited from the ataxia, gluten/neurology, CD, and 
movement disorders clinics based at the Royal Hallamshire Hospital 
(Sheffield, UK) with the kind help of Prof. Marios Hadjivassiliou and David 
Sanders (Table 5.1), and with the approval of the Yorkshire Research Ethics 
Committee. 
The study aimed at comparing classic CD and GRD neurology 
patients with relevant controls.  
Neg$Control$–$Alexa$488 
CD20 CD20 
A B 
C D 
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Patients were divided into 3 groups: coeliac disease (CD), gluten 
ataxia (GA) and control group (Table 5.3). Control patients attended the clinic 
because of non-gluten related disorders (non-GRD). Neurologic controls 
included a patient with idiopathic sporadic ataxia (ISA) and a patient with 
cerebellar variant of multiple system atrophy (MSA-C). 
All patients attended the gastrointestinal clinic in Sheffield, to receive 
an endoscopy. Biopsies were collected endoscopically, from the second part 
of the duodenum (D2), by a specialist gastroenterologist. I personally 
processed all the biopsies immediately after collection, on site, and according 
to the methodology mentioned in section 5.2.4, and subsequently transported 
all tissue to our laboratories in Cardiff. Orientation of biopsies was performed 
so that a transverse section of intestinal crypts and villi could be observed, 
although this was not always possible due to the small size of the biopsies. 
Sectioning of tissue was performed, using a cryostat, in order to obtain 5µm 
serial sections, but this was also not always possible due to loss of tissue 
during sectioning process.  
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Table 5.1 Clinical characteristics of patient cohort. 
ID Age, y Sex Clinical Presentation Serology Anti-gliadin Ab 
2 57 M CD Anti-TG2+ (low) IgG 
3 24 F CD Anti-TG2+ IgA 
4 22 F CD Anti TG2+ IgG/IgA 
5 61 F GA (not on GFD) Anti-TG2+ (low) ND 
6 52 F CD Anti TG2+ ND 
7 43 F 
CD (not on GFD) 
WMA 
Anti-TG2+ Anti TG6- 
Anti-cardiolipin+ 
ND 
8 37 M CD Anti-TG2+ IgA/IgG 
9 20 F CD Anti-TG2+ ND 
10 75 M GA (not on GFD) Anti-TG2- Anti-TG6+ ND 
11 60 F GA (not on GFD) Anti-TG2- Anti-TG6+ ND 
12 39 M 
ISA 
Stiff person syndrome 
Anti-GAD+  
Anti-TG2- Anti-TG6- 
ND 
13 56 F MSA-C Anti-TG2- ND 
14 67 M ISA Anti-TG2- Anti-TG6+ ND 
15 68 F ISA 
Anti-TG2- Anti-GAD+  
Anti-TG6+ (borderline) 
ND 
16 60 F GA/myoclonus Anti-TG2- Anti-TG6- IgA/IgG 
17 61 M GA Anti-TG2- Anti-TG6+ ND 
18 73 F 
CD (on GFD) 
Ataxia/myopathy 
Anti-TG2- ND 
19 44 F control  Anti-TG2+ (low) IgA/IgG 
20 27 F CD Anti-TG2+ ND 
21 68 M 
CD (on GFD)  
myopathy 
Anti-TG2- ND 
22 72 M control ND ND 
23 73 F CD ND ND 
24 63 F control ND ND 
25 28 F control ND ND 
 
Insufficient material of patient 1 was obtained to carry out immunofluorescence analysis.  
Abbreviations: CD = coeliac disease; GA = gluten ataxia; GFD = gluten-free diet; WMA = 
white matter abnormalities; MSA-C = cerebellar variant of multiple system atrophy; ISA = 
idiopathic sporadic ataxia; ND = not determined 
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Table 5.2 Patient cohort: histological findings upon biopsy examination 
ID Age, y Sex Clinical Presentation Notes 
2 57 M CD Residual inflammation related to CD 
3 24 F CD Some inflammation was observed 
4 22 F CD Typical CD biopsy 
5 61 F GA (not on GFD) Normal 
6 52 F CD Some inflammation was observed 
7 43 F 
CD (not on GFD) 
WMA 
Normal 
8 37 M CD Typical CD biopsy 
9 20 F CD Family history of CD 
10 75 M GA (not on GFD) Increased IELs 
11 60 F GA (not on GFD) Normal 
12 39 M 
ISA 
Stiff person syndrome 
Normal 
13 56 F MSA-C Normal 
14 67 M ISA Normal 
15 68 F ISA Normal 
16 60 F GA/myoclonus Normal 
17 61 M GA Normal 
18 73 F 
CD (on GFD) 
Ataxia/myopathy 
Abnormal 
19 44 F control  Increased IELs 
20 27 F CD Typical CD biopsy 
21 68 M 
CD (on GFD)  
myopathy 
Typical CD biopsy 
22 72 M control Normal 
23 73 F CD Typical CD biopsy 
24 63 F control Normal 
25 28 F control Normal 
 
Insufficient material of patient 1 was obtained to carry out immunofluorescence analysis. 
Histological analysis was carried out by a specialist pathologist, at the Royal Hallamshire 
Hospital, Sheffield. Abbreviations: CD = coeliac disease; GA = gluten ataxia; GFD = gluten-
free diet; WMA = white matter abnormalities; MSA-C = cerebellar variant of multiple system 
atrophy; ISA = idiopathic sporadic ataxia; IEL = intra-epithelial leukocytes ND = not 
determined 
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Table 5.3 Final grouping of patients for analysis 
Coeliac disease Patients: 2, 3, 4, 6, 7, 8, 9, 18, 2, 21, 23 n = 11 
Gluten ataxia Patients: 5, 10, 11, 16, 17,  n = 5 
Controls Patients: 12, 13, 14, 15, 19, 22, 24, 25 n = 8 
 
 
5.2.7 Detection of IgA in D2 biopsies 
 
Due to the results obtained when comparing different tissue 
processing methods, the (immuno)histochemistry assays were undertaken 
using the fixed-frozen biopsies.  
IgA staining was performed on sections from patients 2 to 8 and 10 to 
12 (Fig 5.6). The remaining patients were not studied due to lack of time in 
the project. IgA staining was performed for two reasons: firstly because 
deposits colocalised with TG2 are considered to be a specific feature in 
coeliac patients and secondly as the approach identifies cells producing IgA, 
i.e. plasma cells. 
From the patients analysed, all showed IgA staining localized to the 
lamina propria of the small intestine, around the intestinal crypts and villi. 
Numerous IgA+ individual cells were detected. This was not surprising, as 
immune protection of the intestinal mucosa depends on the secretion of IgA 
by plasma cells.  
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Fig. 5.6 Immunofluorescent staining with anti-IgA FITC-conjugated antibody. All patient 
sections analysed were positive for IgA. IgA+ individual cells were detected across the 
lamina propria of the biopsies around the intestinal crypts and also villi when these were 
present in the section. Size bars = 100µm 
 
 
5.2.8 Detection of TG2/TG6-specific plasma cells 
 
Detection of TG2-specific plasma cells in patient biopsy D2 sections 
 
Not all patients were tested for labelled TG2 staining, as the priority 
was to test for anti-TG6 specific antibodies in situ. Labelled TG2 (10µg/ml) 
was incubated on fixed-frozen sections for detection of anti-TG2 antibodies in 
D2 biopsies. Staining was detected in the lamina propria around the intestinal 
crypts and villi of all patients tested (Fig 5.7). This may at least in part relate 
to binding of labelled TG2 to specific ECM components as already discussed 
in section 5.2.3. 
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Fig. 5.7 Overview of labelled TG2 staining pattern in different patients. Staining 
occurred in the lamina propria (LP) of the small intestine, with higher intensity around the 
intestinal villi (V) and crypts (C). Size bars 100µm A higher magnification of P3, is observed 
on the top right of the panel for better imaging of intestinal morphology following 
immunostaining. Size bars = 50µm 
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A low number of individual cells positive for lTG2 binding were 
observed in the lamina propria of the small intestine biospies of patients P2, 
P7 and P9 (Fig 5.8). It is conceivable that other patients also had individual 
cells expressing anti-TG2 antibodies on the membrane surface, but the 
abundant matrix-associated staining made it difficult to evaluate this. Patients 
were considered as having lTG2+ cells when individual cells were clearly 
visible, with nuclei present and staining covering the majority of the cell 
surface. To further address this, double immunostaining was carried out to 
assess if cells binding lTG2 were indeed plasma cells expressing TG2-
specific antibodies. Results showed that individual cells could be detected, 
that bind TG2 and express plasma cell marker CD138 (Fig 5.8). However in 
contrast to what has been reported, such cells were rare in these patient 
biopsies. Note, none of these 3 patients analysed had classic March 3 biopsy 
findings (tyipical coeliac disease biospsy) and this could explain this 
difference. 
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Fig. 5.8 Detection of TG2-specific plasma cells in D2 biopsies for 3 patients. Double 
immunostaining with labelled TG2 and antibody against plasma cell marker CD138 was 
performed. Overlay shows colocalization of plasma cell with labelled TG2 binding (arrows). 
TG2-specific plasma cells were observed in the lamina propria around the intestinal crypts 
(C) in patients P2 and P9 and in the lamina propria (LP) of the intestinal villi (V) in patient 
P7. Size bars = 50µm 
 
 
Detection of TG6-specific B-cells in D2 biopsy section  
 
Atto-565 labelled TG6 (20µg/ml) was incubated with sections for 1h at 
room temperature to facilitate detection of TG6-specific cells. Patients were 
considered to have TG6-specific cells when individual cells were observed, 
where nuclei were fully or at least partially present and lTG6 staining 
occurred in the majority of the cell surface with a more intense signal than 
the background. Sometimes, the typical morphology of plasma cells 
(considerable nucleus-to-cytoplasm ratio, eccentric nucleus) was evident, 
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e.g. Fig. 5.9 P12, but the section plane was frequently outside the central 
plane and therefore assessment was more difficult. Nevertheless, efforts 
were made to count the total number of lTG6+ cells in the section, according 
to the parameters described. This was done on at least 3 separate occasions 
for each patient but unfortunately, due to experimental problems, such as 
tissue loss during staining, data was not available for all attempts for each 
patient (Table 5.4). Therefore it was decided to mark the patients as positive 
(Pos) or negative (Neg) for the presence of TG6-reactive cells. Patients were 
considered negative when the average number of TG6-reactive cells 
observed in different sections was less than 1.  
 Cells with positive staining for labelled TG6 were observed in a total of 
15 patients: 9/11 (81%) CD group, 4/5 (80%) GA group, 2/8 (25%) control 
group (Table 5.5). Within the CD group, one of the negative patients was 
undertaking a gluten-free diet (P18). Within the control group, the 2 positive 
patients presented with markers related to neurological pathologies: P12 
displayed antibodies against multiple autoimmunity marker glutamic acid 
decarboxylase (anti-GAD) and P13 presented with a cerebellar variant of 
multiple system atrophy (MSA-C). A link between anti-GAD, ataxia and GRD 
has been described (Hadjivassiliou et al., 2011). The number of TG6-reactive 
cells varied from patient to patient and within the same patient, from section 
to section and ranged from 0 to 27. A significant different was observed for 
number of patients testing positive for labelled TG6 reactive cells between 
gluten disorder patients and controls (p=0.027). 
A panel with an overview of staining observed for the different patients 
tested is shown in Fig. 5.9. Overall, lTG6+ patients displayed anti-TG6 
antibody expressing cells in the lamina propria of the intestinal tissue, 
particularly around the intestinal crypts and within the intestinal villi. 
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Fig. 5.9 Overview of labelled TG6 staining in patient’s D2 biopsies. Fixed-frozen 
sections were incubated with 20µg/ml of lTG6 for 1h at RT. Size Bar 50µm 
  
P24$ P25$
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Table 5.4 Detection of anti-TG6 antibody expressing cells in different patient groups. 
Group ID Age, y Sex Notes lTG6 
Cell 
count 
Coeliac 
Disease 
2 57 M Anti-TG2+(low) Pos 22;3;f 
3 24 F Anti-TG2+ Pos f;f;4 
4 22 F Anti-TG2+ Pos 2;0;4;12;f 
6 52 F Anti-TG2+ Pos 14;9;11 
7 43 F Anti-TG2+/ Anti-TG6- Pos 1;10;f 
8 37 M Anti-TG2+ Pos 6;f;5 
9 20 F Anti-TG2+ Pos 0;1;0;14 
18 73 F Anti-TG2- (on GFD) Neg f;0;0; 
20 27 F Anti-TG2+ Pos 2;0;f 
21 68 M Anti-TG2- (on GFD) Pos 3;2;1 
23 73 F  Neg 1;1;0;f 
Gluten  
Ataxia 
5 61 F Anti-TG2+(low) (not on GFD) Pos 0;5;5;f 
10 75 M 
Anti-TG2-/Anti-TG6+/  
(not on GFD) 
Pos 
2;0;4;4;6 
11 60 F 
Anti-TG2-/Anti-TG6+/  
(not on GFD) 
Pos 
4;3;4;12 
16 60 F Anti-TG2-/Anti-TG6- Neg 1;0;1 
17 61 M Anti-TG2-/Anti-TG6+ Pos 1;1;2 
Control 
12 39 M 
ISA/ Anti-GAD+ 
Anti-TG2-/Anti-TG6- 
Pos 
7;6;f;27;f 
13 56 F MSA-C/ Anti-TG2- Pos 2;7;f 
14 67 M ISA/Anti-TG6+/ Anti-TG2- Neg 0;0;1 
15 68 F 
ISA 
Anti-TG2-/Anti-GAD+ 
Anti-TG6+(borderline)/  
Neg 
0;0;1 
19 44 F Anti-TG2+(low) Neg 0;0;0 
22 72 M  Neg 0;0;0 
24 63 F  Neg 0;0;f 
25 28 F  Neg 0;0;0 
 
Abbreviations: GFD = gluten-free diet; WMA = white matter abnormalities; MSA-C = 
cerebellar variant of multiple system atrophy; ISA = idiopathic sporadic ataxia. anti-GAD = 
antibodies against glutamic acid decarboxylase; f = experiment failed 
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Table 5.5 Summary of results obtained for labelled-TG6 reactive cells in patients gut 
biopsies. 
 
Results 
Total Negative Positive 
Disease Group Celiac Disease 2 9 11 
Gluten Ataxia 1 4 5 
Control 6 2 8 
Total 9 15 24 
A significant different was observed for number of patients testing positive for labelled TG6 
reactive cells between gluten disorder patients and controls (p=0.027). 
 
To identify the nature of the cells that were binding labelled TG6, B-cell 
marker CD20 and plasma cell marker CD138 were also analysed on the 
same section. Due to poor tissue morphology or loss of tissue during staining 
process, data was not acquired for all the patients. It was expected that 
colocalization of lTG6+ with B-cell and plasma cell markers, CD20 and 
CD138, respectively. Surprisingly, this was not always evident. Since we only 
performed double labelling in each section, it could be that lTG6+CD20- cells 
detected in one section of a patient were in fact lTG6+CD138+ cells and vice-
versa. The nature of all lTG6+ cells present in patient sections was therefore 
impossible to determine based on this approach. Nonetheless, colocalization 
of lTG6+ cells with either CD20 or CD138 was detected. Below we show a 
few examples of patients were colocalization between lTG6 staining and 
CD20 or CD138 was observed (Fig 5.10). 
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Fig. 5.10 Identity of TG6-reactive cells within the intestinal mucosa. Double 
immunostaining of fluorescently labelled-TG6 with either antibodies to B-cell marker CD20, 
or plasma cell marker CD138 in different patients. Colocalization is shown by *. Size bar = 
50µm 
  
CD20 lTG6 
DAPI Overlay 
P16 
* 
 148 
5.3 Discussion 
 
In this chapter, the presence of TG2 and TG6-specific B-cells in small 
intestine D2 biopsies of a cohort of patients presenting with GRD or controls 
was investigated. The main goal of these experiments was to contribute to 
the mechanistic understanding of autoantibody development in extraintestinal 
gluten-related disease manifestations, particularly in gluten ataxia. 
As previously mentioned, three different, but genetically linked, 
transglutaminases have been identified as the autoantigens in different 
gluten related disorders: TG2 in coeliac diease (Dieterich et al., 1997), TG3 
in dermatitis herpetiformis (Sárdy et al. 2002) and TG6 in gluten ataxia 
(Hadjivassiliou et al., 2008). The mechanism for the development of 
antibodies against these ‘self-proteins’ is still not fully understood.  
A study based on in situ detection of autoantibodies with 
immunofluorescence suggested that anti-TG2 antibodies were produced 
locally in the small intestine (Korponay-Szabó et al., 2004), although this is 
still a matter of debate and the exact site of production of anti-TG2 antibodies 
is still unknown. Plasma cells specific for TG2 have been observed in the 
small intestinal tissue of coeliac disease patients (Di Niro et al., 2012). In 
these current experiments, a low number of plasma cells were also 
detectable when performing double immunofluorescent staining with labelled 
TG2 and plasma cell marker CD138. Although not all patient sections were 
studied, plasma cells were present in 2 CD patients and in 1 patient with CD 
and white-matter abnormalities. This was not surprising, as TG2, although 
with less specificity than TG6, has also been implicated in gluten ataxia 
(Hadjivassiliou et al. 2006).  
In the context of coeliac disease, Sollid et al (2007) proposed that 
activation of TG2-reactive B-cells occured through help from gluten-reactive 
T-cells. This proposed model is based on the possibility that TG2-specific B-
cells were able to process and present TG2-gliadin complexes (Sollid et al. 
1997). In fact, such an ability was demonstrated by Di Niro and colleagues, 
therefore favoring this model (Di Niro et al., 2012). More recently, Iversen 
proposed that B-cell receptors serve as substrates for TG2 and become 
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cross-linked to gluten-derived peptides. This model links gluten peptide 
uptake by TG2-specific B-cells directly to peptide deamidation, necessary for 
the activation of gluten-reactive T-cells (Iversen et al. 2015). It is possible 
that a similar mechanism is involved in the pathogenesis of the gluten-related 
neurological pathology, where TG6-specific autoantibodies are produced. In 
this case, gluten-reactive T-cells would provide help to TG6-reactive B-cells 
leading to production of antibodies against the neuronal protein TG6 (which 
are the hallmark of gluten ataxia). In these current experiments it was 
demonstrated that, although at low numbers, TG6-reactive cells do exist in 
the lamina propria of the small intestine of GRD patients. These cells were 
identified mainly in patients diagnosed with coeliac disease and gluten ataxia 
with a prevalence of 81% and 80%, respectively. The control patients 
positive for TG6-reactive cells, presented with neurological abnormalities, 
with 1 of these patients also presenting with elevated anti-glutamic acid 
descarboxylase antibodies (marker of multiple autoimmunity). Overall, it 
appears that TG6-reactive B cells were present primarily in patients with a 
form of gluten-related disorder. Furthermore, some of these cells were 
identified as being CD20+, the main surface marker for B-cells. This supports 
the idea that, like TG2-reactive B-cells in Sollid’s proposed model, TG6-
reactive B-cells are present and could be activated by gluten-reactive T-cells 
in the gut of susceptible individuals. The knowledge that TG6 is able to 
deamidate gluten peptides, that constitute T-cell epitopes (Jorunn Stamnaes, 
Dorum, et al., 2010), in a similar way to TG2, further supports this model. 
The site where the intestinal biopsy was collected could explain the scarce 
number of TG6-reactive/CD20+ cells observed. B-cells have been shown to 
be mainly present in the gut associated lymphoid tissue (GALT) (Spencer & 
Sollid, 2016). Lamina propria adjacent to GALT may contain B-cells that tend 
to be large cells resembling plasmablasts or plasma cells, while distant 
lamina propria contains few, if any, CD20+ B-cells. If patient biopsies were 
taken from a location that did not contain the GALT, detection of these cells 
would be difficult.  
 Additionally, some of the detected TG6-reactive cells that were 
negative for the B-cell marker CD20, did colocalize with the plasma cell 
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marker CD138. The overall number of these cells was also low.  Recently, a 
study by Di Niro demonstrated poor correlation between the density of TG2-
specific plasma cells in the lesion and IgA anti-TG2 antibody levels in the 
serum of CD patients (Di Niro et al., 2016). Therefore, it is possible that 
differentiation of activated B-cells might take place outside the gut. This 
would explain the low number of TG6-specific plasma cells found in our 
experiments. These cells could in fact be long-lived plasma cells, as 
suggested in the study by Mesin (Mesin et al., 2013).  
It has to be stated that the number of CD138+ cells detected in patient 
biopsies was surprisingly low, considering that the intestinal lamina propria is 
the primary location of plasma cells (review by Fagarasan & Honjo, 2003). 
Additionally, a high number of IgA positive cells were found in all patients of 
this study, suggesting that a high number of plasma cells were present in the 
intestinal sections. The unexpected low number of CD138+ cells detected in 
this current study could be explained by inefficient detection of CD138 
(syndcan-1) by the purchased antibody. In fact, signal for plasma cell marker 
CD138 in control tonsil tissue was weak, but since plasma cells are not 
usually abundant in this tissue, the antibody was considered suitable for our 
experiments. This could perhaps explain the origin of the TG6-reactive cells 
that stained apparently negative for CD20 and CD138, and some of these 
may in fact be CD138+, perhaps expressing lower levels of the 
transmembrane proteoglycan. As serial sections of patient biopsies were not 
always possible to obtain, and double immunostaining only allowed 
identification of TG6-reactve cells with either CD20 or CD138 in each case, it 
could also be that TG6-reactive cells negative for CD20 detected in one 
section would be staining positively for CD138, and vice-versa.  
In conclusion optimization of a protocol for immunofluorescence 
staining of TG2 and TG6-reactive cells in the human gut was achieved. 
Furthermore, this study shows for the first time that TG6-reactive cells are 
present in the human gut and they seem to correlate to the presence of a 
gluten-related disorder. However, there are clear limitations in these 
experiments and it is premature to conclude whether or not TG6-reactive 
cells have diagnostic potential in the context of gluten-related disorders. 
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Nonetheless, the presence alone of such cells supports a model for anti-TG6 
antibodies production by plasma cells in the gut and driven by gluten-specific 
T-cells, similar to the one proposed by Sollid for anti-TG2 antibodies. 
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Chapter 6 Transglutaminase expression in macrophages  
 
6.1 Introduction 
 
As discussed in the previous chapter, the knowledge of the 
pathogenic adaptive immune response towards gluten in CD is quite 
comprehensive. However, an understanding of the role of innate immunity in 
the disease pathogenesis is still lacking.  
Adaptive immunity does not appear to be sufficient for establishment 
of the CD lesion, and it has been suggested that stress responses in the 
intestinal epithelium and innate immunity may play a role in the development 
of CD (J. Stamnaes & Sollid, 2015).  
It is established that HLA-DQ molecules are involved in the 
pathogenesis of CD (Ludvig M Sollid & Jabri, 2011), but is still not 
understood where and on which cells these molecules exert their function. 
These molecules are mainly expressed on specialized antigen-presenting 
cells such as monocytes, macrophages and dendritic cells. Gliadin peptides 
have been shown to activate monocytes and macrophages in vitro with 
subsequent release of pro-inflammatory factors such as TNF-α (Tucková et 
al., 2002). A study has also demonstrated a rapid increase of a specific type 
of dendritic cells, expressing HLA-DQ molecules, in the mucosa of coeliac 
disease patients after oral gluten challenge (Brottveit et al., 2012). Such 
findings suggest that a specific subpopulation of cells could present gluten 
peptides to gluten-reactive T-cells. Likewise, although previous research in 
this thesis has demonstrated that TG6-specific B-cells and plasma cells are 
present in the gut, it remains to be shown where TG6 is expressed as, unlike 
TG2 it appears not to be expressed by the major types of cells making up the 
tissue. One hypothesis is that TG6 may be expressed by infiltrating immune 
cells. 
 In this chapter the focus is the analysis of expression of the gluten-
related disorder autoantigens TG2, TG3 and TG6 in different monocytes and 
macrophages cell populations at baseline and upon stimulation. An insight 
into the expression of these enzymes might help the understanding of the 
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role that the innate immune cells play in the pathogenesis of gluten-related 
disorders, specifically, this might identify the site at which the deamidation 
reaction linked to these diseases occurs. 
 
The aims of the chapter: 
 
1. To characterize TG2, TG3 and TG6 gene expression in human and 
murine monocytes before and after differentiation into M1 and M2 
macrophages and after bacterial stimulation.  
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6.2 Results 
 
6.2.1 THP-1 monocyte differentiation into mature macrophages  
 
Initially, a monocyte cell model was chosen to assess expression of 
transglutaminases during different stages of differentiation and in response to 
bacterial stimulation. 
The human leukemia cell line THP-1 has been reported to express 
distinct monocytic markers (Tsuchiya et al., 1980) and was, therefore, 
chosen for this study. More recently, it has been suggested that this cell line 
is actually a precursor cell linked to dendritic cell differentiation. Additionally, 
these cells have been reported to express TG2, upon monocyte to 
macrophage differentiation (Mehta & Eckert, 2005; Mehta & Lopez-Berestein, 
1986), making these cells a good starting point to study the involvement of 
the innate immune response in the context of gluten-related disorders.  
Differentiation of THP-1 monocytes was performed in two sequential 
steps (Fig. 6.1A). Detailed methodology can be found in section 2.21 of 
chapter 2. Initially, monocytes were stimulated with or without 50ng/ml of 
12-O-tetradecanoylphorbol-13-acetate (TPA), for 48h. TPA, or PMA, is a 
strong tumor-promoting phobol diester, that has been shown to potentiate 
differentiation of monocytes into macrophages (Shigeru Tsuchiya et al., 
1982). Changes in cell morphology were assessed during the differentiation 
process (Fig. 6.1B). THP-1 monocytes are rounded cells with a smooth 
surface that grow in suspension. Cells stimulated with TPA, showed the 
typical morphological changes associated with differentiation. These cells 
became adherent, increased in size and presented a more granular 
appearance. This effect was more noticeable after 48h stimulation. No or few 
morphological changes occurred in THP-1 cells stimulated with medium only 
or DMSO, which was used as a carrier. 
Differentiated THP-1 cells (M0) were then polarized towards classical 
(M1) or alternatively activated (M2) macrophages by a 3-day stimulation with 
20ng/ml GM-CSF or M-CSF, respectively. Morphology of the polarized cells 
was assessed on the third day (Fig. 6.1C). Both cell populations were 
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completely adherent and appeared larger, due to extensive cell spreading. 
M1 and M2 cells presented a very similar morphology, with a granular 
surface and formation of colonies, as expected after stimulation with colony 
stimulation factors (CSF). 
 Both of these cell populations were then incubated with either, 
100ng/ml LPS or 1x105 particles of heat killed candida (HKC), for 4 or 24h, to 
promote activation. M1 cells especially, appeared more elongated. The same 
effect was also observed when these cells were incubated with HKC, a less 
powerful stimulator (Fig. 6.1D). 
 Expression of M1/M2 markers was investigated by quantitative real-
time PCR. This allowed confirmation that THP-1 cells were indeed polarized 
into these respective types of macrophages. M1 macrophages are expected 
to have a pro-inflammatory profile and tend to express higher levels of IL-
12p40 compared to M2 cells (Chanput et al. 2013). M2 cells, on the other 
hand, are expected to have an anti-inflammatory profile and express higher 
levels of EBI3 comparing to M1 cells (Zheng et al., 2013). 
 THP-1 expression of IL-12p40 did not seem to be substantially altered 
by stimulation of the cells with TPA. However, increase in expression was 
observed after THP-1 differentiation to M1 or M2 macrophages: M1 cells 
showed a 3.3-fold increase and M2 cells a 2.4-fold increase in expression of 
the gene when compared to the control.  LPS stimulation further increased 
the expression of IL-12p40 in M1 and M2 cells. This was expected for the M1 
population as LPS is a known activator (Mantovani et al., 2004). However, 
such an increase of IL-12p40 in the M2 population was not expected as 
these macrophages usually present an IL-12low profile even upon activation 
(Mantovani et al., 2004). As this effect was only observed after 4h stimulation 
it is possible that LPS, as a strong stimuli, has driven the M2 cells towards an 
M1 profile. This is not surprising as macrophages can be controlled by 
different changes in environmental signals (Gratchev et al., 2006; Porcheray 
et al., 2005). Furthermore, a similar LPS-effect has been previously reported 
in mouse M2 macrophages (Zheng et al., 2013). 
 Analysis of EBI3 gene expression, further confirmed that THP-1 cells 
had successfully been polarized to M1 or M2 macrophages. Anti-
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inflammatory M2 macrophages showed a higher expression of EBI3 
comparing to M1, most clearly evident after 24h of treatment with LPS. 
Unexpectedly, stimulation of M1 macrophages with LPS, also increased the 
expression of EBI3. In contrast to LPS, treatment with HKC appeared to have 
little effect on either expression of IL-12p40 or EBI3. 
 
 
 
 
 
THP-1 monocytes 
M0 macrophages 
resting macrophages 
M1 macrophages 
pro-inflammatory profile 
M2 macrophages 
anti-inflammatory profile 
+ 50ng/ml TPA 
48h  
+ 20ng/ml GM-CFS  
3 days 
+ 20ng/ml M-CFS  
3 days 
THP$1& THP$1&&50ng/ml&TPA&
24
h&
48
h&
50μm& 50μm& 50μm&
50μm& 50μm& 50μm&
THP$1&&
DMSO&control&
A 
B 
 157 
 
 
 
 
 
 
 
M1#$#20ng/ml#GM$CSF#
24
h#
72
h#
50μm# 50μm#
50μm# 50μm#
M2#$#20ng/ml#M$CSF#
M1#
50μm# 50μm#
M2#
1x
10
5 #H
KC
#
10
0n
g/
m
l#L
PS
#
50μm# 50μm#
C 
D 
 158 
 
 
Fig. 6.1 THP-1 monocytes differentiation. A shematic of the process used for 
diferentiation of THP-1 monocytic cells is shown in panel A. THP-1 cells were initially 
diferentiated into macrophages by stimuation with 50ng/ml TPA over for a 48h period. 
Morphology of cells after 24 and 48h stimuation was analysed (B). Differentiated cells were 
polarized into M1 or M2-type macrophages by further stimulation with 20ng/ml of rhGM-CSF 
or rhM-CSF for 3 days. Morphology of cells was analysed after 24h and 72h (C). Cells were 
stimulated with either 100ng/ml of LPS or 1x105 cells of heat killed candida (HKC) (D). To 
confirm success of polarization both stimulated and non-stimulated cells were analysed for 
expression of M1 macrophage marker, IL-12p40 (E) and M2 macrophage marker, EBI3 (F). 
The data is the mean of samples run in triplicate from one experiment. Data reflects sample 
analysis through the 2-∆∆Ct method, normalized for internal control gene GAPDH, and is given 
relative to non-stimulated THP-1 population.  
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6.2.2 Expression of TG2, TG3 and TG6 is linked to inflammatory 
stimulation 
 
 After determining that THP-1 monocytes were successfully 
differentiated into two different macrophages populations, M1 and M2, a 
complete screening of TG2 expression was carried by PCR and products 
were analysed by agarose gel electrophoresis ( 
Fig. 6.2). Human gene 36B4 (h36B4), encoding for acidic ribosomal 
phosphoprotein, was used as an internal control. Detailed methodology for 
these experiments can be found in section 2.26 of chapter 2.  
 Results for expression of different TG gene products are summarized 
in Table 6.1. Non-stimulated THP-1 cells did not express gluten-related TGs 
(TG2, TG3, TG6) ( 
Fig. 6.2A). Lack of TG2 expression in unstimulated THP-1 cells has been 
previously reported by Metha & Lopez-Berestein, 1986. Expression of TG4, 
TG5 and FXIII was also observed in undifferentiated cells.  
 Upon TPA stimulation, the now M0 macrophage-type cells, showed a 
decrease in FXIII and, to a lesser extent TG5 expression. Expression of TG4 
was no longer detectable. TG2 expression was substantially increased ( 
Fig. 6.2A). This is in agreement with observations by Metha & Lopez, 1986. 
Previous work within our group has also demonstrated that TPA and LPS 
both regulate TG2 expression at protein level in THP-1 cells (Adamczyk, 
2013).   
 Non-activated M1 and M2 cell populations kept the tranglutaminase 
profile of TPA-stimulated THP-1 cells, with the exception of TG2, that 
showed a further increase in expression ( 
Fig. 6.2B and C). Activation of the two types of macrophages with LPS led to 
an even greater increase of TG2 expression. The same effect was observed 
with HKC but to a lesser extent. In M2 macrophages, HKC did not elicit an 
apparent response ( 
Fig. 6.2C). TG3 and TG6 expression was also induced upon stimulation with 
LPS but not with HKC, suggesting that a strong stimulus is needed for 
induction of their expression. 
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Expression of TG7 could not be determined due to the small product 
size and the presence of some primer dimers. Internal control gene, h36B4, 
confirms quality of samples and shows similarity of cDNA levels used for the 
experiment, across all samples.  
In summary, the results showed that FXIII and TG4 were expressed 
by undifferentiated monocytes but were downregulated upon differentiation, 
whereas TG2 and to a lesser extent TG3 and TG6 expression was linked to 
inflammatory stimulation.  
 
Table 6.1 Summary of results for transglutaminase RNA expression levels in THP-1 
cells, analysed by gel electrophoresis 
Sample TG1 TG2 TG3 TG4 TG5 TG6 TG7 FXIII 
THP-1 - - - ++ +++ - ND +++ 
THP-1 (DMSO) - - - ++ +++ - ND +++ 
THP-1 (TPA) ND ++ - - ++ - ND + 
M1 - ++ - - ++ - ND (+) 
M1 4h LPS (+) +++ (+) - ++ + ND (+) 
M1 24h LPS + +++ + - ++ + ND (+) 
M1 4h HKC - +++ - - ++ - ND (+) 
M1 24h HKC - +++ - - ++ - ND (+) 
M2  - ++ - - ++ - ND (+) 
M2 4h LPS (+) +++ - - +++ (+) ND (+) 
M2 24h LPS (+) +++ - - ++ - ND - 
M2 4h HKC - ++ - - +++ - ND (+) 
M2 24h HKC - ++ - - +++ ? ND (+) 
Results represent observations from one experiment.  
Marking system: No gene expression (-), low (+), medium (++) and high (+++) expression 
levels; Borderline gene expression that needs further verification ((+)); Gene expression 
could not be unequivocally determined (ND).  
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Fig. 6.2 Screening for expression of members of the TG-family in response to 
differentiation and stimulation of THP-1 cells. Amplified products were obtained by PCR 
and analysed on 1% agarose gel electrophoresis. EtBr stained products were visualized 
through UV light using a gel documentation system.  Migration of size markers is shown on 
the left (1Kb ladder). Amplification of housekeeping gene (h36B4) is shown on the right. 
Factor FXIII and TG4 were expressed by undiferentiated monocytic cells and downregulated 
upon differentiation, whereas TG2 and, to a lesser extent, TG3 and TG6 expression appear 
to be linked to strong inflammatory stimuli. TG5 appears to be expressed but not affected by 
different conditions. 
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6.2.3 TG2 expression was increased in mouse macrophages after LPS 
stimulation 
 
After detection of TG2 and TG6 in LPS-activated macrophages, 
differentiated from THP-1 monocytic cell line, it was decided to assess 
expression of these genes in primary cells. Initially murine macrophages 
were used, as it is comparatively easier to access mouse tissue than human 
tissue.  
Detailed methodology for murine macrophages culture can be found in 
section 2.22 of chapter 2. Briefly, macrophages were isolated from mouse 
bone marrow and differentiated into M1 and M2 macrophages by stimulation 
with mouse GM-CSF or M-CSF, for 7 days. After differentiation, cells were 
trypsinised and reseeded at 2,5x105 cells/well and allowed to adhere 
overnight. Cells were then stimulated with 100ng/ml of LPS and total RNA 
was extracted at 2, 6 and 24h time points. Total RNA was also extracted 
from control cells, which were not stimulated with LPS.  
Success in terms of cell polarization to M1 and M2 macrophages was 
determined through analyses of iNOS and Arginase-1 gene expression by 
real-time quantitative PCR (qPCR). These two genes have been shown to 
have different expression in the two types of macrophages with M1 cells 
expressing higher levels of iNOS comparatively to M2. The inverse is seen 
regarding Arginase-1 expression (Zheng et al., 2013). Analysis of qPCR data 
showed that expression of these two genes in the mouse M1 and M2 
population followed a similar pattern to the one reported by the above study ( 
 
Fig. 6.3 A and B). Without stimulation, no apparent difference was observed 
in the expression of iNOS between the two cell populations. However, an 
increase in iNOS expression was observed after LPS stimulation, with M1 
cells showing higher expression levels ( 
 
Fig. 6.3A). This was expected as it has been reported before (Lu et 
al., 2015). M1 cells continued to show higher expression levels of the gene 
even after 24h LPS-stimulation. 
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At baseline, M2 cells showed a ≈300-fold higher expression of Arginase-1 in 
comparison to M1. These levels of expression were maintained after LPS 
stimulation of M2 cells, and no increase in expression was observed upon 
stimulation of M1 cells, at least for the early time points ( 
 
Fig. 6.3B). Phenotypic plasticity may contribute to the change seen 
after 24h. 
Overall, the results led to the conclusion that the approach used was 
able to successfully polarize mouse bone marrow derived macrophages into 
two different cell populations, M1 and M2.  
 Analysis of TG2 and TG6 expression was also performed by qPCR, 
using a TaqMan assay previously optimized within the group. 
 Expression of TG2 at baseline was higher in the M2 population in 
comparison to the M1 population, with M2 cells showing 8-fold higher 
expression ( 
 
Fig. 6.3 CI).  A substantial increase in expression of TG2 after LPS 
stimulation was detected, in both cell populations. M1 cells showed a 11-fold 
increase in expression compared to the corresponding unstimulated cells, 
whereas M2 showed a 2.6-fold increase ( 
 
Fig. 6.3 CII and III).  
Therefore, similar to what was observed after stimulation of THP-1 
derived macrophages, LPS was able to induce TG2 expression both in M1 
and M2 macrophages.  
TG6 expression was not detectable in the majority of the samples. 
TG6 gene expression was detected in M2 cells at baseline and after 6h and 
24h of LPS stimulation. M1 cells, stimulated for 6h, also showed some level 
of TG6 expression. However, when expression was detected, it was at final 
amplification cycles and hence, near the limit of detection. Apart from 6h-LPS 
stimulated M2 cells, expression was not detected consistently in all sample 
replicates, suggesting that the samples contain only a few copies (and hence 
this is subject to statistical distribution). Therefore no graph of data could be 
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generated and we should take great caution when making conclusions about 
the expression level of this gene in mouse macrophages. Although it is likely 
that TG6 expression is triggered by inflammation, as it was observed for 
THP-1 derived macrophages, it is clear that this gene is expressed at very 
low levels. Digital PCR could be used in the future to further clarify this. 
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Fig. 6.3 Analysis of gene expression in mouse bone marrow derived macrophages 
(M1 and M2 populations). Samples in A and B were run in triplicate. Samples in C were run 
in duplicate. Data reflects sample analysis through the 2-∆∆Ct method, normalized for internal 
control gene β-Actin (A and B) or h36B4 (C) and is given relative to unstimulated M1 
macrophage population. 
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6.2.4 Is TG2 gene expression increased after stimulation HKC? 
 
Access to different RNA samples of bone marrow derived mouse M1 
and M2 macrophages, stimulated with HKC was available. These samples 
were kindly provided by Dr Xiaoqing Wei. Culture and differentiation and total 
RNA extraction was performed within Dr Wei’s group, following methodology 
comparable to the one used in our experiments. In this experiment, M1 and 
M2 cells were stimulated with either medium only, 105 cells HKC, 106 cells 
HKC or 106 cells HKC+10% MC (melanocyte conditioned medium). Analysis 
of TG2 and TG6 expression in these samples was performed by qPCR as 
described for our own samples.  
We were able to detect expression of TG2 in control samples in both cell 
populations, and these showed a similar level of expression (Fig. 6.4A). This 
was surprising, as previous experiments showed differences in TG2 gene 
expression between M1 and M2 macrophages ( 
 
Fig. 6.3). TG2 gene expression was increased after stimulation with 
both HKC only or HKC combined with MC in M1 macrophages (Note, data 
for stimulation with 105 cells of HKC was excluded as internal control gene 
expression wasn’t within acceptable limits). Expression of TG6 was not 
detected by qPCR. 
 From an independent experiment, new cDNA was obtained from these 
samples and  amplified by PCR. Amplified samples were analysed by 
agarose gel electrophoresis and EtBr staining. As expected, TG2 gene 
expression was detected across all samples, although this endpoint PCR did 
not give any quantitative information (Fig. 6.4B top panel). However, using 
this simple approach we were able to detect expression of TG6 (Fig. 6.4 
bottom panel) and confirm upregulation of its expression upon inflammatory 
stimulation. M2 macrophages showed expression of TG6 in both baseline 
and stimulated samples, with an increase in expression after HKC 
stimulation. With regards to the M1 population, TG6 expression was not 
detectable in baseline samples but was upregulated in response to HKC 
stimulation, under all conditions. Although an internal control was not shown 
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in this gel, a separate experiment using the same cDNA confirmed that a 
similar amount of amplified product was obtained across all samples (Fig. 
6.4).  
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Fig. 6.4 Expression of TG2 and TG6 in mouse macrophages after stimulation with heat 
killed candida. A: Expression of TG2 was analysed by qPCR. Samples were run in 
duplicate. Data reflects sample analysis through the 2-∆∆Ct method, normalized for internal 
control gene h36B4 and data is presented relative to unstimulated M1 population. B: 
Expression of TG2 and TG6 was analysed by PCR. PCR products were separated on 1% 
agarose gels and visualized using EtBr. Size markers are shown on the left (1Kb ladder) 
Internal control gene for the same cDNA samples was analysed independently by qPCR, 
and shown here at the bottom as Ct values. HKC = heat-killed candida; MC= melanocyte 
conditioned medium. 
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6.2.5 Expression of TG2, TG3 and TG6 in human PBMC derived 
macrophages 
 
Expression of TG2 and TG6 gene in human peripheral blood 
mononuclear cell (PBMC) derived macrophages from 3 healthy volunteers 
was also analysed.   
Detailed methodology of isolation culture and differentiation of human 
PBMC derived macrophages can be found in section 2.23 of chapter 2. 
Briefly, a total volume varying between 15-20ml of peripheral blood was 
collected from 3 healthy volunteers and mononuclear cells were separated 
using a density gradient media (Ficoll-Paque Premium). Polarization of 
monocytes into M1 and M2 macrophages was achieved by culturing the cells 
for 7 days in medium supplemented with 20ng/ml of either rhGM-CSF or 
rhM-CSF, respectively.  
After 7 days of differentiation, a substantial change in morphology was 
observed for both differentiation regimens across all 3 subjects (Fig. 6.5A). 
Cells presented a more granular elongated surface, and were completely 
adherent to the flasks. In M2 cells, achieved by stimulation with M-CSF, 
irregular protrusions from the cell surface were also observed (Fig. 6.5A).   
Cells were trypsinized, counted and re-seeded at a density of 
0.5x105cell/cm2 and stimulated with medium only, 100ng/ml LPS or 1x105 
particles of HKC, for 4h, and total RNA was extracted. This time point was 
chosen based on the results obtained in the THP-1 cell experiments. After 4h 
stimulation a large increase in TG2, TG3 and TG6 gene expression was 
observed. 
Expression of TG2, TG3 and TG6 was assessed by real-time 
quantitative PCR. Results represent data acquired by two independent 
experiments with cells isolated separately at two different times of blood 
donation (Fig. 6.5B-E). Expression changes are shown relative to 
unstimulated M1 cells from subject S (at time point t1). 
Results showed some variability with regards to the expression of TGs 
between the three patients. Furthermore, it appears that gene expression in 
a given patient also differed between different time points. This was not 
 172 
unexpected, as here, an uncontrolled population is analysed in contrast to 
mice, which had been maintained germ-free. Although these results were 
inconclusive a few observations can be made. Contrary to what was 
observed in mouse macrophages, expression of TG2 was higher in M1 cells 
at baseline compared to M2 cells in both R and D subjects. The opposite 
finding was true in subject S but only for time point 2 (t2) (Fig. 6.5B and C). 
Although differences were small, increase of TG2 gene expression after 
stimulation was not as clear-cut as expected based on results obtained with 
previous macrophages. When an increase was observed it was usually a 
difference of less than 2-fold compared to expression at baseline. A higher 
increase of expression was observed for subject S in LPS-stimulated M1 
cells at t2 and M2 cells at t1.  
Regarding TG3 expression, the same level of variability was 
observed. No substantial increase in TG3 expression was observed after 
stimulation, for either of the macrophage populations (Fig. 6.5 D and E).  
Expression of TG6 was again close to the limit of detection and 
therefore the data was inconclusive.   
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Fig. 6.5 Expression of TG2 and TG3 in human PBMC derived macrophages. A: PBMCs 
from 3 healthy volunteers were cultured and differentiated with 20ng/ml of either rhGM-CSF 
or rhM-CSF to obtain, M1 or M2 macrophages populations, respectively. TG2 (B and C) and 
TG3 (D and E) expression was analysed by quantitative PCR. All samples were run in 
duplicate. Data analysis was performed using the 2-∆∆Ct method, after normalizing for internal 
control h36B4. Results demonstrate data acquired in two independent experiments (t1 and 
t2) and TG expression is shown relative to non-stimulated M1 cells from subject S (at time 
point t1). 
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6.3 Discussion 
 
In this chapter the expression of TG2, TG3 and TG6 genes in 
monocyte and macrophage cell populations derived from a cell line THP-1, 
mouse bone marrow or human peripheral blood, was assessed. 
Macrophages have been implicated in the pathogenesis of the gluten-
related disorder coeliac disease. Studies have shown that gliadin fragments 
are able to induce activation of macrophages in vitro, with a subsequent 
increase in production of pro-inflammatory cytokines such as TNF-α 
(Jelínková et al., 2004; Tucková et al., 2002). However, how and where the 
gliadin peptides interact with macrophages in vivo remains elusive. 
Permeability of the intestinal mucosa might explain this interaction. In fact, 
studies have found gliadin to be a potent inducer of intestinal permeability 
(Lammers et al., 2008; Thomas et al., 2006). These studies support a role for 
the innate immune response to gliadin in the initiation of CD pathogenesis. 
Monocytes have been shown to express TG2 at the protein level upon 
differentiation (Metha & Lopez-Berestein, 1986; Adamczyk, 2013). 
Furthermore, expression is increased upon LPS stimulation (Adamczyk, 
2013). In these current experiments, it was possible to detect TG2 
expression at the transcription level in differentiated monocytes derived from 
the monocytic cell-line THP-1 upon TPA stimulation. Also, expression was 
further increased after LPS stimulation. These results were consistent with 
the previous findings by Metha & Lopez-Berestein, 1986 and Adamczyk, 
2013, who investigated protein expression. The data confirm dramamtic 
upregulation in response to Toll-like receptor activation. Additionally, it was 
also shown that, to some extent, LPS stimulation of these cells was able to 
increase expression of TG3 and TG6, although a more thorough analysis 
needs to be carried out. This suggests that all 3 genes relevant to GRD are 
upregulated in the context of a pro-inflammatory stimulus, but not other 
members of this gene family. 
Upon analysis of primary mouse macrophages, similar results were 
observed regarding TG2 expression. However, in these cells, a higher 
expression of this enzyme at baseline was observed in anti-inflammatory M2 
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macrophages compared to M1 macrophages. However, pro-inflammatory M1 
macrophages showed the highest increase in TG2 expression after LPS 
stimulation.  
Differentiated mouse macrophages stimulated with heat-killed candida 
(HKC) were also analysed. In these cells, expression of TG2 was present 
across all samples, as expected. However, further analysis of the samples 
revealed an upregulation of TG6 expression in response to stimulation with 
HKC. This correlated with the findings described for THP-1 derived 
macrophages, and further substantiates the link between inflammatory 
activation and TG6 expression.  
Human primary macrophages collected from 3 healthy volunteers and 
stimulated with LPS or HKC were also analysed for TG expression. Although 
TG2 and TG3 were both detectable at baseline and in stimulated samples, 
the great variation in gene expression between and within different subjects 
did not allow for any clear conclusions to be drawn. 
Overall, it was shown that differentiated macrophages are able to 
express the three transglutaminase enzymes recognized as autoantigens in 
gluten-related disorders. Furthermore, other studies have shown enzyme 
activity of TG2 in the membrane of human peripheral blood monocyte 
derived macrophages and dendritic cells (Hodrea et al., 2010).  
Taken together, these results suggest that deamidation of gluten 
peptides might be linked to an increase in expression of TG2 and also TG3 
and TG6, by intestinal macrophages or dendritic cells. 
As the highest ratio of TG2 expression upregulation between 
stimulated and unstimulated macrophages was seen in the pro-inflammatory 
M1 macrophages, expression of the enzyme could be a response to and take 
place along side the release of pro-inflammatory cytokines. This is consistent 
with TG2 being transcriptionally regulated by IL-1, IL-6, TNF-α, IFN-γ and IL-
15 (Bayardo et al., 2012). As external TG2 has been shown to undergo 
reversible inactivation under oxidative conditions (Stamnaes et al., 2010), in 
the context of the above model, it is possible that the increase in mucosal 
permeability by gliadin and subsequent activation of macrophages with a 
release of pro-inflammatory cytokines, could create the optimal conditions for 
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TG2 externalization and activation and consequent deamidation of gluten 
peptides. A mechanism for co-secretion of TG2 and thioredoxin-1 has 
recently been identified (Adamczyk et al., 2015) and could drive generation 
of active extracellular TG2 in this context.  
TG3 and TG6 gene expression following macrophage stimulation was 
also demonstrated. These enzyme have both been linked to gluten related 
disorders with extra-intestinal manifestations: TG3 is linked to skin disorder, 
dermatitis herpetiformis (Sárdy et al., 2002) and TG6 is linked to neurologic 
disorder gluten ataxia (Hadjivassiliou et al., 2008). If expression of these 
enzymes could be identified at protein level in skin macrophages or brain 
microglia, and if these enzymes were shown to be present at the cell surface, 
this could be the link between gluten challenge at gut level and the extra-
intestinal symptoms. However, autoantibodies are likely derived from the 
circulation as shown in the model for DH (Zone et al., 2011). 
Expression of TG2 or TG6 at the surface of microglia cells would allow 
for this interaction between the self-proteins and circulating autoantibodies. 
This ultimately could lead to permeability or a breach in the blood–brain 
barrier and prolonged exposure of the CNS to the gluten-related antibodies. 
As gluten ataxia may be associated with antibody cross-reactivity between 
antigenic epitopes on Purkinje cells and gluten protein (Hadjivassiliou et al., 
2002), exposure of the CNS to gluten-reactive antibodies could lead to the 
loss of these cells as detected in GA patients. Alternatively, TG-specific 
antibodies may be involved directly in causing neuronal damage. In fact, 
Boscolo and colleagues have demonstrated that antibodies from GRD 
patients are capable of causing ataxia when transferred into the central 
nervous system of mice (Boscolo et al., 2007, 2010). Additionally, it was 
reported that recombinant TG-specific scFv ‘antibodies’ that lack the Fc 
region lead to a loss of motor function in mice, suggesting an scFv-antigen 
interaction, independent of complement activation or Fc receptor 
engagement, as the trigger for the immune response in the disease process 
(Boscolo et al., 2010). 
In conclusion these experiments have shown that TG2, TG3 and TG6 
gene expression is indeed upregulated in differentiates macrophages and 
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upon stimulation. This led to the belief that macrophages could potentially be 
the source for TG6 and TG3 in the gut of gluten-disorder patients and this 
way provide the missing link for the hypothesis that autoantibody 
development against TG6 and TG3 could originate in the gut.  
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Chapter 7 General Discussion 
 
The aim of this discussion is to summarise the different hypothesis 
regarding autoantibody production in gluten-related disorders and contrast 
them to the observations from this study. I am proposing a new model for the 
pathological mechanism of gluten-related disorders and, more specifically, 
gluten ataxia: Autoantibodies that drive extraintestinal manifestations of 
gluten-related disorders are developed in the gut of susceptive individuals. 
The results presented in this thesis show, for the first time, the presence of 
TG6 specific B-cells in the small intestine of patients presenting with gluten-
related disorders.  
With gluten-related disorders affecting 1-2% of the general population, 
it is crucial to identify the pathological mechanism behind the disease 
progression. This would allow for the identification of new biological markers 
and development of new therapeutic targets. In gluten ataxia specifically, an 
early identification of these patients is essential, as they will suffer from 
irreversible damage to the neural tissue.  
Sollid has proposed a mechanism for production of anti-TG2 
antibodies in the context of coeliac disease, where TG2-(deamidated)gluten 
complexes act as a hapten carrier in the activation of TG2-reactive B cells by 
gluten-reactive T-cells (Sollid et al., 1997). It is possible that production of 
autoantibodies against TG6, which have been linked to gluten ataxia, follows 
a similar model. The presence of TG6-reactive B-cells in the intestinal 
mucosa of GRD patients reported by this study along side the observation 
that TG6 is able to deamidate gluten peptides reported elsewhere (Stamnaes 
et al. 2010), further supports this hypothesis.  
Another two important questions linked to this model that require 
further investigation are: 1) the presence of TG6 at the gut level to allow the 
formation of TG6-(deamidated) gluten peptide complexes that would act as 
hapten carrier in the activation of TG6-specific B-cells by gluten-specific 
T-cells and 2) the catalysis of the deamidation reaction of gluten peptides by 
TGs in an environment that would favour transamidation.  
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Although expression of TG6 has been associated with the 
development of the CNS (H. Thomas et al., 2013), evidence is still lacking 
when it comes to its expression at the intestinal level. 
Regarding the catalysis of deamidation reaction by TGs, studies have 
shown the selective deamidation of a glutamine residue in the small heat 
shock protein Hsp20 by TG2, under conditions where other glutamine 
residues were transamidated (Boros et al. 2006). Another study has also 
demonstrated that direct deamidation reactions in the presence of an amine-
donor are conditioned by peptide sequences as well as enzyme 
concentration (Stamnaes et al. 2008). These results suggest that 
deamidation could be influenced by both substrates and reaction conditions. 
More recently, work performed by Adamczyk, suggested that the nature of 
the amine also has an impact in the preference for transamidation or 
deamidation reactions by TG2 (Adamczyk, 2013). 
 
7.1 Expression of TGs by activated macrophages  
 
Previous studies have shown TG2 to be expressed in macrophages 
differentiated from a monocytic-derived cell line (Mehta & Lopez-Berestein, 
1986). Furthermore, TG2 expression was shown to be increased upon LPS 
stimulation (Adamczyk, 2013). In the present study, expression of this 
enzyme was also observed in non-stimulated and stimulated pro-
inflammatory and anti-inflammatory macrophage populations, derived from 
the monocytic cell-line and additionally, in macrophages derived from mouse 
bone marrow or human peripheral blood monocytes.  
Moreover, this research reported that expression of TG3 and TG6 
genes was also unregulated in response to inflammatory stimuli in both cell-
line and primary macrophages. This new finding may have an impact on the 
understanding of the pathogenesis of the gluten-related disorders dermatitis 
herpetiformis and gluten ataxia, where TG3 (Sárdy et al., 2002) and TG6 
(Hadjivassiliou et al., 2008) are the respective recognized autoantigens. 
Macrophages have been implicated in the pathogenesis of the gluten-
related disorder coeliac disease. In fact, studies have shown the ability of 
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gliadin fragments to induce activation of macrophages in vitro, with a 
subsequent increase in production of pro-inflammatory cytokines such as 
TNF-α (Jelínková et al., 2004; Tucková et al., 2002). Therefore, it is possible 
that activation of intestinal macrophages by gliadin, could lead to an increase 
in expression of TG2, TG3 and TG6, in a similar way to what was observed 
in these current studies after stimulation of macrophages in vitro with LPS or 
HKC. However, how and where the gliadin peptides interact with 
macrophages in vivo remains elusive. Increased permeability of the intestinal 
mucosa might explain this interaction, as studies have found gliadin to be a 
potent inducer of intestinal permeability (Lammers et al., 2008; Thomas et 
al., 2006). Gliadin could then interact with any of these members of the TG 
family, either within the macrophages or extracelullarly, resulting in the 
production of deamidated gluten peptides and gluten-TG complexes. In fact, 
the ability to deamidate gluten peptides with the formation of gluten-TG 
complexes has been shown for not only TG2 but also TG3 and TG6 
(Stamnaes et al., 2010). As in the proposed model by Sollid for TG2 and 
coeliac disease, gluten-TG3 and gluten-TG6 thiolester complexes would be 
able to act as hapten carriers and facilitate activation of TG3 or TG6-reactive 
B cells by gluten-reactive T cells leading to the production of the anti-TG3 or 
TG6 antibodies, characteristic of dermatitis hermetiformis or gluten ataxia, 
respectively.  
 
7.2 Production of autoantibodies in gluten ataxia 
 
TG6 has been identified has the autoantigen in gluten ataxia 
(Hadjivassiliou et al., 2008). However, the mechanism for the development of 
antibodies against this self-protein is still not fully understood.  
In this thesis, the presence of TG2 and TG6-specific B-cells in small 
intestine D2 biopsies of a cohort of patients presenting with GRD or controls 
was investigated. The presence of these cells at the intestinal level starts to 
provide a mechanistic understanding of autoantibody development in 
extraintestinal gluten-related disease manifestations, particularly in gluten 
ataxia. 
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Here, the presence of TG6-reactive cells in the small intestinal 
mucosa of GRD patients was demonstrated. Furthermore, the studies 
suggested a prevalence of these cells in approximately 80% of both coeliac 
disease and gluten ataxia patients. This suggests that there is a link between 
the occurrence of TG6-reactive cells in the gut and these gluten-related 
disorders, but not necessarily the type of manifestation present. The studies 
were also able to identify some of these cells as being B-cells or plasma 
cells.  
Based on this evidence, I propose that the development of anti-TG6 
antibodies, the hallmark of gluten ataxia, has its origin in the intestinal 
mucosa of susceptible subjects.  
 
7.3 Proposed model: Autoantibodies that drive extraintestinal 
manifestations of GRD are developed in the gut. 
 
Based on the model previously suggested by Sollid for autoantibody 
development in coeliac disease (L M Sollid et al., 1997), I propose the 
following revised model for the development of autoantibodies that drive 
extraintestinal manifestations of gluten-related disorders, in particular gluten 
ataxia. 
Gluten peptide gliadin reaches the intestinal lumen due to its high 
proline content and subsequent resistance to gastric enzymes (Stepniak & 
Koning, 2006). Gliadin induces intestinal permeability and is able to enter the 
intestinal mucosa (Lammers et al., 2008; Thomas et al., 2006). Here, it 
interacts with and activates intestinal macrophages (Jelínková et al., 2004; 
Tucková et al., 2002) leading to expression of TG6. TG6 catalyses the 
deamidation of gliadin (Stamnaes et al., 2010), either within macrophages or 
extracellularly, with production of TG6-peptide complexes. These complexes 
act as a hapten carrier and allow activation of TG6-reactive B cells at the 
GALT, by gluten-reactive T cells, with subsequent development of anti-TG6 
antibodies. 
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7.4 Involvement of microglia in the pathogenesis of gluten ataxia 
 
It is unclear if the CNS pathology associated with gluten sensitivity is 
the result of access of circulating antibodies that react with brain antigens 
upon compromise of the blood-brain barrier.  
Hadjivassiliou et al, have reported the colocalization of TG6 deposits 
with perivascular IgA deposits, upon post mortem examination of a gluten 
ataxia patient (Hadjivassiliou et al. 2008). Additionally, location of these 
deposits, mainly around brain vessels, suggests that vasculature-centered 
inflammation may compromise the blood-brain barrier. It is also known that 
patients with GA have increased serological levels of antibodies primarily 
directed against TG6 (Hadjivassiliou et al., 2008).   
In chapter 6 of this thesis the in vitro expression of TG6 by 
macrophages in response to an inflammatory stimuli was reported. 
Microglia are the most abundant and best studied macrophage 
population of the CNS. These cells play an important role in CNS 
homeostasis during development, adulthood and ageing. Additionally, they 
are known to respond not only to changes in the brain’s structural integrity 
but also to very subtle alterations in their microenviroment, such as 
imbalances in ion homeostasis (Kreutzberg, 1996; Perry & Teeling, 2013).  
If microglia were shown to express and externalize TG6 upon 
activation, it is possible that circulating anti-TG6 autoantibodies would be 
able to interact with the protein. This interaction could ultimately lead to 
permeability of the blood–brain barrier and prolonged exposure of the CNS to 
the gluten-related antibodies. This hypothesis is supported by studies 
demonstrating that serologic antibodies from GRD patients are capable of 
causing ataxia, when transferred into the central nervous system of mice 
(Boscolo et al., 2007, 2010). Additionally, it has been reported that 
recombinant TG-specific scFv ‘antibodies’ that lack the Fc region lead to a 
loss of motor function in mice, suggesting an scFv-antigen interaction, 
independent of complement activation or Fc receptor engagement, as the 
trigger for neuronal degeneration in the disease process (Boscolo et al., 
2010). Expression of TG6 at the surface of microglia cells would allow for this 
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interaction between the self-proteins and circulating autoantibodies. A 
disruption in the blood-brain barrier potentially linked to this interaction would 
then allow the exposure of the CNS to gluten-related pathogenic antibodies, 
including anti-TG6 antibodies and anti-gliadin antibodies. As gluten ataxia 
may be associated with antibody cross-reactivity between antigenic epitopes 
on Purkinje cells and gluten-derived proteins (Hadjivassiliou et al., 2002), 
exposure of the CNS to gluten-reactive antibodies could lead to the loss of 
these cells as detected in GA patients. 
 
7.5 GTP-binding capacity of TG2 is required for catalytic activity  
 
For identification of TG2 and TG6-reactive cells in intestinal biopsies, 
TG2 and TG6 were successfully produced and chemically labelled using 
specific fluorophores.  These fluorophores were attached using NHS ester 
chemistry to the primary amine on the side chain of any lysine residue. 
Effects of amine-labelling on TG2 functionality were analysed. Changes were 
observed regarding enzyme functionality, dependent on conditions. 
Surprisingly, when labelling was performed in the absence of GTP, TG2 
isopeptidase activity was lost, while addition of the nucleotide during labelling 
led to an enzymatically active protein. This was observed for NHS ester 
labelling with two chemically different fluorophores, suggesting that the loss 
of isopeptidase activity after labelling does not depend on the nature of the 
fluorophore, but rather structural hindrance caused by label binding to 
specific lysine residues.  
Since TG2 activity is tightly regulated by Ca2+/GTP allosteric 
conformational changes (Begg et al., 2006; Casadio et al., 1999), it is 
understandable that interruption of these binding sites, or the adoption of 
associated conformational states, will lead to the differences in enzyme 
function. 
GTP binding causes a large conformational change, shifting the 
protein to a closed conformation, limiting active site access to substrates and 
therefore negatively regulating enzyme activity. The loss of isopeptidase 
activity observed in labelled TG2 when labelling was performed in the 
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absence of GTP, suggested incorporation of the fluorophore at a lysine in a 
position detrimental to either the catalytic region or substrate-binding site.  
The TG2-GTP binding site has been shown to be located in a pocket 
between the first β-barrel domain and the loop that connects it to the next β-
strand (Jang et al., 2014). Furthermore, two residues from the catalytic core, 
Lys 173 and Phe 174, have been shown to contribute to the GTP interaction 
(Begg et al., 2006; Jang et al., 2014; Liu et al. 2002).  
Jeon at al., suggested that conformational changes caused by GTP 
binding may help maintain physiological enzyme stability, to display 
transamidation activity at high calcium concentrations (Jeon et al., 2002). 
Furthermore, it has been shown that mutations at S171, involved in GTP-
binding, can cause reduction or loss of transamidation activity (Antonyak et 
al., 2001; Jeon et al., 2002).  
As previously mentioned, NHS ester labelling occurs by reaction of the 
ester group with primary amine found in lysines. During labelling in the 
presence of GTP, Lys173 would be already bound to the nucleotide and 
therefore, not available for labelling. Conversely, labelling in the absence of 
the nucleotide would allow for modification of this catalytic core residue. This 
could provide an explanation for the loss of isopeptidase activity observed 
when TG2 was labelled in the absence of GTP and suggests that GTP-
binding capacity of TG2 is required for catalytic activity or, at least, a 
conformational transition linked to catalysis.  
In a similar way to S171, it is possible that Lys173 might be implicated 
in this conformational transition or stabilization of TG2 and may be required 
for the enzyme to display isopeptidase activity. Therefore, further studies 
involving mutations at Lys173 should be carried out. 
 
7.6 TG2 displays a second structural pocket with high affinity for an 
amine substrate 
 
In this study it has been postulated that TG2 may contain a second 
structural pocket with high affinity for an amine substrate. This hypothesis 
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comes from evidence collected by analysis of open-conformation TG2 using 
an ‘in gel’ activity assay.  
Initially, native electrophoresis of different forms of TG2 was 
performed to correlate loss of isopeptidase activity with any structural 
changes generated by modification of the protein with NHS ester labels. 
Labelled proteins were analysed along side native TG2 and a form of 
TG2 trapped in the ‘open’ conformation, as comparison for any shifts in 
mobility of bands of TG2 labelled in the presence or absence of GTP. The 
initial ‘open’- form TG2 used in this assay was commercially purchased TG2, 
conjugated with an inhibitor at the active site Cys residue in order to stabilize 
the open conformation. This protein was not expected to display any catalytic 
activity.  
Upon an ‘in gel’ activity assay where, native gels were incubated with 
a solution containing FITC-cadaverine and calcium, it was observed that 
inhibited ‘open’ TG2 was somehow able to retain the amine substrate. This 
led to the speculation that inhibited enzyme, which reflects an intermediate 
state during catalysis, had a high-affinity binding site for the amine donor 
substrate. After several experiments performed in order to confirm specificity 
of the binding, including the in-house inhibition of TG2 with different catalytic 
site directed inhibitors, it was concluded that interaction of FITC-cadaverine 
with the ‘open’ TG2 was specific and not due to residual catalytic activity, and 
untimely the existence of the second structural pocket with high affinity for an 
amine substrate was proposed. Furthermore, it appears that this pocket 
becomes available upon reaction of the enzyme with a first substrate, an 
event mimicked by reaction with the catalytic site-inhibitor in our experiment. 
This is an important observation that will hopefully clarify, in the future, how 
the enzyme interacts with the amine substrate, and how exactly this leads to 
subsequent transamidation or deamidation of the glutaminyl substrate.  
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7.7 Final conclusions 
 
In summary, the results presented in this thesis have advanced our 
mechanistic understanding of autoantibody development and extraintestinal 
manifestations in the context of gluten-related disorders.  
It has been successfully shown that both B and plasma-cells reactive 
to TG6 are present in the gut of patients presenting with a form of gluten-
related disorder. Therefore, providing for the first time, evidence that 
autoantibodies that drive extraintestinal manifestations, such as the ones 
observed in gluten ataxia, may be developed in the gut.  
Furthermore it has been have shown that inflammatory stimulation of 
macrophages in vitro, induces expression of TG6. These cells could 
therefore be the major source of TG6 at the intestinal level, which would 
allow for the formation of TG6-gluten complexes necessary for activation of 
TG6-reactive B-cells by gluten-reactive T-cells.  
Additionally, it has been reported that TG2 trapped in an intermediate 
stage of catalysis is able to bind a second amine-donor substrate. This novel 
observation opens the door for structural studies investigating the elements 
directing the reactions leading to transamination and deamidation.  
 
7.8 Future work 
 
While this thesis has provided new knowledge in the field of gluten-
related disorders and more specifically in gluten ataxia, there are several 
lines of research arising from this work that I believe should be pursued 
further to gain an in-depth understanding of disease process. This section 
presents some of these directions.  
 
1. Further characterize TG2 and TG6-specific B cells/plasma cells 
present in the small intestine of GRD patients. Can such B cells be 
isolated from the circulation? 
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2. Analyse TG6 expression in the human intestine in helath and in the 
context of GRD. Are TG6 deposits present in the intestine? Which 
cells express TG6 (resident cells or infiltrating cells)? Is the expression 
altered in the presence of a gluten-related disorder?  
 
3. Analyse TG2, TG3 and TG6 expression, at gene and protein level, in 
human macrophages/dendritic cells after gliadin stimulation of GRD 
patients as well as appropriate controls. 
 
4. Identify whether autoantibody-binding to microglia cells affects 
permeability across endothelial-microglia cell barrier. 
a. Confirm TG2 and TG6 expression in human microglial cells at 
rest and upon inflammatory stimulation 
b. Establish a human brain/blood barrier model to investigate the 
cellular response to stimulation with TG2/TG6-specific 
antibodies and whether this could explain the autoantigen 
antibody reaction in the brain. 
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